Corporate_JJ responsibility_NN Product_NNP Contributing_VBG to_TO society_NN highlights_VBZ GlaxoSmithKline_NNP is_VBZ committed_VBN to_TO enhancing_VBG its_PRP$ position_NN as_IN Ten_CD major_JJ products_NNS ,_, accounting_VBG for_IN 7.6_CD billion_CD of_IN turnover_NN ,_, a_DT responsible_JJ corporate_JJ citizen_NN and_CC to_TO building_VBG community_NN grew_VBD in_IN strong_JJ double_JJ digits_NNS ,_, including_VBG Seretide_NNP Advair_NNP for_IN partnerships_NNS ._.
We_PRP also_RB know_VBP that_IN people_NNS want_VBP to_TO be_VB reassured_VBN asthma_NN and_CC chronic_JJ obstructive_JJ pulmonary_JJ disease_NN COPD_NNP about_IN the_DT sound_JJ ethical_JJ basis_NN of_IN our_PRP$ business_NN ._.
and_CC Avandia_NNP Avandamet_NNP for_IN diabetes_NN ._.
Corporate_JJ responsibility_NN We_PRP continued_VBD our_PRP$ support_NN for_IN two_CD organizations_NNS Top_JJ pharmaceutical_JJ products_NNS Product_NNP turnover_NN breakdown_NN GSK_NNP is_VBZ committed_VBN to_TO connecting_VBG business_NN in_IN Ireland_NNP and_CC France_NNP that_WDT provide_VBP therapeutic_JJ decisions_NNS to_TO ethical_JJ ,_, social_JJ and_CC environmental_JJ recreation_NN for_IN children_NNS with_IN cancer_NN or_CC serious_JJ concerns_NNS ._.
Solid_JJ financial_JJ performance_NN is_VBZ closely_RB illnesses_NNS ,_, and_CC started_VBD a_DT three-year_JJ program_NN in_IN Turnover_NN Top_NNP 5_CD pharmaceutical_JJ Top_NNP 5_CD Consumer_NNP Healthcare_NNP connected_VBD to_TO ethical_JJ business_NN practices_NNS ._.
It_PRP is_VBZ not_RB five_CD European_JJ countries_NNS that_WDT partners_NNS with_IN young_JJ products_NNS total_VBP turnover_NN products_NNS total_VBP turnover_NN just_RB how_WRB much_JJ profit_NN GSK_NNP makes_VBZ that_IN matters_NNS ._.
people_NNS living_VBG with_IN HIV_NNP AIDS_NNP to_TO help_VB alleviate_VB HIV_NNP -_: 15_CD %_NN People_NNS want_VBP to_TO know_VB how_WRB that_DT profit_NN is_VBZ made_VBN ._.
Consumer_NNP 1_CD Seretide_NNP Advair_NNP 2,214_CD m_NN 1_CD Aquafresh_NNP 332m_CD Healthcare_NNP 2_CD Seroxat_NNP Paxil_NNP 1,877_CD m_NN 2_CD Smoking_VBG control_NN 325m_CD 3.2_CD billion_CD GSK_NNP reports_NNS on_IN corporate_JJ responsibility_NN issues_NNS In_IN the_DT UK_NNP and_CC in_IN Philadelphia_NNP ,_, our_PRP$ IMPACT_NN 3_CD Wellbutrin_NNP 953m_CD 3_CD Lucozade_NNP 252m_CD and_CC how_WRB we_PRP manage_VBP them_PRP in_IN a_DT separate_JJ Awards_NNP rewarded_VBD the_DT work_NN of_IN voluntary_JJ Corporate_JJ Responsibility_NN Report_NNP ._.
To_TO guide_VB community-based_JJ organizations_NNS tackling_VBG issues_NNS 4_CD Avandia_NNP Avandamet_NNP 931m_CD 4_CD Sensodyne_NNP 210m_CD employees_NNS on_IN the_DT standards_NNS to_TO which_WDT the_DT such_JJ as_IN sexual_JJ abuse_NN ,_, mental_JJ health_NN ,_, elderly_JJ day_NN 5_CD Augmentin_NNP 825m_CD 5_CD Ribena_NNP 195m_CD company_NN is_VBZ committed_VBN ,_, in_IN 2003_CD we_PRP developed_VBD care_NN and_CC disability_NN ._.
In_IN addition_NN ,_, we_PRP supported_VBD a_DT set_NN of_IN corporate_JJ responsibility_NN principles_NNS for_IN medical_JJ research_NN charities_NNS in_IN the_DT UK_NNP focused_VBD on_IN 85_CD %_NN GSK_NNP which_WDT are_VBP published_VBN in_IN the_DT Report_NNP ._.
neonatal_JJ care_NN ,_, epilepsy_NN ,_, spinal_JJ and_CC osteoporosis_NN Pharmaceutical_NNP research_NN ._.
18.2_CD billion_CD The_DT principles_NNS set_VBN out_RP the_DT approach_NN to_TO ten_VB areas_NNS :_: standards_NNS of_IN ethical_JJ conduct_NN :_: leadership_NN In_IN 2003_CD ,_, GSK_NNP donated_VBD and_CC advocacy_NN :_: research_NN and_CC innovation_NN :_: products_NNS Vaccines_NNP New_NNP product_NN performance_NN medicines_NNS valued_VBN at_IN and_CC customers_NNS :_: access_NN to_TO medicines_NNS :_: employment_NN practices_NNS :_: human_JJ rights_NNS :_: community_NN investment_NN :_: 105_CD million_CD to_TO support_VB caring_NN for_IN the_DT environment_NN :_: and_CC engagement_NN with_IN stakeholders_NNS ._.
relief_NN efforts_NNS in_IN over_IN 80_CD 4.6_CD billion_CD countries_NNS We_PRP continue_VBP to_TO work_VB towards_IN developing_VBG simple_JJ ways_NNS to_TO measure_VB the_DT progress_NN we_PRP are_VBP making_VBG in_IN 39_CD %_NN 24_CD %_NN Turnover_NN of_IN new_JJ each_DT of_IN these_DT areas_NNS ._.
The_DT largest_JJS part_NN of_IN our_PRP$ community_NN investment_NN sales_NNS growth_NN sales_NNS growth_NN is_VBZ the_DT donation_NN of_IN essential_JJ medicines_NNS for_IN products_NNS ,_, those_DT 2,214_CD m_NN 931m_CD Community_NNP investment_NN humanitarian_JJ relief_NN efforts_NNS ._.
In_IN 2003_CD ,_, we_PRP SERETIDE_VBP ADVAIR_NNP AVANDIA_NNP AVANDAMET_NNP launched_VBD in_IN the_DT Working_NNP as_IN partners_NNS with_IN under-served_JJ donated_VBN medicines_NNS such_JJ as_IN antibiotics_NNS valued_VBN Sales_NNS in_IN the_DT USA_NNP were_VBD up_RB GSK_NNP is_VBZ building_VBG a_DT strong_JJ communities_NNS in_IN both_DT the_DT developed_VBN and_CC the_DT at_IN 105_CD million_CD to_TO support_VB relief_NN efforts_NNS in_IN over_IN 54_CD %_NN to_TO 1,235_CD million_CD ._.
franchise_NN in_IN the_DT treatment_NN last_JJ five_CD years_NNS ,_, developing_VBG world_NN is_VBZ an_DT integral_JJ activity_NN that_WDT 80_CD countries_NNS ._.
Donations_NNS are_VBP made_VBN at_IN the_DT request_NN Europe_NNP and_CC International_NNP of_IN diabetes_NN which_WDT affects_VBZ supports_NNS GSKs_NNS mission_NN of_IN improving_VBG the_DT quality_NN of_IN governments_NNS and_CC major_JJ charities_NNS ._.
Our_PRP$ sales_NNS rose_VBD 18_CD %_NN and_CC 37_CD %_NN over_IN 175_CD million_CD people_NNS increased_VBN by_IN 29_CD %_NN ._.
GSKs_NNS global_JJ community_NN investment_NN products_NNS were_VBD among_IN the_DT first_JJ to_TO be_VB airlifted_VBN respectively_RB ._.
activities_NNS in_IN 2003_CD were_VBD valued_VBN at_IN 338_CD million_CD ._.
This_DT into_IN Iraq_NNP following_VBG the_DT start_NN of_IN the_DT conflict_NN ._.
of_IN the_DT top_JJ ten_NN selling_VBG Top_NNP Kenya_NNP AIDS_NNP group_NN GSKs_NNP pioneering_JJ Positive_NNP Action_NNP program_NN has_VBZ included_VBN 125_CD million_CD for_IN the_DT Patient_NNP Assistance_NNP pharmaceutical_JJ products_NNS supported_VBD some_DT 28_CD organizations_NNS in_IN 34_CD countries_NNS in_IN Program_NN and_CC other_JJ medicine_NN donations_NNS for_IN low_JJ GSKs_NNS science_NN education_NN program_NN aims_VBZ to_TO give_VB worldwide_NN ._.
2003_CD ,_, such_JJ as_IN the_DT Movement_NNP of_IN Men_NNP Against_IN AIDS_NNP in_IN income_NN groups_NNS in_IN the_DT USA_NNP see_VB page_NN 9_CD ,_, plus_CC 105_CD science_NN context_NN and_CC enhance_VB science_NN teaching_NN ._.
Community-based_JJ organizations_NNS are_VBP frequently_RB the_DT sole_JJ source_NN of_IN education_NN ,_, support_NN ,_, homemillion_NN of_IN humanitarian_JJ product_NN donations_NNS ._.
We_PRP continued_VBD our_PRP$ INSPIRE_NNP INnovative_NNP Scheme_NNP based_VBN care_NN and_CC treatment_NN for_IN people_NNS living_VBG with_IN HIV_NNP AIDS_NNP for_IN Post-doctorates_NNP In_NNP Research_NNP and_CC Education_NNP Top_NNP Consumer_NNP Healthcare_NNP products_NNS in_IN developing_VBG countries_NNS ._.
New_NNP product_NN launches_VBZ Our_PRP$ programs_NNS reach_VBP over_IN 100_CD countries_NNS and_CC partnership_NN to_TO support_VB specialist_NN science_NN schools_NNS Left_VBN PHASE_NN in_IN Nicaragua_NNP focus_NN on_IN improving_VBG health_NN and_CC education_NN ._.
We_PRP also_RB supported_VBD Science_NNP Across_IN the_DT GSKs_NNP Personal_NNP Hygiene_NNP And_CC Sanitation_NNP Education_NNP our_PRP$ three_CD major_JJ public_JJ health_NN programs_NNS are_VBP World_NNP ,_, a_DT web-based_JJ educational_JJ resource_NN PHASE_NN is_VBZ a_DT simple_JJ handwashing_NN program_NN that_WDT During_IN 2003_CD ,_, GSK_NNP Wellbutrin_NNP XL_NNP Excellent_NNP uptake_NN continues_VBZ with_IN the_DT new_JJ in_IN lymphatic_JJ filariasis_NN ,_, HIV_NNP AIDS_NNP and_CC malaria_NN see_VBP program_NN that_IN promotes_VBZ discussion_NN of_IN science_NN reduces_VBZ diarrhoea-related_JJ disease_NN and_CC deaths_NNS in_IN school_NN formulation_NN accounting_NN for_IN 40_CD %_NN of_IN new_JJ children_NNS ._.
It_PRP has_VBZ now_RB expanded_VBN from_IN Kenya_NNP ,_, Nicaragua_NNP obtained_VBD regulatory_JJ page_NN 11_CD ,_, our_PRP$ businesses_NNS are_VBP actively_RB involved_VBN in_IN issues_NNS within_IN and_CC between_IN schools_NNS in_IN almost_RB 100_CD Wellbutrin_NNP prescriptions_NNS ._.
and_CC Peru_NNP to_TO include_VB Zambia_NNP and_CC is_VBZ incorporated_VBN into_IN the_DT numerous_JJ activities_NNS that_WDT help_VBP build_VB healthy_JJ countries_NNS ._.
In_IN the_DT USA_NNP ,_, our_PRP$ support_NN for_IN the_DT awardapproval_NN for_IN ten_NN important_JJ school_NN curriculum_NN in_IN some_DT countries_NNS ._.
winning_VBG Science_NN in_IN the_DT Summer_NNP initiative_NN entered_VBD Levitra_NNP Launched_NNP in_IN the_DT USA_NNP in_IN August_NNP 2003_CD and_CC in_IN new_JJ products_NNS and_CC new_JJ Europe_NNP in_IN the_DT first_JJ half_NN of_IN the_DT year_NN ,_, Levitra_NNP is_VBZ Right_RB IMPACT_NNP SHARE_VBP its_PRP$ 17th_JJ year_NN with_IN more_JJR than_IN 60,000_CD children_NNS GSKs_NNP IMPACT_NNP Awards_NNPS in_IN the_DT UK_NNP and_CC the_DT USA_NNP and_CC the_DT making_VBG strong_JJ market_NN share_NN gains_NNS ._.
indications_NNS including_VBG Levitra_NNP In_IN healthcare_NN ,_, many_JJ of_IN our_PRP$ grants_NNS target_NN voluntary_JJ experiencing_VBG this_DT free_JJ ,_, library-based_JJ science_NN 2003_CD SHARE_NNP Awards_NNPS in_IN the_DT USA_NNP reward_NN excellence_NN in_IN community-based_JJ organizations_NNS working_VBG in_IN health_NN education_NN program_NN ._.
for_IN erectile_JJ dysfunction_NN ,_, healthcare_NN ,_, enabling_VBG community-based_JJ organizations_NNS to_TO Lexiva_NNP A_NNP new_JJ protease_NN inhibitor_NN launched_VBN in_IN December_NNP continue_VBP their_PRP$ valuable_JJ work_NN and_CC access_NN ongoing_JJ education_NN and_CC often_RB with_IN children_NNS ._.
In_IN 2003_CD ,_, these_DT 2003_CD for_IN the_DT treatment_NN of_IN HIV_NNP ._.
ranged_VBD from_IN a_DT sexual_JJ health_NN awareness_NN program_NN GSKs_NNS commitment_NN to_TO communities_NNS increases_NNS Lexiva_NNP for_IN HIV_NNP AIDS_NNP and_CC for_IN street_NN children_NNS in_IN Panama_NNP to_TO a_DT scheme_NN that_IN the_DT number_NN of_IN people_NNS who_WP benefit_VBP from_IN the_DT Advair_NNP FDA_NNP approval_NN for_IN use_NN in_IN the_DT treatment_NN of_IN ensures_VBZ continuity_NN of_IN care_NN for_IN medically_RB under_IN companys_NNS success_NN and_CC ensures_VBZ that_IN the_DT spirit_NN Advair_NNP for_IN COPD_NNP COPD_NNP which_WDT is_VBZ the_DT fourth_JJ leading_VBG cause_NN of_IN served_VBN ,_, high-risk_JJ children_NNS in_IN the_DT USA_NNP ._.
of_IN do_VBP more_JJR ,_, feel_VB better_RB ,_, live_VBP longer_RBR means_VBZ death_NN worldwide_NN ._.
14_CD Annual_JJ Review_NNP 2003_CD Annual_JJ Review_NNP 2003_CD 15_CD The_DT Board_NNP The_DT Corporate_NNP Executive_NNP Team_NNP The_NNP Board_NNP of_IN Directors_NNS is_VBZ ultimately_RB accountable_JJ for_IN the_DT Groups_NNS activities_NNS ,_, strategy_NN The_DT executive_NN management_NN of_IN the_DT Group_NNP is_VBZ through_IN the_DT Corporate_NNP Executive_NNP Team_NNP CET_NNP ,_, and_CC financial_JJ performance_NN ._.
comprising_VBG the_DT Chief_NNP Executive_NNP Officer_NNP ,_, the_DT Chief_NNP Financial_NNP Officer_NNP and_CC other_JJ senior_JJ managers_NNS ._.
Sir_NNP Christopher_NNP Hogg_NNP Jean-Pierre_NNP Garnier_NNP John_NNP Coombe_NNP Michle_NNP Barzach_NNP Lawrence_NNP Culp_NNP Crispin_NNP Davis_NNP Sir_NNP Peter_NNP Job_NNP `_`` Jean-Pierre_NNP Garnier_NNP Rupert_NNP Bondy_NNP Ford_NNP Calhoun_NNP John_NNP Coombe_NNP Marc_NNP Dunoyer_NNP Russell_NNP Greig_NNP Dan_NNP Phelan_NNP John_NNP McArthur_NNP Donald_NNP McHenry_NNP Sir_NNP Ian_NNP Prosser_NNP Ronaldo_NNP Schmitz_NNP Lucy_NNP Shapiro_NNP Sir_NNP Robert_NNP Wilson_NNP Tachi_NNP Yamada_NNP David_NNP Pulman_NNP David_NNP Stout_NNP Chris_NNP Viehbacher_NNP Andrew_NNP Witty_NNP Tachi_NNP Yamada_NNP Jennie_NNP Younger_NNP Jack_NNP Ziegler_NNP Sir_NNP Christopher_NNP Hogg_NNP Aged_VBD 67_CD Michle_NNP Barzach_NNP Aged_VBD 60_CD Sir_NNP Peter_NNP Job_NNP Aged_VBD 62_CD Lucy_NNP Shapiro_NNP Aged_VBD 63_CD Jean-Pierre_NNP Garnier_NNP Marc_NNP Dunoyer_NNP David_NNP Stout_NNP Jennie_NNP Younger_NNP Appointed_VBN on_IN 23rd_JJ May_NNP 2000_CD Appointed_VBN on_IN 23rd_JJ May_NNP 2000_CD Appointed_VBN on_IN 23rd_JJ May_NNP 2000_CD Appointed_VBN on_IN 23rd_JJ May_NNP 2000_CD Chief_NNP Executive_NNP Officer_NNP President_NNP President_NNP Senior_NNP Vice_NNP President_NNP Non-Executive_NNP Chairman_NNP ._.
Sir_NNP Peter_NNP was_VBD Non-Executive_JJ Director_NNP ._.
Lucy_NNP Shapiro_NNP As_IN Chief_NNP Executive_NNP Officer_NNP ,_, JP_NNP is_VBZ Pharmaceuticals_NNPS Japan_NNP Pharmaceutical_NNP Operations_NNP Corporate_NNP Communications_NNPS was_VBD formerly_RB a_DT Non-Executive_JJ Director_NNP was_VBD formerly_RB a_DT Non-Executive_JJ Director_NNP formerly_RB a_DT Non-Executive_JJ Director_NNP of_IN Glaxo_NNP was_VBD formerly_RB a_DT Non-Executive_JJ Director_NNP of_IN responsible_JJ for_IN the_DT management_NN of_IN Marc_NNP was_VBD appointed_VBN President_NNP ,_, David_NNP is_VBZ responsible_JJ for_IN the_DT global_JJ &_CC Community_NNP Partnerships_NNS of_IN SmithKline_NNP Beecham_NNP plc._NN ._.
He_PRP is_VBZ Nonof_NNP Glaxo_NNP Wellcome_NNP plc._NN ._.
She_PRP is_VBZ a_DT member_NN Wellcome_NNP plc._NN ._.
He_PRP is_VBZ a_DT Non-Executive_JJ SmithKline_NNP Beecham_NNP plc._NN ._.
He_PRP oversees_VBZ all_DT operational_JJ Pharmaceuticals_NNPS Japan_NNP in_IN March_NNP 2003_CD ._.
He_PRP pharmaceuticals_NNS and_CC vaccines_NNS businesses_NNS ._.
Jennie_NNP is_VBZ responsible_JJ for_IN the_DT Groups_NNS Executive_NNP Chairman_NNP of_IN Reuters_NNP Group_NNP of_IN the_DT International_NNP Cooperation_NNP High_NNP Director_NNP of_IN Schroders_NNP plc_NN ,_, Shell_NNP Transport_NNP Professor_NNP of_IN Cancer_NNP Research_NNP in_IN the_DT aspects_NNS including_VBG establishing_VBG policies_NNS ,_, joined_VBD the_DT Group_NNP in_IN 1999_CD and_CC was_VBD Senior_JJ He_PRP joined_VBD SmithKline_NNP Beecham_NNP in_IN 1996_CD internal_JJ and_CC external_JJ communications_NNS ,_, PLC_NNP and_CC a_DT member_NN of_IN the_DT Supervisory_NNP Council_NNP ,_, Chairman_NNP of_IN the_DT Board_NNP of_IN and_CC Trading_NNP Company_NNP plc_NN ,_, TIBCO_NNP Software_NNP Department_NNP of_IN Developmental_NNP Biology_NNP objectives_NNS and_CC initiatives_NNS ,_, and_CC directs_VBZ Vice_NNP President_NNP and_CC Regional_NNP Director_NNP ,_, as_IN head_NN of_IN US_NNP Sales_NNS and_CC Marketing_NNP ,_, its_PRP$ image_NN and_CC partnerships_NNS with_IN global_JJ Board_NNP of_IN Air_NNP Liquide_NNP S._NNP A._NN and_CC Chairman_NNP Equilibres_NNP et_NNP Populations_NNPS and_CC Director_NNP of_IN Inc._NNP and_CC Instinet_NNP Group_NNP Inc._NNP ._.
He_PRP is_VBZ also_RB a_DT and_CC Director_NNP of_IN the_DT Beckman_NNP Center_NNP for_IN long-term_JJ strategy_NN ._.
He_PRP was_VBD formerly_RB Japan_NNP ,_, until_IN his_PRP$ current_JJ appointment_NN ._.
and_CC was_VBD President_NNP ,_, US_NNP Pharmaceuticals_NNP communities_NNS ._.
She_PRP joined_VBD Glaxo_NNP of_IN The_DT Royal_NNP National_NNP Theatre_NNP ._.
the_DT Board_NNP of_IN Project_NNP Hope_NNP ._.
International_NNP member_NN of_IN the_DT Supervisory_NNP Boards_NNPS of_IN Molecular_JJ and_CC Genetic_JJ Medicine_NN at_IN the_DT Chief_NNP Executive_NNP Officer_NNP of_IN SmithKline_NNP until_IN his_PRP$ current_JJ appointment_NN in_IN Wellcome_NNP in_IN 1996_CD as_IN Director_NNP consultant_NN in_IN health_NN strategy_NN ,_, she_PRP was_VBD Deutsche_NNP Bank_NNP AG_NNP and_CC Bertelsmann_NNP AG_NNP ._.
Stanford_NNP University_NNP School_NNP of_IN Medicine_NNP Russell_NNP Greig_NNP Jean-Pierre_NNP Garnier_NNP Aged_VBD 56_CD Beecham_NNP ,_, having_VBG joined_VBN the_DT Group_NNP January_NNP 2003_CD ._.
of_IN Investor_NNP Relations_NNPS ._.
formerly_RB French_NNP Minister_NNP of_IN Health_NNP and_CC and_CC a_DT Non-Executive_JJ Director_NNP of_IN Anacor_NNP President_NNP Appointed_VBN on_IN 23rd_JJ May_NNP 2000_CD John_NNP McArthur_NNP Aged_VBD 69_CD in_IN 1990_CD ._.
Pharmaceuticals_NNP Inc._NNP ._.
She_PRP holds_VBZ a_DT PhD_NNP in_IN Pharmaceuticals_NNP International_NNP Chris_NNP Viehbacher_NNP Jack_NNP Ziegler_NNP Chief_NNP Executive_NNP Officer_NNP ._.
JP_NNP Garnier_NNP was_VBD Appointed_VBN on_IN 23rd_JJ May_NNP 2000_CD molecular_JJ biology_NN from_IN the_DT Albert_NNP Rupert_NNP Bondy_NNP Russell_NNP leads_VBZ the_DT pharmaceutical_JJ President_NNP President_NNP appointed_VBD an_DT Executive_NNP Director_NNP of_IN Lawrence_NNP Culp_NNP Aged_VBD 40_CD Non-Executive_JJ Director_NNP ._.
John_NNP McArthur_NNP Einstein_NNP College_NNP of_IN Medicine_NNP ._.
Senior_JJ Vice_NNP President_NNP and_CC General_NNP operations_NNS outside_IN the_DT USA_NNP and_CC most_JJS US_PRP Pharmaceuticals_NNPS Consumer_NNP Healthcare_NNP SmithKline_NNP Beecham_NNP plc_NN in_IN 1992_CD ,_, and_CC Appointed_VBN on_IN 1st_CD July_NNP 2003_CD was_VBD formerly_RB a_DT Non-Executive_JJ Director_NNP of_IN Counsel_NNP of_IN Europe_NNP ,_, covering_VBG more_JJR than_IN 100_CD Chris_NNP has_VBZ been_VBN responsible_JJ for_IN US_NNP Jack_NNP is_VBZ head_NN of_IN the_DT global_JJ Consumer_NN became_VBD Chief_NNP Executive_NNP Officer_NNP in_IN April_NNP Non-Executive_NNP Director_NNP ._.
Lawrence_NNP Culp_NNP Glaxo_NNP Wellcome_NNP plc._NN ._.
He_PRP is_VBZ a_DT Non-Executive_JJ Sir_NNP Robert_NNP Wilson_NNP Aged_VBD 60_CD Rupert_NNP is_VBZ responsible_JJ for_IN legal_JJ matters_NNS countries_NNS ._.
He_PRP joined_VBD the_DT Group_NNP in_IN 1980_CD Pharmaceuticals_NNS since_IN January_NNP 2003_CD ._.
Healthcare_NNP business_NN ,_, which_WDT produces_VBZ oral_JJ 2000_CD ._.
He_PRP is_VBZ a_DT Non-Executive_JJ Director_NNP of_IN is_VBZ President_NNP and_CC CEO_NNP of_IN Danaher_NNP Director_NNP of_IN BCE_NNP Inc._NNP ._.
BCE_NNP Emergis_NNP Inc._NNP ._.
Appointed_VBN on_IN 1st_CD November_NNP 2003_CD across_IN the_DT Group_NNP ,_, together_RB with_IN and_CC was_VBD Senior_JJ Vice_NNP President_NNP ,_, He_PRP joined_VBD Wellcome_NNP in_IN 1988_CD and_CC healthcare_NN ,_, over-the-counter_JJ medicines_NNS United_NNP Technologies_NNPS Corporation_NNP and_CC a_DT Corporation_NNP ._.
Prior_RB to_TO joining_VBG Danaher_NNP ,_, Cabot_NNP Corporation_NNP ,_, HCA_NNP Corporation_NNP ,_, Koc_NNP Non-Executive_NNP Director_NNP ._.
Sir_NNP Robert_NNP is_VBZ Nonenvironmental_JJ ,_, health_NN and_CC safety_NN issues_NNS ,_, Worldwide_NNP Business_NNP Development_NNP for_IN became_VBD Director_NNP ,_, Continental_NNP Europe_NNP ,_, and_CC nutritional_JJ healthcare_NN products_NNS ._.
He_PRP member_NN of_IN the_DT Board_NNP of_IN Trustees_NNPS of_IN the_DT he_PRP held_VBD positions_NNS in_IN Accenture_NNP ,_, Holdings_NNP A._NNP S._NNP Rohm_NNP and_CC Haas_NNP Company_NNP ,_, Executive_NNP Chairman_NNP of_IN BG_NNP Group_NNP plc_NN and_CC insurance_NN and_CC security_NN ._.
He_PRP was_VBD a_DT lawyer_NN R&D_NNP prior_RB to_TO his_PRP$ current_JJ appointment_NN at_IN Glaxo_NNP Wellcome_NNP in_IN 1999_CD ._.
He_PRP was_VBD joined_VBN SmithKline_NNP Beecham_NNP in_IN 1991_CD and_CC Eisenhower_NNP Exchange_NNP Fellowships_NNP ._.
Telsat_NNP Canada_NNP and_CC The_DT AES_NNP Corporation_NNP ._.
the_DT Economist_NNP Group_NNP and_CC was_VBD previously_RB in_IN private_JJ practice_NN before_IN joining_VBG in_IN March_NNP 2003_CD ._.
responsible_JJ for_IN GlaxoSmithKlines_NNS in_IN 1998_CD was_VBD appointed_VBN President_NNP of_IN the_DT holds_VBZ a_DT PhD_NNP in_IN pharmacology_NN from_IN the_DT He_PRP is_VBZ also_RB Senior_JJ Advisor_NNP to_TO the_DT President_NNP Executive_NNP Chairman_NNP of_IN Rio_NNP Tinto_NNP plc._NN ._.
Crispin_NNP Davis_NNP Aged_VBD 54_CD SmithKline_NNP Beecham_NNP in_IN 1995_CD ._.
European_JJ Pharmaceuticals_NNS business_NN Consumer_NN Healthcare_NNP business_NN ._.
University_NNP of_IN Louis_NNP Pasteur_NNP in_IN France_NNP and_CC an_DT of_IN the_DT World_NNP Bank_NNP ._.
Dan_NNP Phelan_NNP Appointed_VBN on_IN 1st_CD July_NNP 2003_CD Tachi_NNP Yamada_NNP Aged_VBD 58_CD before_IN his_PRP$ current_JJ appointment_NN ._.
MBA_NNP from_IN Stanford_NNP University_NNP in_IN the_DT USA_NNP ._.
Ford_NNP Calhoun_NNP Senior_NNP Vice_NNP President_NNP Other_JJ members_NNS Non-Executive_JJ Director_NNP ._.
Crispin_NNP Davis_NNP is_VBZ Donald_NNP McHenry_NNP Aged_VBD 67_CD Appointed_VBN on_IN 1st_CD January_NNP 2004_CD Chief_NNP Information_NNP Officer_NNP Human_NNP Resources_NNPS Andrew_NNP Witty_NNP Howard_NNP Pien_NNP left_VBD the_DT Group_NNP on_IN 31st_CD John_NNP Coombe_NNP Aged_VBD 58_CD Chief_NNP Executive_NNP of_IN Reed_NNP Elsevier_NNP PLC._NNP ._.
Appointed_VBN on_IN 23rd_JJ May_NNP 2000_CD Chairman_NNP ,_, Research_NNP &_CC Development_NNP ._.
Ford_NNP is_VBZ responsible_JJ for_IN information_NN Dan_NNP is_VBZ responsible_JJ for_IN benefits_NNS ,_, President_NNP March_NNP 2003_CD to_TO pursue_VB another_DT role_NN in_IN Appointed_VBN on_IN 23rd_JJ May_NNP 2000_CD Prior_RB to_TO that_DT ,_, he_PRP was_VBD Chief_NNP Executive_NNP of_IN Non-Executive_NNP Director_NNP ._.
Donald_NNP McHenry_NNP Tachi_NNP Yamada_NNP was_VBD formerly_RB a_DT Nontechnology_NNP ,_, a_DT global_JJ function_NN that_WDT compensation_NN ,_, recruitment_NN ,_, organization_NN Pharmaceuticals_NNP Europe_NNP the_DT pharmaceutical_JJ industry_NN ._.
Bob_NNP Ingram_NNP Chief_NNP Financial_NNP Officer_NNP ._.
John_NNP Coombe_NNP was_VBD Aegis_NNP Group_NNP plc_NN ,_, which_WDT he_PRP joined_VBD from_IN was_VBD formerly_RB a_DT Non-Executive_JJ Director_NNP Executive_NNP Director_NNP ,_, and_CC subsequently_RB enables_VBZ key_JJ business_NN processes_VBZ across_IN all_DT development_NN ,_, leadership_NN development_NN Andrew_NNP has_VBZ been_VBN responsible_JJ for_IN the_DT continues_VBZ to_TO work_VB part-time_JJ as_IN Vice_NNP formerly_RB an_DT Executive_NNP Director_NNP of_IN Glaxo_NNP Guinness_NNP plc_NN ,_, where_WRB he_PRP was_VBD Group_NNP of_IN SmithKline_NNP Beecham_NNP plc._NN ._.
His_PRP$ other_JJ an_DT Executive_NNP Director_NNP ,_, of_IN SmithKline_NNP parts_NNS of_IN the_DT Group_NNP ._.
With_IN doctoral_JJ and_CC and_CC succession_NN planning_NN ,_, human_JJ Groups_NNS pharmaceuticals_NNS operations_NNS in_IN Chairman_NNP of_IN Pharmaceuticals_NNP ,_, acting_VBG Wellcome_NNP plc_NN where_WRB he_PRP was_VBD responsible_JJ Managing_VBG Director_NNP of_IN United_NNP Distillers_NNPS Non-Executive_JJ directorships_NNS include_VBP Beecham_NNP plc._NN ._.
Prior_RB to_TO joining_VBG SmithKline_NNP post-doctoral_JJ training_NN in_IN microbiology_NN ,_, resource_NN information_NN systems_NNS and_CC Europe_NNP since_IN January_NNP 2003_CD ._.
He_PRP joined_VBD as_IN special_JJ advisor_NN to_TO the_DT Group_NNP and_CC for_IN Finance_NNP and_CC Investor_NNP Relations_NNPS ._.
He_PRP is_VBZ and_CC a_DT member_NN of_IN the_DT main_JJ board_NN of_IN The_DT Coca-Cola_NNP Company_NNP ,_, FleetBoston_NNP Beecham_NNP he_PRP was_VBD Chairman_NNP of_IN the_DT genetics_NNS ,_, biomathematics_NNS and_CC computer_NN employee_NN health_NN management_NN ._.
He_PRP Glaxo_NNP in_IN 1985_CD and_CC at_IN GlaxoSmithKline_NNP attending_VBG CET_NNP meetings_NNS in_IN that_DT capacity_NN ._.
a_DT member_NN of_IN the_DT Supervisory_NNP Board_NNP of_IN Guinness_NNP plc._NN ._.
He_PRP spent_VBD his_PRP$ early_JJ career_NN Financial_NNP Corporation_NNP ,_, International_NNP Department_NNP of_IN Internal_NNP Medicine_NNP at_IN the_DT science_NN ,_, Ford_NNP joined_VBD Smith_NNP Kline_NNP &_CC French_NNP was_VBD a_DT lawyer_NN in_IN private_JJ practice_NN before_IN was_VBD Senior_JJ Vice_NNP President_NNP ,_, Asia_NNP Pacific_NNP ,_, Siemens_NNP AG_NNP and_CC the_DT Code_NNP Committee_NNP of_IN with_IN Procter_NNP &_CC Gamble_NNP ._.
Paper_NNP Company_NNP and_CC AT&T_NNP Corporation_NNP ._.
University_NNP of_IN Michigan_NNP Medical_NNP School_NNP in_IN 1984_CD ._.
joining_VBG Smith_NNP Kline_NNP &_CC French_NNP in_IN 1981_CD until_IN his_PRP$ current_JJ appointment_NN ._.
and_CC Physician-in-Chief_NNP of_IN the_DT University_NNP Sir_NNP Ian_NNP Prosser_NNP Aged_VBD 60_CD and_CC in_IN 1994_CD was_VBD appointed_VBN Senior_NNP of_IN Michigan_NNP Medical_NNP Center_NNP ._.
He_PRP is_VBZ a_DT John_NNP Coombe_NNP Tachi_NNP Yamada_NNP Appointed_VBN on_IN 23rd_JJ May_NNP 2000_CD Vice_NNP President_NNP and_CC Director_NNP ,_, Human_NNP member_NN of_IN the_DT Board_NNP of_IN diaDexus_NNP ,_, Inc._NNP ._.
Chief_NNP Financial_NNP Officer_NNP Chairman_NNP Non-Executive_NNP Director_NNP ._.
Sir_NNP Ian_NNP was_VBD Resources_NNP ,_, SmithKline_NNP Beecham_NNP ._.
and_CC is_VBZ a_DT Trustee_NN of_IN the_DT Rockefeller_NNP As_IN head_NN of_IN the_DT finance_NN function_NN ,_, John_NNP is_VBZ Research_NNP &_CC Development_NNP formerly_RB a_DT Non-Executive_JJ Director_NNP Brothers_NNPS Fund_NNP ._.
responsible_JJ for_IN activities_NNS such_JJ as_IN financial_JJ David_NNP Pulman_NNP Tachi_NNP leads_VBZ the_DT Groups_NNS complex_JJ business_NN of_IN SmithKline_NNP Beecham_NNP plc._NN ._.
He_PRP was_VBD reporting_VBG and_CC control_NN ,_, tax_NN and_CC treasury_NN ,_, President_NNP of_IN drug_NN discovery_NN and_CC development_NN ,_, Membership_NN of_IN Board_NNP Committees_NNS is_VBZ indicated_VBN in_IN the_DT following_VBG table_NN :_: Chairman_NNP of_IN Six_CD Continents_NNP PLC_NNP and_CC Other_JJ Directors_NNS investor_NN relations_NNS ,_, finance_NN systems_NNS ,_, Global_JJ Manufacturing_NNP &_CC Supply_NNP creating_VBG new_JJ medicines_NNS through_IN the_DT World_NNP Travel_NNP &_CC Tourism_NNP Council_NNP and_CC Sir_NNP Roger_NNP Hurn_NNP ,_, Non-Executive_NNP Deputy_NNP internal_JJ audit_NN and_CC real_JJ estate_NN ._.
He_PRP joined_VBD David_NNP is_VBZ responsible_JJ for_IN the_DT global_JJ research_NN ._.
He_PRP joined_VBD SmithKline_NNP Beecham_NNP is_VBZ Non-Executive_JJ Deputy_NNP Chairman_NNP of_IN BP_NNP Chairman_NNP and_CC Paul_NNP Allaire_NNP ,_, NonGlaxo_NNP in_IN 1986_CD as_IN Group_NNP Financial_NNP manufacturing_NN and_CC supply_NN chain_NN in_IN 1994_CD as_IN a_DT Non-Executive_JJ member_NN of_IN plc._NN ._.
He_PRP is_VBZ a_DT member_NN of_IN the_DT CBI_NNP Executive_NNP Director_NNP ,_, both_DT retired_VBN from_IN Controller_NNP and_CC was_VBD appointed_VBN Group_NNP network_NN ._.
He_PRP joined_VBD Glaxo_NNP in_IN 1978_CD and_CC the_DT Board_NNP and_CC became_VBD Chairman_NNP ,_, R&D_NNP ,_, Presidents_NNP Committee_NNP ._.
Finance_NNP Director_NNP in_IN 1992_CD ._.
was_VBD responsible_JJ for_IN the_DT North_JJ American_JJ Pharmaceuticals_NNS in_IN 1999_CD ._.
He_PRP was_VBD Audit_NNP M_NNP M_NNP C_NNP M_NNP supply_NN network_NN ,_, manufacturing_VBG strategy_NN appointed_VBN to_TO the_DT Board_NNP of_IN Directors_NNS Corporate_JJ Administration_NNP M_NNP M_NNP M_NNP M_NNP M_NNP M_NNP M_NNP M_NNP M_NNP M_NNP M_NNP M_NNP M_NNP M_NNP Ronaldo_NNP Schmitz_NNP Aged_VBD 65_CD &_CC Transactions_NNS and_CC logistics_NNS until_IN his_PRP$ current_JJ on_IN 1st_CD January_NNP 2004_CD ._.
Appointed_VBN on_IN 23rd_JJ May_NNP 2000_CD Corporate_JJ Responsibility_NN M_NNP M_NNP C_NNP M_NNP appointment_NN in_IN 2002_CD ._.
Ronaldo_NNP Schmitz_NNP Financial_NNP Results_NNS M_NNP M_NNP M_NNP M_NNP M_NNP M_NNP M_NNP M_NNP M_NNP M_NNP M_NNP M_NNP M_NNP M_NNP was_VBD formerly_RB a_DT Non-Executive_JJ Director_NNP Nominations_NNPS C_NNP M_NNP M_NNP of_IN Glaxo_NNP Wellcome_NNP plc._NN ._.
He_PRP is_VBZ a_DT NonRemuneration_NNP M_NNP M_NNP M_NNP C_NNP M_NNP Executive_NNP Director_NNP of_IN Legal_NNP &_CC General_NNP Key_NNP :_: C_NNP Chairman_NNP M_NNP Member_NNP Group_NNP plc_NN and_CC a_DT member_NN of_IN the_DT Board_NNP Details_NNS of_IN the_DT terms_NNS of_IN reference_NN of_IN the_DT Board_NNP Committees_NNS may_MD be_VB found_VBN on_IN page_NN 21_CD ._.
of_IN Directors_NNS of_IN Rohm_NNP and_CC Haas_NNP Company_NNP and_CC Cabot_NNP Corporation_NNP ._.
16_CD Annual_JJ Review_NNP 2003_CD Annual_JJ Review_NNP 2003_CD 17_CD Hogg_NNP Garnier_NNP Coombe_NNP Barzach_NNP Culp_NNP Davis_NNP Job_NNP McArthur_NNP McHenry_NNP Prosser_NNP Schmitz_NNP Shapiro_NNP Wilson_NNP Yamada_NNP Summary_NNP Remuneration_NNP Report_NNP FOR_IN THE_DT YEAR_NN TO_TO 31ST_CD DECEMBER_NNP 2003_CD Summary_NNP Remuneration_NNP Report_NNP FOR_IN THE_DT YEAR_NN TO_TO 31ST_CD DECEMBER_NNP 2003_CD a_DT commitment_NN to_TO be_VB a_DT leader_NN of_IN good_JJ remuneration_NN practice_NN in_IN the_DT Annual_JJ bonus_NN The_DT Committee_NNP has_VBZ decided_VBN for_IN the_DT 2003_CD grant_NN that_IN if_IN the_DT performance_NN Introduction_NN pharmaceutical_JJ industry_NN ._.
All_DT bonuses_NNS are_VBP determined_VBN on_IN the_DT basis_NN of_IN a_DT formal_JJ review_NN of_IN annual_JJ condition_NN is_VBZ not_RB met_VBN in_IN full_JJ after_IN the_DT three_CD year_NN period_NN ,_, performance_NN will_MD performance_NN against_IN stretching_VBG financial_JJ targets_NNS based_VBN on_IN business_NN be_VB measured_VBN again_RB over_IN the_DT four_CD financial_JJ years_NNS following_VBG the_DT date_NN of_IN The_DT Summary_NNP Remuneration_NNP Report_NNP sets_VBZ out_RP the_DT annual_JJ remuneration_NN In_IN formulating_VBG the_DT policy_NN ,_, the_DT Committee_NNP also_RB decided_VBD that_IN :_: performance_NN profit_NN before_IN interest_NN and_CC tax_NN and_CC are_VBP subject_JJ to_TO detailed_JJ grant_NN of_IN the_DT option_NN ._.
To_TO the_DT extent_NN the_DT option_NN performance_NN conditions_NNS earned_VBN in_IN 2003_CD together_RB with_IN any_DT gains_NNS under_IN long-term_JJ incentive_NN the_DT remuneration_NN structure_NN must_MD support_VB the_DT business_NN by_IN securing_VBG ,_, assessment_NN of_IN individual_JJ ,_, business_NN unit_NN and_CC group_NN achievements_NNS against_IN have_VBP not_RB been_VBN met_VBN at_IN the_DT end_NN of_IN four_CD years_NNS ,_, the_DT option_NN will_MD lapse_NN ._.
It_PRP also_RB describes_VBZ the_DT background_NN and_CC outlines_VBZ the_DT Groups_NNS retaining_VBG and_CC motivating_VBG key_JJ talent_NN in_IN a_DT very_RB competitive_JJ market_NN objectives_NNS ._.
The_DT Committee_NNP considers_VBZ re-measurement_NN to_TO be_VB an_DT important_JJ feature_NN remuneration_NN policy_NN together_RB with_IN the_DT performance_NN graph_NN as_IN required_VBN by_IN place_NN :_: for_IN the_DT 2003_CD grant_NN in_IN the_DT light_NN of_IN the_DT imposition_NN of_IN performance_NN the_DT Directors_NNS Remuneration_NNP Report_NNP Regulations_NNPS 2002_CD the_DT Regulations_NNPS ._.
UK_NNP shareholder_NN guidelines_NNS would_MD be_VB followed_VBN to_TO the_DT maximum_NN extent_NN Bonus_NNP awards_NNS for_IN 2003_CD reflected_VBD the_DT Committees_NNS belief_NN that_IN the_DT company_NN conditions_NNS in_IN an_DT industry_NN where_WRB most_JJS of_IN the_DT major_JJ competitors_NNS do_VBP not_RB consistent_JJ with_IN the_DT needs_NNS of_IN the_DT business_NN and_CC the_DT company_NN would_MD produced_VBD superior_JJ results_NNS during_IN the_DT year_NN ,_, after_IN taking_VBG account_NN of_IN factors_NNS apply_VBP them_PRP to_TO options_NNS ._.
The_DT Committee_NNP will_MD consider_VB prior_RB to_TO each_DT annual_JJ The_DT Remuneration_NNP Committee_NNP the_DT Committee_NNP is_VBZ responsible_JJ for_IN making_VBG maintain_VB a_DT regular_JJ dialogue_NN with_IN shareholders_NNS :_: outside_IN the_DT control_NN of_IN management_NN ,_, notably_RB exchange_NN rates_NNS and_CC the_DT grant_NN of_IN options_NNS whether_IN a_DT re-measurement_NN will_MD be_VB permitted_VBN ._.
recommendations_NNS to_TO the_DT Board_NNP on_IN the_DT companys_NNS remuneration_VBP policy_NN global_JJ pharmaceutical_JJ companies_NNS are_VBP the_DT primary_JJ pay_NN comparator_NN group_NN :_: launch_NN of_IN generic_JJ competition_NN to_TO Paxil_NNP in_IN the_DT USA_NNP ._.
and_CC ,_, within_IN the_DT terms_NNS of_IN the_DT agreed_JJ policy_NN ,_, determining_VBG the_DT total_JJ performance_NN conditions_NNS would_MD be_VB based_VBN on_IN the_DT measurable_JJ delivery_NN The_DT performance_NN condition_NN for_IN options_NNS granted_VBN prior_RB to_TO 2003_CD was_VBD individual_JJ remuneration_NN packages_NNS of_IN the_DT Executive_NNP Directors_NNS and_CC members_NNS of_IN strong_JJ financial_JJ performance_NN and_CC the_DT delivery_NN of_IN superior_JJ returns_NNS Long-term_JJ incentives_NNS that_IN ,_, for_IN the_DT options_NNS to_TO vest_NN in_IN full_JJ ,_, Business_NNP Performance_NNP EPS_NNP growth_NN ,_, of_IN the_DT CET_NNP Executives_NNS ._.
The_DT members_NNS of_IN the_DT Remuneration_NNP Committee_NNP to_TO shareholders_NNS as_IN compared_VBN with_IN other_JJ pharmaceutical_JJ companies_NNS :_: The_DT remuneration_NN policy_NN provides_VBZ that_IN annual_JJ long-term_JJ incentive_NN awards_NNS excluding_VBG currency_NN and_CC exceptional_JJ items_NNS ,_, had_VBD on_IN average_NN to_TO be_VB at_IN least_JJS are_VBP set_VBN out_RP on_IN page_NN 16_CD ._.
a_DT high_JJ proportion_NN of_IN the_DT total_JJ remuneration_NN opportunity_NN would_MD be_VB will_MD normally_RB be_VB made_VBN up_IN of_IN a_DT performance_NN share_NN award_NN and_CC a_DT share_NN three_CD percentage_NN points_NNS per_IN annum_NN more_RBR than_IN the_DT increase_NN in_IN RPI_NNP over_IN based_VBN on_IN performance-related_JJ remuneration_NN which_WDT will_MD be_VB delivered_VBN option_NN award_NN ._.
The_DT new_JJ remuneration_NN policy_NN increases_VBZ the_DT emphasis_NN on_IN any_DT three-year_JJ performance_NN period_NN ._.
During_IN 2003_CD the_DT Committee_NNP reviewed_VBN and_CC developed_VBN the_DT remuneration_NN over_IN the_DT medium_NN to_TO long-term_JJ :_: and_CC the_DT use_NN of_IN performance_NN shares_NNS ._.
policy_NN to_TO align_VB executive_JJ remuneration_NN with_IN the_DT interests_NNS of_IN shareholders_NNS no_DT ex-gratia_NN payments_NNS would_MD be_VB made_VBN ._.
Pensions_NNS whilst_VBP meeting_VBG the_DT imperative_NN of_IN recruiting_NN and_CC retaining_VBG the_DT executive_NN As_IN part_NN of_IN the_DT review_NN process_NN ,_, the_DT Committee_NNP considered_VBN which_WDT The_DT Executives_NNS participate_VB in_IN GlaxoSmithKline_NNP senior_JJ executive_NN pension_NN talent_NN essential_JJ to_TO the_DT leadership_NN of_IN the_DT company_NN ._.
Overall_RB the_DT policy_NN is_VBZ intended_VBN to_TO provide_VB median_JJ total_JJ remuneration_NN for_IN performance_NN conditions_NNS should_MD be_VB applied_VBN to_TO the_DT long-term_JJ incentives_NNS ._.
The_DT pension_NN arrangements_NNS are_VBP structured_VBN in_IN accordance_NN with_IN the_DT median_JJ performance_NN ._.
Poor_NNP performance_NN will_MD result_VB in_IN total_JJ remuneration_NN The_DT Committee_NNP concluded_VBD that_IN it_PRP was_VBD appropriate_JJ to_TO measure_VB plans_NNS operated_VBN for_IN Executives_NNS in_IN the_DT country_NN in_IN which_WDT the_DT Executives_NNS are_VBP The_DT new_JJ remuneration_NN policy_NN was_VBD finalized_VBN after_IN undertaking_VBG an_DT extensive_JJ significantly_RB below_IN the_DT pay_NN comparator_NN group_NN median_NN ,_, with_IN the_DT opportunity_NN performance_NN using_VBG a_DT combination_NN of_IN absolute_JJ financial_JJ results_NNS based_VBN likely_JJ to_TO retire_VB ._.
Benefits_NNS are_VBP normally_RB payable_JJ at_IN age_NN 60_CD ._.
consultation_NN process_NN with_IN shareholders_NNS and_CC institutional_JJ bodies_NNS during_IN the_DT to_TO earn_VB upper_JJ quartile_JJ total_JJ remuneration_NN for_IN exceptional_JJ performance_NN ._.
on_IN earnings_NNS per_IN share_NN -_: EPS_NNP and_CC the_DT delivery_NN of_IN superior_JJ value_NN to_TO course_NN of_IN 2003_CD ._.
During_IN the_DT year_NN the_DT Chairman_NNP of_IN GlaxoSmithKline_NNP and_CC shareholders_NNS based_VBN on_IN Total_JJ Shareholder_NN Return_NN -_: TSR_NNP ._.
the_DT Chairman_NNP of_IN the_DT Committee_NNP met_VBD shareholders_NNS ,_, representing_VBG nearly_RB Executive_NNP Director_NNP terms_NNS and_CC conditions_NNS This_DT strong_JJ alignment_NN with_IN performance_NN is_VBZ demonstrably_RB in_IN the_DT interests_NNS half_NN of_IN GlaxoSmithKlines_NNP share_NN capital_NN ,_, to_TO ensure_VB that_IN the_DT Committee_NNP of_IN shareholders_NNS and_CC provides_VBZ the_DT Executives_NNS with_IN unambiguous_JJ signals_NNS For_IN the_DT Executives_NNS ,_, the_DT level_NN of_IN performance_NN shares_NNS vesting_VBG is_VBZ based_VBN on_IN obtained_VBN a_DT clear_JJ understanding_NN of_IN shareholder_NN expectations_NNS and_CC to_TO The_DT policy_NN regarding_VBG the_DT Executive_NNP Directors_NNS contracts_NNS was_VBD the_DT subject_NN of_IN about_IN the_DT importance_NN of_IN delivering_VBG success_NN to_TO the_DT companys_NNS the_DT companys_NNS TSR_NNP relative_JJ to_TO the_DT performance_NN comparator_NN group_NN over_IN communicate_VBP the_DT competitive_JJ issues_NNS facing_VBG the_DT company_NN ._.
extensive_JJ review_NN and_CC change_NN during_IN 2003_CD ._.
The_DT new_JJ policy_NN provides_VBZ the_DT shareholders_NNS ._.
If_IN GlaxoSmithKline_NNP is_VBZ ranked_VBN at_IN the_DT framework_NN for_IN contracts_NNS for_IN Executive_NNP Directors_NNS appointed_VBN in_IN the_DT future_NN ._.
median_NN of_IN the_DT performance_NN comparator_NN group_NN ,_, 35_CD %_NN of_IN the_DT shares_NNS will_MD The_DT revised_VBN remuneration_NN policy_NN is_VBZ designed_VBN to_TO establish_VB a_DT framework_NN for_IN Commitment_NNP vest_NN ._.
Only_RB if_IN GlaxoSmithKline_NNP is_VBZ one_CD of_IN the_DT top_JJ two_CD companies_NNS will_MD all_DT of_IN remuneration_NN which_WDT is_VBZ consistent_JJ with_IN the_DT companys_NNS scale_NN and_CC scope_NN of_IN Dr_NNP Garnier_NNP and_CC Mr_NNP Coombe_NNP have_VBP agreed_VBN to_TO changes_NNS in_IN their_PRP$ own_JJ The_DT Committee_NNP will_MD apply_VB this_DT policy_NN on_IN a_DT consistent_JJ and_CC transparent_JJ the_DT shares_NNS vest_NN ._.
When_WRB determining_VBG vesting_NN levels_NNS ,_, the_DT Committee_NNP will_MD operations_NNS ,_, meets_VBZ the_DT recruitment_NN needs_NNS of_IN the_DT business_NN and_CC is_VBZ closely_RB contractual_JJ terms_NNS without_IN compensation_NN to_TO bring_VB their_PRP$ contractual_JJ basis_NN ._.
Any_DT significant_JJ change_NN will_MD be_VB discussed_VBN with_IN shareholders_NNS in_IN have_VBP regard_NN for_IN the_DT companys_NNS underlying_VBG financial_JJ performance_NN ._.
aligned_VBN with_IN the_DT shareholder_NN guidelines_NNS ._.
terms_NNS broadly_RB in_IN line_NN with_IN the_DT new_JJ contractual_JJ framework_NN ,_, including_VBG the_DT advance_NN of_IN implementation_NN ._.
reduction_NN of_IN contractual_JJ notice_NN period_NN from_IN 24_CD to_TO 12_CD calendar_NN months_NNS ._.
Prior_RB to_TO 2003_CD ,_, performance_NN share_NN awards_NNS were_VBD in_IN two_CD parts_NNS :_: half_NN could_MD 2003_CD Independent_NNP review_NN of_IN executive_NN remuneration_NN However_RB ,_, to_TO honor_VB certain_JJ aspects_NNS of_IN their_PRP$ old_JJ contractual_JJ terms_NNS there_RB Pay_VB and_CC performance_NN comparators_NNS be_VB earned_VBN by_IN reference_NN to_TO GlaxoSmithKline_NNP 's_POS TSR_NNP performance_NN compared_VBN As_IN indicated_VBN in_IN the_DT 2002_CD Remuneration_NNP Report_NNP ,_, the_DT Committee_NNP appointed_VBN are_VBP a_DT number_NN of_IN individual_JJ features_NNS which_WDT will_MD be_VB retained_VBN ._.
In_IN the_DT event_NN The_DT following_JJ table_NN sets_VBZ out_RP the_DT companies_NNS used_VBN for_IN pay_NN and_CC performance_NN with_IN the_DT FTSE_NNP 100_CD and_CC the_DT other_JJ half_NN of_IN the_DT award_NN was_VBD dependent_JJ upon_IN Deloitte_NNP &_CC Touche_NNP LLP_NNP Deloitte_NNP to_TO conduct_VB a_DT comprehensive_JJ independent_JJ of_IN early_JJ termination_NN by_IN the_DT company_NN ,_, Dr_NNP Garnier_NNP and_CC Mr_NNP Coombe_NNP would_MD comparison_NN :_: the_DT companys_NNS business_NN performance_NN EPS_NNP growth_NN ._.
review_NN of_IN the_DT remuneration_NN of_IN the_DT Executives_NNS of_IN GlaxoSmithKline_NNP ._.
Deloitte_NNP receive_VB ,_, in_IN respect_NN of_IN that_DT 12_CD months_NNS notice_NN ,_, a_DT cash_NN sum_NN representing_VBG Market_NN Cap_NNP reported_VBD exclusively_RB to_TO the_DT Committee_NNP and_CC the_DT Chairman_NNP of_IN the_DT company_NN ._.
annual_JJ salary_NN ,_, on_IN target_NN bonus_NN and_CC pension_NN contributions_NNS ._.
31.12.03_CD The_DT share_NN options_NNS granted_VBN in_IN 2003_CD to_TO the_DT Executives_NNS are_VBP linked_VBN to_TO the_DT Deloitte_NNP reviewed_VBD all_DT aspects_NNS of_IN the_DT remuneration_NN policy_NN ,_, each_DT element_NN of_IN Company_NN Country_NN m_NN achievement_NN of_IN compound_JJ annual_JJ EPS_NNP growth_NN over_IN the_DT performance_NN remuneration_NN ,_, the_DT performance_NN measures_NNS used_VBN and_CC the_DT terms_NNS and_CC TSR_NNP performance_NN graph_NN Abbott_NNP Laboratories_NNP USA_NNP 40,700_CD period_NN ,_, which_WDT is_VBZ the_DT three_CD years_NNS following_VBG the_DT grant_NN of_IN an_DT option_NN ._.
conditions_NNS of_IN the_DT Executives_NNS contracts_NNS ._.
The_DT following_JJ graph_NN sets_VBZ out_RP the_DT performance_NN of_IN the_DT company_NN relative_JJ AstraZeneca_NNP UK_NNP 45,465_CD to_TO the_DT FTSE_NNP 100_CD index_NN of_IN which_WDT the_DT company_NN is_VBZ a_DT constituent_NN and_CC ,_, for_IN Aventis_NNP France_NNP 29,593_CD When_WRB setting_VBG EPS_NNP targets_VBZ the_DT Committee_NNP will_MD consider_VB the_DT companys_NNS Their_PRP$ review_NN also_RB included_VBD consideration_NN of_IN the_DT relevant_JJ comparator_NN information_NN ,_, to_TO the_DT median_NN of_IN the_DT performance_NN comparator_NN group_NN since_IN Bristol-Myers_NNP Squibb_NNP USA_NNP 30,985_CD internal_JJ projections_NNS and_CC analysts_NNS forecasts_NNS for_IN GlaxoSmithKlines_NNP EPS_NNP companies_NNS for_IN performance_NN measurement_NN and_CC pay_VB benchmarking_VBG for_IN the_DT merger_NN on_IN 27th_JJ December_NNP 2000_CD ._.
The_DT graph_NN has_VBZ been_VBN prepared_VBN in_IN Eli_NNP Lilly_NNP USA_NNP 44,119_CD performance_NN as_RB well_RB as_IN analysts_NNS forecasts_NNS for_IN the_DT pharmaceutical_JJ industry_NN ._.
accordance_NN with_IN the_DT Regulations_NNPS and_CC is_VBZ not_RB an_DT indication_NN of_IN the_DT likely_JJ GlaxoSmithKline_NNP UK_NNP 76,153_CD vesting_NN of_IN awards_NNS granted_VBN under_IN any_DT of_IN the_DT companys_NNS incentive_NN plans_NNS ._.
Johnson_NNP &_CC Johnson_NNP USA_NNP 85,661_CD For_IN the_DT 2003_CD grant_NN ,_, vesting_VBG increases_NNS on_IN a_DT straight_JJ line_NN basis_NN for_IN EPS_NNP Deloittes_NNPS independent_JJ review_NN produced_VBD the_DT following_VBG key_JJ findings_NNS :_: Merck_NNP USA_NNP 57,427_CD performance_NN between_IN the_DT hurdles_NNS set_VBN out_RP in_IN the_DT table_NN below_IN ._.
the_DT link_NN between_IN pay_NN and_CC performance_NN needed_VBN strengthening_NN :_: Novartis_NNP Switzerland_NNP 68,457_CD 100_CD the_DT potential_NN for_IN payment_NN for_IN failure_NN needed_VBN addressing_VBG :_: Annualised_NNP Percentage_NN of_IN Pfizer_NNP USA_NNP 150,627_CD stronger_JJR alignment_NN to_TO UK_NNP best_JJS practice_NN and_CC shareholder_NN guidelines_NNS growth_NN in_IN EPS_NNP ._.
award_NN vesting_NN 90_CD Roche_NNP Holdings_NNP Switzerland_NNP 39,658_CD was_VBD needed_VBN :_: Sanofi-Synthelabo_NNP France_NNP 30,811_CD RPI_NNP 5_CD %_NN 100_CD %_NN 80_CD other_JJ global_JJ pharmaceutical_JJ companies_NNS are_VBP the_DT primary_JJ market_NN Schering-Plough_NNP USA_NNP 14,276_CD RPI_NNP 4_CD %_NN 75_CD %_NN for_IN talent_NN :_: and_CC Takeda_NNP Chemical_NNP Industries_NNPS Japan_NNP 19,684_CD RPI_NNP 3_CD %_NN 50_CD %_NN 70_CD the_DT long-term_JJ incentive_NN opportunity_NN was_VBD uncompetitive_JJ ._.
Wyeth_NNP USA_NNP 31,584_CD RPI_NNP 3_CD %_NN 0_CD %_NN 60_CD 31_CD 12_CD 00_CD 31_CD 12_CD 01_CD 31_CD 12_CD 02_CD 31_CD 12_CD 03_CD Remuneration_NN policy_NN GSK_NNP Total_NNP Return_NN FTSE_NNP 100_CD Total_JJ Return_NN Index_NNP GSK_NNP Performance_NNP Comparator_NNP Group_NNP GlaxoSmithKlines_NNP Executive_NNP remuneration_NN consists_VBZ of_IN the_DT This_DT performance_NN condition_NN is_VBZ substantially_RB consistent_JJ with_IN UK_NNP shareholder_NN following_VBG components_NNS :_: guidelines_NNS and_CC expectations_NNS and_CC is_VBZ considerably_RB more_RBR demanding_VBG than_IN Principles_NNPS any_DT operated_VBN by_IN other_JJ global_JJ pharmaceutical_JJ companies_NNS ._.
This_DT change_NN is_VBZ The_DT Committee_NNP considered_VBD the_DT findings_NNS and_CC established_VBN three_CD core_NN Base_NNP salary_NN consistent_JJ with_IN the_DT new_JJ policy_NN of_IN providing_VBG pay_NN for_IN performance_NN and_CC only_RB principles_NNS which_WDT underpin_VBP the_DT new_JJ remuneration_NN policy_NN for_IN Base_NNP salaries_NNS will_MD be_VB set_VBN by_IN reference_NN to_TO the_DT median_NN for_IN the_DT relevant_JJ for_IN performance_NN ._.
For_IN Executives_NNS this_DT is_VBZ the_DT pharmaceutical_JJ pay_NN comparator_NN group_NN ._.
pay_NN for_IN performance_NN and_CC only_RB for_IN performance_NN :_: Base_NNP salary_NN is_VBZ the_DT only_JJ element_NN of_IN remuneration_NN that_WDT is_VBZ fixed_VBN ._.
robust_JJ and_CC transparent_JJ governance_NN structures_NNS :_: and_CC 18_CD Annual_JJ Review_NNP 2003_CD Annual_JJ Review_NNP 2003_CD 19_CD Summary_NNP Remuneration_NNP Report_NNP FOR_IN THE_DT YEAR_NN TO_TO 31ST_CD DECEMBER_NNP 2003_CD Corporate_JJ governance_NN Annual_JJ remuneration_NNP Board_NNP committees_NNS Governance_NNP and_CC policy_NN 2003_CD 2002_CD Audit_NNP Committee_NNP Total_NNP Total_NNP The_NNP Board_NNP and_CC Executive_NNP Fees_NNS and_CC Other_JJ Annual_JJ annual_JJ annual_JJ The_DT Audit_NNP Committee_NNP reviews_VBZ the_DT financial_JJ and_CC internal_JJ reporting_NN process_NN ,_, salary_NN benefits_NNS bonus_NN remuneration_NN remuneration_NN The_DT Directors_NNS are_VBP listed_VBN under_IN The_DT Board_NNP on_IN page_NN 16_CD ._.
the_DT system_NN of_IN internal_JJ control_NN and_CC management_NN of_IN risks_NNS and_CC the_DT external_JJ Directors_NNS of_IN GlaxoSmithKline_NNP 000 000 000 000_CD 000_CD and_CC internal_JJ audit_NN process_NN ._.
The_DT Committee_NNP also_RB proposes_VBZ to_TO the_DT Executive_NNP Directors_NNS The_DT Board_NNP is_VBZ responsible_JJ for_IN the_DT Groups_NNS system_NN of_IN corporate_JJ governance_NN shareholders_NNS the_DT appointment_NN of_IN the_DT external_JJ auditors_NNS and_CC is_VBZ directly_RB Dr_JJ J_NNP P_NNP Garnier_NNP 916_CD 386_CD 1,485_CD 2,787_CD 2,452_CD and_CC is_VBZ ultimately_RB accountable_JJ for_IN the_DT Groups_NNS activities_NNS ,_, strategy_NN and_CC responsible_JJ for_IN their_PRP$ remuneration_NN and_CC oversight_NN of_IN their_PRP$ work_NN ._.
The_DT Mr_NNP J_NNP D_NNP Coombe_NNP 490_CD 17_CD 730_CD 1,237_CD 947_CD financial_JJ performance_NN ._.
Committee_NNP consists_VBZ entirely_RB of_IN independent_JJ Non-Executive_JJ Directors_NNS ._.
The_DT Board_NNP comprises_VBZ three_CD Executive_NNP and_CC 11_CD Non-Executive_JJ Directors_NNS ._.
Current_JJ Non-Executive_JJ Directors_NNS Whilst_VBP the_DT Board_NNP considers_VBZ all_DT of_IN its_PRP$ Non-Executive_JJ Directors_NNS to_TO be_VB Sir_NNP Christopher_NNP Hogg_NNP 374 374 252_CD Remuneration_NNP Committee_NNP independent_JJ in_IN character_NN and_CC judgement_NN ,_, in_IN accordance_NN with_IN the_DT Dr_NNP M_NNP Barzach_NNP 107 107 100_CD The_DT Remuneration_NNP Committee_NNP determines_VBZ the_DT terms_NNS of_IN service_NN and_CC 1998_CD Code_NNP ,_, it_PRP has_VBZ determined_VBN that_IN four_CD Non-Executive_JJ Directors_NNS -_: Mr_NNP L_NNP Culp_NNP 29_CD 29_CD remuneration_NN of_IN the_DT Executive_NNP Directors_NNS and_CC members_NNS of_IN the_DT CET_NNP and_CC ,_, the_DT Chairman_NNP ,_, Dr_NNP Barzach_NNP ,_, Mr_NNP McHenry_NNP and_CC Dr_NNP Shapiro_NNP -_: should_MD not_RB Mr_NNP C_NNP Davis_NNP 29_CD 29_CD with_IN the_DT assistance_NN of_IN external_JJ independent_JJ advisors_NNS ,_, it_PRP evaluates_VBZ and_CC be_VB considered_VBN as_IN independent_JJ under_IN the_DT 2003_CD Code_NNP ._.
In_IN the_DT case_NN of_IN Sir_NNP Peter_NNP Job_NNP 57_CD 57_CD 59_CD makes_VBZ recommendations_NNS to_TO the_DT Board_NNP on_IN overall_JJ executive_NN remuneration_NN the_DT Chairman_NNP and_CC Mr_NNP McHenry_NNP this_DT is_VBZ due_JJ to_TO their_PRP$ length_NN of_IN service_NN with_IN Mr_NNP J_NNP H_NNP McArthur_NNP 62_CD 62_CD 62_CD policy_NN ._.
The_DT Committee_NNP consists_VBZ entirely_RB of_IN independent_JJ Non-Executive_JJ GlaxoSmithKline_NNP and_CC its_PRP$ predecessor_NN companies_NNS and_CC ,_, in_IN the_DT case_NN of_IN Drs_NNP Mr_NNP D_NNP F_NN McHenry_NNP 65_CD 65_CD 62_CD Directors_NNS ._.
It_PRP meets_VBZ at_IN least_JJS four_CD times_NNS a_DT year_NN and_CC otherwise_RB as_RB necessary_JJ ._.
Barzach_NNP and_CC Shapiro_NNP ,_, due_JJ to_TO remuneration_VB that_IN they_PRP have_VBP received_VBN from_IN Sir_NNP Ian_NNP Prosser_NNP 66_CD 66_CD 59_CD the_DT Group_NNP in_IN other_JJ capacities_NNS ._.
These_DT four_CD Non-Executive_JJ Directors_NNS have_VBP Dr_VBN R_NN Schmitz_NNP 67_CD 67_CD 69_CD Nominations_NNPS Committee_NNP resigned_VBD their_PRP$ positions_NNS on_IN Board_NNP Committees_NNS where_WRB independence_NN is_VBZ Dr_NNP L_NNP Shapiro_NNP 109 109 118_CD The_DT Nominations_NNPS Committee_NNP reviews_VBZ the_DT structure_NN ,_, size_NN and_CC composition_NN required_VBN under_IN the_DT 2003_CD Code_NNP ._.
Sir_NNP Robert_NNP Wilson_NNP 10_CD 10_CD of_IN the_DT Board_NNP and_CC the_DT appointment_NN of_IN members_NNS of_IN the_DT Board_NNP and_CC the_DT CET_NNP ,_, and_CC makes_VBZ recommendations_NNS to_TO the_DT Board_NNP as_IN appropriate_JJ ._.
The_DT 975 975 781_CD The_NNP Board_NNP considers_VBZ that_IN Mr_NNP McArthur_NNP ,_, Dr_NNP Schmitz_NNP ,_, Mr_NNP Culp_NNP ,_, Mr_NNP Davis_NNP ,_, Committee_NNP also_RB monitors_VBZ the_DT planning_NN of_IN succession_NN to_TO the_DT Board_NNP and_CC Former_NNP Non-Executive_NNP Directors_NNS Sir_NNP Peter_NNP Job_NNP ,_, Sir_NNP Ian_NNP Prosser_NNP and_CC Sir_NNP Robert_NNP Wilson_NNP are_VBP independent_JJ under_IN Senior_NNP Management_NNP ._.
The_DT Committee_NNP consists_VBZ entirely_RB of_IN Non-Executive_JJ Sir_NNP Richard_NNP Sykes_NNP 958 958 162_CD the_DT 2003_CD Code_NNP ._.
The_DT Board_NNP noted_VBD that_IN Dr_NNP Schmitz_NNP and_CC Mr_NNP McArthur_NNP are_VBP Directors_NNS of_IN whom_WP a_DT majority_NN are_VBP independent_JJ and_CC meets_VBZ at_IN least_JJS once_RB Sir_NNP Roger_NNP Hurn_NNP 50_CD 50_CD 121_CD associated_VBN as_IN non-executive_JJ directors_NNS of_IN other_JJ public_JJ companies_NNS -_: Rohm_NNP a_DT year_NN to_TO consider_VB succession_NN planning_NN and_CC otherwise_RB as_RB necessary_JJ ._.
Sir_NNP Peter_NNP Walters_NNP 53_CD and_CC Haas_NNP Company_NNP and_CC Cabot_NNP Corporation_NNP -_: but_CC do_VBP not_RB consider_VB the_DT Mr_NNP P_NNP A_NNP Allaire_NNP 28_CD 28_CD 68_CD associations_NNS to_TO be_VB of_IN sufficient_JJ economic_JJ significance_NN to_TO compromise_VB Financial_NNP Results_NNS Committee_NNP Mr_NNP D_NNP C_NNP Bonham_NNP 5_CD their_PRP$ independence_NN ._.
The_DT Financial_NNP Results_NNS Committee_NNP reviews_VBZ and_CC approves_VBZ ,_, on_IN behalf_NN of_IN Mr_NNP J_NNP A_NNP Young_NNP 31_CD the_DT Board_NNP ,_, the_DT Annual_JJ Report_NNP and_CC Form_NN 20-F_NN ,_, the_DT Annual_JJ Review_NNP and_CC At_IN the_DT date_NN of_IN publication_NN ,_, a_DT majority_NN of_IN the_DT Board_NNP members_NNS ,_, excluding_VBG 78_CD 958_CD 1,036_CD 440_CD the_DT convening_VBG of_IN the_DT AGM_NNP ,_, together_RB with_IN the_DT preliminary_JJ and_CC quarterly_JJ the_DT Chairman_NNP ,_, were_VBD independent_JJ Non-Executive_JJ Directors_NNS ,_, in_IN accordance_NN Total_JJ Non-Executive_JJ Directors_NNS 1,053_CD 958_CD 2,011_CD 1,221_CD statements_NNS of_IN trading_NN results_NNS ._.
Each_DT Director_NNP is_VBZ a_DT member_NN of_IN the_DT with_IN the_DT recommendations_NNS of_IN the_DT 2003_CD Code_NNP ._.
Committee_NNP and_CC the_DT quorum_NN for_IN a_DT meeting_NN is_VBZ any_DT three_CD members_NNS ._.
To_TO be_VB Total_JJ remuneration_NN 2,459_CD 1,361_CD 2,215_CD 6,035_CD 4,620_CD quorate_NN ,_, each_DT meeting_NN must_MD include_VB the_DT Chairman_NNP or_CC the_DT Chairman_NNP of_IN Dr_NNP Barzach_NNP ,_, Mr_NNP McArthur_NNP and_CC Mr_NNP McHenry_NNP will_MD be_VB retiring_VBG from_IN the_DT Board_NNP the_DT Audit_NNP Committee_NNP and_CC the_DT CEO_NNP or_CC the_DT CFO_NNP ._.
The_DT Committee_NNP meets_VBZ at_IN the_DT conclusion_NN of_IN the_DT Annual_JJ General_NNP Meeting_VBG AGM_NNP on_IN 17th_JJ May_NNP Following_VBG the_DT merger_NN ,_, those_DT participants_NNS in_IN the_DT legacy_NN schemes_NNS who_WP elected_VBD to_TO exchange_VB their_PRP$ legacy_NN options_NNS for_IN options_NNS over_IN GlaxoSmithKline_NNP as_RB necessary_JJ ._.
Following_VBG their_PRP$ retirement_NN and_CC assuming_VBG that_IN the_DT other_JJ Directors_NNS shares_NNS were_VBD granted_VBN an_DT additional_JJ cash_NN benefit_NN equal_JJ to_TO 10_CD per_IN cent_NN of_IN the_DT grant_NN price_NN of_IN the_DT original_JJ option_NN ._.
This_DT additional_JJ benefit_NN is_VBZ known_VBN seeking_VBG re-election_NN at_IN the_DT AGM_NNP are_VBP elected_VBN or_CC re-elected_VBN ,_, the_DT Board_NNP will_MD as_IN the_DT Exchange_NNP Offer_NN Incentive_NNP EOI_NNP and_CC is_VBZ only_RB payable_JJ when_WRB the_DT new_JJ option_NN is_VBZ exercised_VBN or_CC lapses_NNS above_IN market_NN value_NN ._.
To_TO qualify_VB for_IN this_DT Corporate_JJ Responsibility_NNP Committee_NNP comprise_VBP three_CD Executive_NNP Directors_NNS and_CC eight_CD Non-Executive_JJ Directors_NNS with_IN additional_JJ cash_NN benefit_NN ,_, participants_NNS had_VBD to_TO retain_VB these_DT options_NNS until_IN at_IN least_JJS the_DT second_JJ anniversary_NN of_IN the_DT effective_JJ date_NN of_IN the_DT merger_NN ._.
During_IN The_DT Corporate_JJ Responsibility_NNP Committee_NNP formerly_RB the_DT Corporate_JJ Social_NNP a_DT majority_NN of_IN the_DT Board_NNP ,_, excluding_VBG the_DT Chairman_NNP ,_, being_VBG independent_JJ the_DT year_NN Dr_NNP J_NNP P_NNP Garnier_NNP received_VBD 182,478_CD relating_VBG to_TO options_NNS exercised_VBN and_CC Sir_NNP Richard_NNP Sykes_NNP received_VBD 940,499_CD ,_, under_IN the_DT EOI_NNP ,_, as_IN a_DT result_NN of_IN Responsibility_NNP Committee_NNP consists_VBZ entirely_RB of_IN Non-Executive_JJ Directors_NNS and_CC Non-Executive_JJ Directors_NNS ._.
Sir_NNP Ian_NNP Prosser_NNP is_VBZ the_DT Senior_JJ Independent_NNP Director_NNP ._.
his_PRP$ options_NNS lapsing_NN above_IN market_NN value_NN ._.
Those_DT amounts_NNS are_VBP included_VBN in_IN other_JJ benefits_NNS in_IN the_DT table_NN above_IN ._.
provides_VBZ a_DT Board_NNP level_NN forum_NN for_IN the_DT regular_JJ review_NN of_IN external_JJ issues_NNS that_WDT have_VBP the_DT potential_NN for_IN serious_JJ impact_NN upon_IN the_DT Groups_NNS business_NN and_CC From_IN 1st_CD June_NNP 2002_CD Sir_NNP Richard_NNP Sykes_NNP was_VBD appointed_VBN Senior_JJ Advisor_NNP to_TO the_DT company_NN ,_, at_IN a_DT salary_NN of_IN 49,000_CD per_IN annum_NN which_WDT he_PRP received_VBD in_IN Board_NNP process_NN reputation_NN ._.
The_DT Committee_NNP is_VBZ also_RB responsible_JJ for_IN annual_JJ governance_NN ,_, addition_NN to_TO the_DT fees_NNS and_CC salary_NN above_IN which_WDT he_PRP received_VBD as_IN a_DT former_JJ director_NN ._.
The_DT Board_NNP meets_VBZ at_IN least_JJS six_CD times_NNS a_DT year_NN ._.
It_PRP has_VBZ a_DT formal_JJ schedule_NN oversight_NN of_IN the_DT Groups_NNS worldwide_JJ donations_NNS and_CC community_NN support_NN ._.
of_IN matters_NNS reserved_VBN to_TO it_PRP for_IN decision_NN but_CC otherwise_RB delegates_NNS specific_JJ The_DT Committee_NNP meets_VBZ formally_RB twice_RB a_DT year_NN and_CC has_VBZ further_JJ meetings_NNS Non-Executive_JJ Directors_NNS are_VBP required_VBN to_TO receive_VB a_DT significant_JJ part_NN of_IN their_PRP$ fees_NNS in_IN the_DT form_NN of_IN shares_NNS and_CC ADSs_NNS and_CC may_MD also_RB elect_VB to_TO invest_VB part_NN responsibilities_NNS to_TO Board_NNP committees_NNS ,_, as_IN described_VBN below_IN ._.
The_DT Board_NNP and_CC consultations_NNS as_IN required_VBN ._.
or_CC all_DT of_IN the_DT balance_NN of_IN their_PRP$ fees_NNS in_IN the_DT form_NN of_IN shares_NNS and_CC ADSs_NNS ._.
The_DT value_NN of_IN these_DT shares_NNS and_CC ADSs_NNS at_IN the_DT dates_NNS of_IN award_NN are_VBP included_VBN in_IN fees_NNS works_VBZ to_TO an_DT agreed_NN business_NN agenda_NN in_IN reviewing_VBG the_DT key_JJ activities_NNS of_IN and_CC salary_NN above_IN ._.
These_DT shares_NNS and_CC ADSs_NNS are_VBP not_RB paid_VBN out_RP until_IN the_DT Directors_NNS retirement_NN from_IN the_DT Board_NNP ._.
the_DT business_NN ,_, and_CC receives_VBZ papers_NNS and_CC presentations_NNS to_TO enable_VB it_PRP to_TO do_VB Corporate_JJ Administration_NNP &_CC Transactions_NNS Committee_NNP so_RB effectively_RB ._.
The_DT Board_NNP considers_VBZ and_CC reviews_VBZ the_DT work_NN undertaken_VBN by_IN Following_VBG their_PRP$ retirement_NN on_IN 5th_JJ June_NNP 2003_CD ,_, Sir_NNP Roger_NNP Hurn_NNP and_CC Mr_NNP Allaire_NNP received_VBD the_DT then_RB value_NN of_IN their_PRP$ shares_NNS and_CC ADSs_NNS as_IN awarded_VBN under_IN The_DT Corporate_JJ Administration_NNP &_CC Transactions_NNS Committee_NNP reviews_VBZ and_CC its_PRP$ Committees_NNS ._.
the_DT Non-Executive_NNP Directors_NNS share_VBP arrangements_NNS and_CC equivalent_JJ SmithKline_NNP Beecham_NNP arrangements_NNS ._.
Sir_NNP Roger_NNP Hurn_NNP elected_VBD to_TO receive_VB his_PRP$ approves_VBZ matters_NNS in_IN connection_NN with_IN the_DT administration_NN of_IN the_DT Groups_NNS entitlement_NN in_IN instalments_NNS and_CC Mr_NNP Allaire_NNP elected_VBD to_TO receive_VB his_PRP$ full_JJ entitlement_NN immediately_RB ._.
business_NN ,_, and_CC of_IN certain_JJ corporate_JJ transactions_NNS ._.
The_DT Committee_NNP consists_VBZ The_DT Company_NNP Secretary_NNP is_VBZ responsible_JJ to_TO the_DT Board_NNP and_CC is_VBZ available_JJ of_IN the_DT Directors_NNS ,_, Corporate_NNP Executive_NNP Team_NNP members_NNS and_CC the_DT Company_NN to_TO individual_JJ Directors_NNS in_IN respect_NN of_IN Board_NNP procedures_NNS ._.
The_DT Company_NN In_IN addition_NN to_TO annual_JJ compensation_NN ,_, GlaxoSmithKline_NNP operates_VBZ share_NN plans_NNS to_TO provide_VB incentives_NNS to_TO Executive_NNP Directors_NNS to_TO achieve_VB longer-term_JJ Secretary_NNP ._.
The_DT Committee_NNP meets_VBZ as_RB necessary_JJ ._.
Secretary_NNP is_VBZ Simon_NNP Bicknell_NNP who_WP was_VBD appointed_VBN in_IN May_NNP 2000_CD ._.
He_PRP is_VBZ a_DT growth_NN in_IN shareholder_NN value_NN ._.
Gains_NNS under_IN such_JJ plans_NNS are_VBP recognized_VBN on_IN exercise_NN or_CC award_NN ,_, but_CC reflect_VBP value_NN earned_VBN over_IN a_DT period_NN of_IN years_NNS ._.
The_DT timing_NN of_IN exercise_NN is_VBZ normally_RB at_IN the_DT discretion_NN of_IN the_DT Director_NNP ._.
Gains_NNS in_IN 2003_CD on_IN exercise_NN of_IN options_NNS were_VBD :_: share_NN option_NN plans_VBZ 3,097,260_CD 2002_CD barrister_NN and_CC joined_VBD the_DT Group_NNP in_IN 1984_CD ._.
He_PRP is_VBZ secretary_NN to_TO all_PDT the_DT Board_NNP Corporate_NNP Executive_NNP Team_NNP nil_NN :_: long-term_JJ incentive_NN plan_NN 256,134_CD 2002_CD 293,370_CD ._.
Full_JJ details_NNS of_IN the_DT awards_NNS granted_VBN under_IN the_DT companys_NNS share_NN plans_VBZ during_IN 2003_CD Committees_NNS ._.
The_DT Corporate_NNP Executive_NNP Team_NNP CET_NNP assists_VBZ the_DT CEO_NNP in_IN the_DT executive_NN can_MD be_VB found_VBN in_IN the_DT Annual_JJ Report_NNP 2003_CD -_: refer_VBP to_TO Shareholder_NN information_NN ._.
The_DT CET_NNP meets_VBZ 11_CD times_NNS a_DT year_NN ._.
The_DT members_NNS and_CC their_PRP$ responsibilities_NNS are_VBP given_VBN on_IN page_NN 17_CD ._.
The_DT accrued_VBN annual_JJ benefits_NNS under_IN the_DT defined_VBN benefit_NN schemes_NNS operated_VBN by_IN the_DT Group_NNP were_VBD :_: Dr_VB J_NNP P_NNP Garnier_NNP 565,294_CD :_: Mr_NNP J_NNP D_NNP Coombe_NNP 317,211_CD ._.
In_IN addition_NN ,_, Dr_NNP J_NNP P_NNP Garnier_NNP is_VBZ also_RB a_DT member_NN of_IN a_DT money_NN purchase_NN scheme_NN into_IN which_WDT contributions_NNS of_IN 88,609_CD were_VBD paid_VBN ._.
Remuneration_NNP of_IN Directors_NNS None_NN of_IN the_DT above_JJ Directors_NNS received_VBD expenses_NNS during_IN the_DT year_NN requiring_VBG separate_JJ disclosure_NN as_IN defined_VBN by_IN the_DT Regulations_NNPS ._.
Information_NN on_IN the_DT remuneration_NN of_IN Directors_NNS is_VBZ given_VBN in_IN the_DT Summary_NNP Remuneration_NNP Report_NNP on_IN pages_NNS 18_CD to_TO 20_CD ._.
20_CD Annual_JJ Review_NNP 2003_CD Annual_JJ Review_NNP 2003_CD 21_CD Business_NN operating_NN review_NN Business_NN operating_VBG review_NN Products_NNPS drive_VBP growth_NN Total_JJ pharmaceutical_JJ turnover_NN grew_VBD five_CD per_IN cent_NN in_IN 2003_CD to_TO just_RB over_IN 18_CD billion_CD -_: a_DT good_JJ performance_NN given_VBN the_DT generic_JJ erosion_NN Pharmaceutical_NNP turnover_NN by_IN therapeutic_JJ area_NN Consumer_NN Healthcare_NNP 2003_CD 2002_CD %_NN CER_NNP of_IN two_CD of_IN GSKs_NNS biggest_JJS products_NNS ,_, Augmentin_NNP and_CC Paxil_NNP ._.
Excluding_VBG m_FW m_FW Growth_NN Total_JJ Consumer_NN Healthcare_NNP sales_NNS grew_VBD four_CD per_IN cent_NN in_IN 2003_CD to_TO 3.3_CD billion_CD ._.
CNS_NNP 4,455_CD 4,511_CD 4_CD sales_NNS of_IN these_DT products_NNS ,_, pharmaceutical_JJ turnover_NN grew_VBD 9_CD per_IN cent_NN ._.
Respiratory_NNP 4,417_CD 3,987_CD 14_CD Over-the-counter_NN medicine_NN sales_NNS were_VBD 1.6_CD billion_CD ,_, up_RB two_CD per_IN cent_NN ._.
Anti-virals_NNS 2,349_CD 2,299_CD 5_CD Sales_NNS of_IN smoking_NN control_NN and_CC gastro-intestinal_JJ products_NNS were_VBD down_RB Anti-bacterials_JJ 1,815_CD 2,210_CD 16_CD significantly_RB in_IN the_DT USA_NNP ,_, primarily_RB due_JJ to_TO flat_JJ market_NN conditions_NNS and_CC Within_IN anti-virals_NNS ,_, HIV_NNP medicines_NNS grew_VBD across_IN all_DT regions_NNS and_CC totalled_VBD Pharmaceuticals_NNP Vaccines_NNP 1,123_CD 1,080_CD 2_CD private_JJ label_NN competition_NN ._.
Growth_NN from_IN smoking_NN control_NN products_NNS 1.5_CD billion_CD in_IN sales_NNS ,_, up_RB six_CD per_IN cent_NN ._.
Sales_NNS of_IN Trizivir_NNP ,_, GSKs_NNP triple_JJ Oncology_NNP and_CC emesis_NN 1,001_CD 977_CD 9_CD recently_RB launched_VBN in_IN Europe_NNP and_CC sales_NNS of_IN dermatological_JJ products_NNS combination_NN therapy_NN ,_, grew_VBD 22_CD per_IN cent_NN ._.
Global_JJ sales_NNS of_IN Valtrex_NNP ,_, which_WDT In_IN the_DT central_JJ nervous_JJ system_NN therapy_NN area_NN ,_, sales_NNS grew_VBD four_CD per_IN cent_NN ._.
Sales_NNS Metabolic_NNP 1,079_CD 960_CD 20_CD acquired_VBN earlier_RBR this_DT year_NN helped_VBD to_TO offset_VB these_DT declines_NNS ._.
Oral_JJ care_NN sales_NNS received_VBD FDA_NNP approval_NN in_IN August_NNP 2003_CD to_TO reduce_VB the_DT risk_NN of_IN transmission_NN of_IN Seroxat_NNP Paxil_NNP ,_, a_DT leading_VBG product_NN for_IN depression_NN and_CC anxiety_NN disorders_NNS ,_, Cardiovascular_NNP and_CC urogenital_JJ 771_CD 661_CD 22_CD were_VBD 1.1_CD billion_CD ,_, up_RB three_CD per_IN cent_NN ._.
GSKs_NNP Sensodyne_NNP brand_NN continues_VBZ of_IN genital_JJ herpes_NNS ,_, rose_VBD 23_CD per_IN cent_NN ._.
US_NNP sales_NNS declined_VBD nine_CD per_IN cent_NN to_TO 1,179_CD million_CD Other_JJ 1,171_CD 1,310_CD 8_CD to_TO grow_VB in_IN all_DT regions_NNS ._.
Nutritional_NNP healthcare_NN products_NNS grew_VBD nine_CD per_IN following_VBG the_DT launch_NN of_IN a_DT generic_JJ paroxetine_NN in_IN September_NNP 2003_CD ._.
Lucozade_NNP Sport_NNP and_CC Lucozade_NNP Hydroactive_NNP a_DT sustained_VBN release_NN formulation_NN ,_, increased_VBD its_PRP$ share_NN of_IN total_JJ prescriptions_NNS continued_VBD to_TO drive_VB growth_NN in_IN this_DT category_NN ._.
Several_JJ significant_JJ product_NN launches_NNS and_CC filings_NNS planned_VBN for_IN since_IN the_DT generic_JJ paroxetine_JJ launch_NN from_IN 33_CD per_IN cent_NN to_TO 37_CD per_IN cent_NN ._.
Paxil_NNP 2004_CD include_VBP :_: CR_NN sales_NNS in_IN 2003_CD were_VBD 387_CD million_CD ._.
European_JJ sales_NNS declined_VBD eight_CD per_IN Legal_JJ proceedings_NNS cent_NN but_CC International_JJ sales_NNS grew_VBD 25_CD per_IN cent_NN led_VBN by_IN continued_VBN strong_JJ Solifenacin_NNP for_IN over-active_JJ bladder_NN Trading_NN profit_NN and_CC EPS_NNP growth_NN in_IN Japan_NNP ._.
Sales_NNS of_IN Wellbutrin_NNP ,_, for_IN depression_NN ,_, grew_VBD 18_CD per_IN cent_NN to_TO The_DT Group_NNP is_VBZ involved_VBN in_IN patent_NN litigation_NN with_IN manufacturers_NNS seeking_VBG to_TO Avandaryl_NNP ,_, a_DT fixed-dose_JJ combination_NN treatment_NN for_IN type_NN 2_CD 953_CD million_CD ._.
Wellbutrin_NNP XL_NNP ,_, a_DT new_JJ improved_VBN formulation_NN ,_, was_VBD launched_VBN market_NN generic_JJ versions_NNS of_IN many_JJ of_IN the_DT Groups_NNS most_RBS important_JJ products_NNS ,_, diabetes_NN Business_NN performance_NN trading_NN profit_NN was_VBD 6.9_CD billion_CD with_IN a_DT growth_NN in_IN 2003_CD and_CC now_RB accounts_VBZ for_IN 40_CD per_IN cent_NN of_IN branded_JJ Wellbutrin_NNP including_VBG Wellbutrin_NNP ,_, Seretide_NNP ,_, Avandia_NNP ,_, Imitrex_NNP ,_, Valtrex_NNP ,_, Lamictal_NNP and_CC of_IN nine_CD per_IN cent_NN ,_, stronger_JJR than_IN turnover_NN growth_NN of_IN five_CD per_IN cent_NN ,_, prescriptions_NNS and_CC 7_CD per_IN cent_NN of_IN sales_NNS in_IN 2003_CD ._.
Limited_JJ generic_JJ competition_NN Epivir_NNP Ziagen_NNP ,_, the_DT first_JJ once-daily_JJ combination_NN HIV_NNP AIDS_NNP Zofran_NNP ,_, prior_RB to_TO the_DT expiration_NN of_IN the_DT Groups_NNS patents_NNS ._.
The_DT Group_NNP is_VBZ demonstrating_VBG an_DT improved_JJ trading_NN margin_NN of_IN 0.7_CD points_NNS to_TO 32.3_CD per_IN cent_NN to_TO Wellbutrin_NNP began_VBD in_IN the_DT USA_NNP in_IN January_NNP 2004_CD for_IN the_DT 100_CD mg_NN dose_NN ._.
currently_RB a_DT defendant_NN in_IN a_DT number_NN of_IN product_NN liability_NN lawsuits_NNS ,_, including_VBG compared_VBN with_IN 2002_CD ._.
This_DT was_VBD principally_RB due_JJ to_TO cost_VB savings_NNS derived_VBN Generic_JJ competition_NN across_IN all_DT dose_NN forms_NNS of_IN Wellbutrin_NNP SR_NNP is_VBZ expected_VBN at_IN class_NN actions_NNS ,_, that_WDT involve_VBP substantial_JJ claims_NNS for_IN damages_NNS related_VBN to_TO the_DT from_IN merger_NN integration_NN ,_, manufacturing_NN and_CC other_JJ initiatives_NNS ,_, partly_RB offset_VBN any_DT time_NN ._.
Lamictal_NNP ,_, for_IN epilepsy_NN ,_, continued_VBD to_TO grow_VB across_IN all_DT regions_NNS with_IN Groups_NNS pharmaceutical_JJ products_NNS ._.
The_DT Group_NNP is_VBZ also_RB a_DT defendant_NN in_IN by_IN charges_NNS relating_VBG to_TO operational_JJ excellence_NN cost_NN saving_VBG programs_NNS and_CC sales_NNS up_IN 31_CD per_IN cent_NN driven_VBN by_IN the_DT FDA-approved_JJ long_JJ term_NN maintenance_NN anti-trust_JJ actions_NNS filed_VBN following_VBG adverse_JJ outcomes_NNS in_IN prosecution_NN of_IN Anti-bacterial_JJ sales_NNS declined_VBD 16_CD per_IN cent_NN worldwide_NN and_CC 41_CD per_IN cent_NN in_IN higher_JJR pension_NN costs_NNS ._.
Further_RB ,_, the_DT Group_NNP is_VBZ responding_VBG to_TO federal_JJ the_DT USA_NNP ._.
Augmentins_NNP US_NNP sales_NNS were_VBD down_RB 51_CD per_IN cent_NN in_IN the_DT year_NN as_IN a_DT and_CC state_NN governmental_JJ investigations_NNS in_IN the_DT USA_NNP into_IN pricing_NN ,_, marketing_NN result_NN of_IN generic_JJ competition_NN that_WDT began_VBD in_IN the_DT third_JJ quarter_NN of_IN 2002_CD ._.
Full_JJ year_NN business_NN performance_NN earnings_NNS per_IN share_NN EPS_NNP of_IN 82.1_CD pence_NN In_IN respiratory_JJ ,_, GSK_NNP continues_VBZ to_TO be_VB the_DT global_JJ leader_NN in_IN respiratory_JJ and_CC reimbursement_NN of_IN a_DT number_NN of_IN prescription_NN drug_NN products_NNS ._.
See_VB Note_VB In_IN the_DT USA_NNP ,_, GSKs_NNP two_CD new_JJ antibiotics_NNS ,_, Augmentin_NNP ES_NNP for_IN children_NNS and_CC increased_VBD 10_CD per_IN cent_NN ,_, and_CC five_CD per_IN cent_NN in_IN sterling_NN terms_NNS ,_, reflecting_VBG a_DT pharmaceuticals_NNS with_IN sales_NNS of_IN its_PRP$ three_CD key_JJ products_NNS Seretide_NNP Advair_NNP ,_, 30_CD to_TO the_DT Financial_NNP statements_NNS Legal_JJ proceedings_NNS in_IN the_DT Annual_JJ Report_NNP Augmentin_NNP XR_NNP for_IN adults_NNS ,_, recorded_VBN sales_NNS of_IN 237_CD million_CD in_IN 2003_CD in_IN spite_NN weakening_NN of_IN the_DT US_NNP dollar_NN ._.
Full_JJ year_NN statutory_JJ EPS_NNP was_VBD 77.2_CD p_NN ,_, an_DT increase_NN Flixotide_NNP Flovent_NNP and_CC Serevent_NNP amounting_VBG to_TO 3.4_CD billion_CD ,_, up_IN 17_CD per_IN cent_NN ._.
2003_CD for_IN a_DT discussion_NN of_IN proceedings_NNS and_CC governmental_JJ investigations_NNS of_IN generic_JJ competition_NN ._.
Sales_NNS of_IN Seretide_NNP Advair_NNP ,_, GSKs_NNP largest_JJS product_NN ,_, grew_VBD 39_CD per_IN cent_NN to_TO in_IN which_WDT the_DT Group_NNP is_VBZ currently_RB involved_VBN ._.
2.2_CD billion_CD although_IN this_DT contributed_VBD to_TO declines_NNS in_IN Serevent_NNP and_CC Flixotide_NNP ,_, Within_IN vaccines_NNS ,_, Infanrix_NNP Pediarix_NNP grew_VBD 32_CD per_IN cent_NN to_TO 336_CD million_CD ._.
The_DT growth_NN prospects_NNS for_IN Advair_NNP were_VBD further_JJ GSK_NNP delivered_VBD business_NN performance_NN Pediarix_NNP adds_VBZ protection_NN against_IN hepatitis_NNP B_NNP and_CC poliomyelitis_NNS to_TO the_DT strengthened_VBN with_IN an_DT FDA_NNP approval_NN for_IN use_NN in_IN the_DT treatment_NN of_IN Chronic_NNP EPS_NNP growth_NN of_IN 10_CD per_IN cent_NN in_IN line_NN Infanrix_NNP combination_NN and_CC results_NNS in_IN up_RB to_TO six_CD fewer_JJR injections_NNS for_IN infants_NNS ._.
Obstructive_NNP Pulmonary_NNP Disease_NNP COPD_NNP in_IN the_DT fourth_JJ quarter_NN of_IN 2003_CD ._.
Business_NNP performance_NN ,_, which_WDT is_VBZ the_DT primary_JJ performance_NN measure_NN The_DT hepatitis_NN franchise_NN declined_VBD 13_CD per_IN cent_NN reflecting_VBG competitive_JJ with_IN guidance_NN ._.
used_VBN by_IN management_NN ,_, is_VBZ presented_VBN after_IN excluding_VBG merger_NN items_NNS ,_, pressure_NN in_IN the_DT USA_NNP and_CC Europe_NNP ._.
integration_NN and_CC restructuring_NN costs_NNS and_CC disposal_NN of_IN businesses_NNS ._.
Management_NNP believes_VBZ that_IN exclusion_NN of_IN these_DT items_NNS provides_VBZ a_DT better_JJR Taxation_NNP In_IN oncology_NN ,_, sales_NNS of_IN Zofran_NNP grew_VBD 16_CD per_IN cent_NN to_TO 774_CD million_CD ,_, driven_VBN by_IN GSKs_NNS underlying_VBG growth_NN driven_VBN by_IN a_DT broad_JJ portfolio_NN of_IN fast_JJ reflection_NN of_IN the_DT way_NN in_IN which_WDT the_DT business_NN is_VBZ managed_VBN and_CC gives_VBZ an_DT a_DT strong_JJ US_NNP performance_NN ,_, up_RB 20_CD per_IN cent_NN to_TO 575_CD million_CD ._.
growing_VBG ,_, high_JJ value_NN products_NNS :_: indication_NN of_IN the_DT performance_NN of_IN the_DT Group_NNP in_IN terms_NNS of_IN those_DT GSK_NNP has_VBZ open_JJ tax_NN issues_NNS with_IN the_DT revenue_NN authorities_NNS in_IN the_DT USA_NNP ,_, UK_NNP ,_, elements_NNS of_IN revenue_NN and_CC expenditure_NN which_WDT local_JJ management_NN is_VBZ Seretide_NNP Advair_NNP 2.2_CD billion_CD up_IN 39_CD %_NN Japan_NNP and_CC Canada_NNP ,_, but_CC by_IN far_RB the_DT largest_JJS relates_VBZ to_TO Glaxo_NNP heritage_NN In_IN metabolic_JJ ,_, the_DT Avandia_NNP franchise_NN Avandia_NNP and_CC Avandamet_NNP grew_VBD 24_CD able_JJ to_TO influence_VB ._.
This_DT information_NN ,_, which_WDT is_VBZ provided_VBN in_IN addition_NN to_TO products_NNS in_IN the_DT USA_NNP ._.
The_DT Group_NNP has_VBZ now_RB received_VBN a_DT claim_NN for_IN additional_JJ per_IN cent_NN for_IN the_DT year_NN ._.
Avandamet_NNP ,_, a_DT combination_NN of_IN Avandia_NNP and_CC Avandia_NNP Avandamet_NNP 0.9_CD billion_CD up_IN 24_CD %_NN the_DT statutory_JJ results_NNS prepared_VBN under_IN UK_NNP GAAP_NNP ,_, is_VBZ given_VBN to_TO assist_VB taxes_NNS that_IN the_DT IRS_NNP asserts_VBZ legacy_NN company_NN Glaxo_NNP Wellcome_NNP owes_VBZ for_IN the_DT metformin_NN HCI_NNP ,_, expanded_VBD the_DT Avandia_NNP metabolic_JJ franchise_NN with_IN its_PRP$ US_NNP Wellbutrin_NNP 0.9_CD billion_CD up_IN 18_CD %_NN shareholders_NNS to_TO gain_VB a_DT clearer_JJR understanding_NN of_IN the_DT underlying_VBG years_NNS 1989_CD to_TO 1996_CD ._.
This_DT statutory_JJ notice_NN of_IN deficiency_NN for_IN $_$ 2.7_CD billion_CD launch_NN in_IN the_DT fourth_JJ quarter_NN of_IN 2002_CD ._.
In_IN Europe_NNP ,_, the_DT franchise_NN should_MD performance_NN of_IN the_DT business_NN and_CC to_TO increase_VB comparability_NN for_IN the_DT 1.5_CD billion_CD in_IN tax_NN principally_RB relates_VBZ to_TO the_DT allocation_NN of_IN profits_NNS for_IN Glaxo_NNP benefit_NN further_RBR from_IN the_DT EU_NNP approval_NN of_IN Avandamet_NNP in_IN December_NNP 2003_CD ._.
Zofran_NNP 0.8_CD billion_CD up_IN 16_CD %_NN periods_NNS presented_VBN ._.
heritage_NN products_NNS between_IN the_DT USA_NNP and_CC other_JJ countries_NNS ._.
To_TO the_DT extent_NN Avandia_NNP also_RB did_VBD very_RB well_RB in_IN International_JJ markets_NNS with_IN sales_NNS of_IN 106_CD Lamictal_JJ 0.6_CD billion_CD up_IN 31_CD %_NN that_IN the_DT IRS_NNP was_VBD successful_JJ in_IN its_PRP$ claim_NN ,_, interest_NN would_MD be_VB payable_JJ ._.
In_IN order_NN to_TO illustrate_VB underlying_VBG performance_NN ,_, it_PRP is_VBZ the_DT Groups_NNS estimates_VBZ the_DT interest_NN on_IN the_DT full_JJ claim_NN to_TO date_NN would_MD be_VB approximately_RB Valtrex_NNP 0.5_CD billion_CD up_IN 23_CD %_NN practice_NN to_TO discuss_VB the_DT results_NNS in_IN terms_NNS of_IN constant_JJ exchange_NN rates_NNS $_$ 2.5_CD billion_CD 1.4_CD billion_CD ,_, net_NN of_IN federal_JJ tax_NN relief_NN ._.
However_RB ,_, there_EX In_IN cardiovascular_JJ and_CC urogenital_JJ ,_, Coreg_NNP sales_NNS grew_VBD 28_CD per_IN cent_NN benefiting_VBG Trizivir_NNP 0.4_CD billion_CD up_IN 22_CD %_NN CER_NNP growth_NN ._.
This_DT represents_VBZ growth_NN calculated_VBN as_IN if_IN the_DT exchange_NN continues_VBZ to_TO be_VB a_DT wide_JJ difference_NN of_IN views_NNS between_IN the_DT Group_NNP and_CC the_DT from_IN recent_JJ data_NNS that_WDT showed_VBD a_DT highly_RB significant_JJ statistical_JJ difference_NN in_IN rates_NNS used_VBN to_TO determine_VB the_DT results_NNS of_IN overseas_JJ companies_NNS in_IN sterling_NN Coreg_NNP 0.4_CD billion_CD up_IN 28_CD %_NN IRS_NNP ._.
The_DT ultimate_JJ liability_NN for_IN such_JJ matters_NNS may_MD vary_VB significantly_RB from_IN survival_NN between_IN Coreg_NNP and_CC metopropol_NN in_IN patients_NNS with_IN heart_NN failure_NN ._.
had_VBD remained_VBN unchanged_JJ from_IN those_DT used_VBN in_IN the_DT previous_JJ period_NN ._.
amounts_NNS provided_VBD and_CC is_VBZ dependent_JJ upon_IN the_DT outcome_NN of_IN litigation_NN Levitra_NNP vardenafil_NN ,_, a_DT new_JJ agent_NN for_IN the_DT treatment_NN of_IN erectile_JJ dysfunction_NN ,_, Infanrix_NNP Pediarix_NNP 0.3_CD billion_CD up_IN 32_CD %_NN Growth_NN rates_NNS are_VBP therefore_RB at_IN CER_NNP unless_IN otherwise_RB stated_VBN ._.
proceedings_NNS and_CC negotiations_NNS with_IN the_DT relevant_JJ tax_NN authorities_NNS ._.
was_VBD launched_VBN in_IN the_DT USA_NNP in_IN August_NNP 2003_CD and_CC in_IN Europe_NNP in_IN the_DT first_JJ half_NN of_IN the_DT year_NN ._.
22_CD Annual_JJ Review_NNP 2003_CD Annual_JJ Review_NNP 2003_CD 23_CD Responsibility_NN statements_NNS Summary_NNP financial_JJ statements_NNS FOR_IN THE_DT YEAR_NN TO_TO 31ST_CD DECEMBER_NNP 2003_CD Summary_NNP consolidated_JJ profit_NN and_CC loss_NN account_NN Annual_JJ Review_NNP Corporate_NNP governance_NN Merger_NNP ,_, restructuring_NN and_CC Business_NN performance_NN disposal_NN of_IN subsidiaries_NNS Statutory_JJ 2003_CD 2002_CD Growth_NN 2003 2002 2003 2002_CD The_DT Annual_JJ Review_NNP is_VBZ a_DT summary_NN report_NN and_CC does_VBZ not_RB contain_VB sufficient_JJ The_DT Combined_NNP Code_NNP Principles_NNPS of_IN Good_JJ Governance_NN and_CC Code_NNP of_IN Best_JJS m_FW m_FW CER_CD %_NN m_NN m_FW m_FW m_FW information_NN to_TO allow_VB as_IN full_JJ an_DT understanding_NN of_IN the_DT results_NNS and_CC state_NN Practice_NN is_VBZ specified_VBN by_IN the_DT Listing_NNP Rules_NNP of_IN the_DT Financial_NNP Services_NNPS Authority_NNP of_IN affairs_NNS of_IN the_DT Group_NNP as_IN is_VBZ provided_VBN by_IN the_DT Annual_JJ Report_NNP 2003_CD ._.
for_IN the_DT guidance_NN of_IN listed_VBN companies_NNS 1998_CD Combined_NNP Code_NNP ._.
The_DT Board_NNP Turnover_NN Shareholders_NNS requiring_VBG more_JJR detailed_JJ information_NN may_MD obtain_VB ,_, free_JJ of_IN considers_VBZ that_IN throughout_IN 2003_CD and_CC up_RB to_TO the_DT date_NN of_IN approval_NN of_IN this_DT Pharmaceuticals_NNP 18,181_CD 17,995_CD 5_CD 18,181_CD 17,995_CD charge_NN ,_, a_DT copy_NN of_IN the_DT Annual_JJ Report_NNP 2003_CD and_CC may_MD also_RB elect_VB to_TO receive_VB review_NN ,_, GlaxoSmithKline_NNP plc_NN applied_VBD the_DT principles_NNS of_IN the_DT 1998_CD Combined_VBN Consumer_NNP Healthcare_NNP 3,260_CD 3,217_CD 4_CD 3,260_CD 3,217_CD a_DT copy_NN of_IN the_DT Annual_JJ Report_NNP in_IN future_JJ years_NNS refer_VBP to_TO Shareholder_NN Code_NNP and_CC ,_, with_IN the_DT exception_NN of_IN matters_NNS where_WRB the_DT companys_NNS position_NN Total_JJ turnover_NN 21,441_CD 21,212_CD 5_CD 21,441_CD 21,212_CD information_NN ._.
is_VBZ described_VBN in_IN the_DT Annual_JJ Report_NNP ,_, complied_VBN with_IN the_DT provisions_NNS of_IN the_DT Combined_NNP Code_NNP ,_, and_CC the_DT guidance_NN on_IN internal_JJ control_NN issued_VBN by_IN the_DT Cost_NN of_IN sales_NNS 4,188_CD 4,243_CD 356_CD 366_CD 4,544_CD 4,609_CD The_DT Independent_NNP Auditors_NNS report_VBP on_IN the_DT full_JJ financial_JJ statements_NNS of_IN the_DT 1998_CD Turnbull_NNP Committee_NNP ._.
Selling_VBG ,_, general_JJ and_CC administrative_JJ expenditure_NN 7,563_CD 7,543_CD 4_CD 18_CD 498_CD 7,581_CD 8,041_CD Research_NNP and_CC development_NN expenditure_NN 2,770_CD 2,732_CD 4_CD 21_CD 168_CD 2,791_CD 2,900_CD Group_NNP for_IN the_DT year_NN ended_VBD 31st_CD December_NNP 2003_CD is_VBZ unqualified_JJ and_CC does_VBZ not_RB contain_VB any_DT statement_NN concerning_VBG inadequate_JJ accounting_NN records_NNS The_DT Annual_JJ Review_NNP ,_, including_VBG Summary_NNP financial_JJ statements_NNS ,_, has_VBZ been_VBN Trading_NN profit_NN 6,920_CD 6,694_CD 9_CD 395_CD 1,032_CD 6,525_CD 5,662_CD or_CC failure_NN to_TO obtain_VB necessary_JJ information_NN and_CC explanations_NNS ._.
approved_VBN by_IN the_DT Board_NNP of_IN Directors_NNS and_CC signed_VBN on_IN its_PRP$ behalf_NN by_IN Other_JJ operating_NN income_NN expenses_NNS 133 111 133 111_CD Sir_NNP Christopher_NNP Hogg_NNP Profits_NNPS of_IN associates_NNS 93_CD 75_CD 93_CD 75_CD Chairman_NNP Profit_NN on_IN disposal_NN of_IN products_NNS and_CC businesses_NNS -_: 5_CD 21_CD 5_CD 21_CD Summary_NNP financial_JJ statements_NNS 3rd_VBP March_NNP 2004_CD Net_JJ interest_NN payable_JJ 161 141 161 141_CD A_DT columnar_NN presentation_NN has_VBZ been_VBN adopted_VBN in_IN the_DT Summary_NNP consolidated_JJ Profit_NN before_IN taxation_NN 6,719_CD 6,517_CD 8_CD 390_CD 1,011_CD 6,329_CD 5,506_CD profit_NN and_CC loss_NN account_NN in_IN order_NN to_TO illustrate_VB business_NN performance_NN which_WDT is_VBZ Independent_JJ auditors_NNS statement_NN to_TO the_DT Taxation_NNP 1,848_CD 1,760_CD 109_CD 299_CD 1,739_CD 1,461_CD the_DT primary_JJ measure_NN used_VBN by_IN management_NN ._.
For_IN this_DT purpose_NN certain_JJ items_NNS members_NNS of_IN GlaxoSmithKline_NNP plc_NN are_VBP identified_VBN separately_RB and_CC are_VBP excluded_VBN from_IN business_NN performance_NN ._.
Profit_NN after_IN taxation_NN 4,871_CD 4,757_CD 281_CD 712_CD 4,590_CD 4,045_CD These_DT comprise_VBP merger_NN items_NNS ,_, including_VBG merger_NN related_VBN product_NN Minority_NNP interests_NNS 94_CD 110_CD 94_CD 110_CD We_PRP have_VBP examined_VBN the_DT Summary_NNP financial_JJ statements_NNS which_WDT comprise_VBP divestments_NNS ,_, costs_NNS relating_VBG to_TO previously_RB announced_VBN manufacturing_NN and_CC Preference_NN share_NN dividends_NNS 12_CD 20_CD 12_CD 20_CD the_DT Summary_NNP consolidated_JJ profit_NN and_CC loss_NN account_NN ,_, Summary_NNP consolidated_VBD other_JJ restructuring_NN ,_, and_CC disposal_NN of_IN businesses_NNS ._.
Management_NNP believes_VBZ that_IN Earnings_NNS 4,765_CD 4,627_CD 8_CD 281_CD 712_CD 4,484_CD 3,915_CD balance_NN sheet_NN and_CC Summary_NNP consolidated_JJ cash_NN flow_NN statement_NN and_CC the_DT exclusion_NN of_IN these_DT non-recurring_JJ items_NNS provides_VBZ a_DT better_JJR reflection_NN of_IN the_DT Summary_NNP Report_NNP of_IN the_DT Directors_NNS including_VBG the_DT Summary_NNP Remuneration_NNP Earnings_NNS per_IN share_NN 82.1_CD p_NN 78.3_CD p_NN 10_CD 77.2_CD p_NN 66.2_CD p_NN way_NN the_DT business_NN is_VBZ managed_VBN and_CC gives_VBZ an_DT indication_NN of_IN the_DT performance_NN Report_NNP ._.
of_IN the_DT Group_NNP in_IN terms_NNS of_IN those_DT elements_NNS of_IN revenue_NN and_CC expenditure_NN Dividends_NNS 2,374_CD 2,346_CD which_WDT local_JJ management_NN is_VBZ able_JJ to_TO influence_VB ._.
Business_NNP performance_NN is_VBZ Respective_JJ responsibilities_NNS of_IN Directors_NNS and_CC Auditors_NNS To_TO illustrate_VB Business_NNP performance_NN ,_, which_WDT is_VBZ the_DT primary_JJ measure_NN used_VBN by_IN management_NN ,_, merger_NN items_NNS ,_, integration_NN and_CC restructuring_NN costs_NNS and_CC disposal_NN of_IN businesses_NNS have_VBP been_VBN excluded_VBN and_CC an_DT adjusted_JJ discussed_VBN in_IN the_DT Business_NN operating_VBG review_NN ._.
Statutory_JJ results_NNS include_VBP these_DT items_NNS ._.
Business_NNP performance_NN growth_NN is_VBZ at_IN constant_JJ exchange_NN rates_NNS CER_NNP ._.
The_DT Directors_NNS are_VBP responsible_JJ for_IN preparing_VBG the_DT Annual_JJ Review_NNP in_IN accordance_NN with_IN applicable_JJ law_NN ._.
Our_PRP$ responsibility_NN is_VBZ to_TO report_VB to_TO you_PRP our_PRP$ Earnings_NNS and_CC shareholders_NNS funds_NNS are_VBP also_RB restated_VBN in_IN accordance_NN with_IN US_NNP opinion_NN on_IN the_DT consistency_NN of_IN the_DT Summary_NNP financial_JJ statements_NNS within_IN the_DT Summary_NNP consolidated_JJ balance_NN sheet_NN GAAP_NNP as_IN additional_JJ information_NN provided_VBN to_TO US_NNP shareholders_NNS ._.
Annual_JJ Review_NNP with_IN the_DT Annual_JJ financial_JJ statements_NNS ,_, the_DT Report_NNP of_IN the_DT 2003_CD 2002_CD Directors_NNS and_CC the_DT Directors_NNS Remuneration_NNP Report_NNP ,_, and_CC its_PRP$ compliance_NN with_IN m_NN m_NN Statement_NN by_IN the_DT Directors_NNS the_DT relevant_JJ requirements_NNS of_IN Section_NN 251_CD of_IN the_DT United_NNP Kingdom_NNP Companies_NNP Act_NNP 1985_CD and_CC the_DT regulations_NNS made_VBD thereunder_RB ._.
We_PRP also_RB read_VBD the_DT other_JJ Fixed_JJ assets_NNS 11,350_CD 11,578_CD The_DT Annual_JJ Review_NNP 2003_CD is_VBZ the_DT Summary_NNP Directors_NNS report_NN and_CC includes_VBZ information_NN contained_VBN in_IN the_DT Annual_JJ Review_NNP and_CC consider_VB the_DT implications_NNS Current_JJ assets_NNS 12,625_CD 10,749_CD Creditors_NNPS :_: amounts_NNS due_JJ within_IN one_CD year_NN 8,597_CD 8,808_CD the_DT Summary_NNP financial_JJ statements_NNS of_IN GlaxoSmithKline_NNP plc_NN for_IN the_DT year_NN for_IN our_PRP$ report_NN if_IN we_PRP become_VBP aware_JJ of_IN any_DT apparent_JJ misstatements_NNS or_CC Net_JJ current_JJ assets_NNS 4,028_CD 1,941_CD ended_VBD 31st_CD December_NNP 2003_CD ,_, which_WDT is_VBZ published_VBN in_IN hard-copy_JJ printed_VBN form_NN material_NN inconsistencies_NNS with_IN the_DT Summary_NNP financial_JJ statements_NNS ._.
Total_JJ assets_NNS less_RBR current_JJ liabilities_NNS 15,378_CD 13,519_CD and_CC on_IN the_DT website_NN ._.
The_DT Business_NN operating_VBG review_NN ,_, the_DT Summary_NNP financial_JJ Creditors_NNS :_: amounts_NNS due_RB after_IN one_CD year_NN 3,883_CD 3,298_CD statements_NNS ,_, the_DT Summary_NNP Remuneration_NNP Report_NNP and_CC the_DT statement_NN on_IN This_DT statement_NN ,_, including_VBG the_DT opinion_NN ,_, has_VBZ been_VBN prepared_VBN for_IN and_CC only_RB Provisions_NNS for_IN liabilities_NNS and_CC charges_NNS 3,030_CD 2,833_CD Corporate_JJ governance_NN are_VBP summaries_NNS of_IN information_NN in_IN the_DT Annual_JJ Report_NNP for_IN the_DT companys_NNS members_NNS as_IN a_DT body_NN in_IN accordance_NN with_IN Section_NN 251_CD Net_JJ assets_NNS 8,465_CD 7,388_CD 2003_CD ._.
of_IN the_DT Companies_NNS Act_NNP 1985_CD and_CC for_IN no_DT other_JJ purpose_NN ._.
We_PRP do_VBP not_RB ,_, Capital_NNP and_CC reserves_NNS in_IN giving_VBG this_DT opinion_NN ,_, accept_VB or_CC assume_VB responsibility_NN for_IN any_DT other_JJ Equity_NN shareholders_NNS funds_NNS 7,720_CD 6,581_CD The_DT Directors_NNS are_VBP responsible_JJ for_IN the_DT maintenance_NN and_CC integrity_NN of_IN the_DT purpose_NN or_CC to_TO any_DT other_JJ person_NN to_TO whom_WP this_DT statement_NN is_VBZ shown_VBN Minority_NNP interests_NNS 745_CD 807_CD Annual_JJ Review_NNP on_IN the_DT website_NN in_IN accordance_NN with_IN the_DT UK_NNP legislation_NN or_CC into_IN whose_WP$ hands_NNS it_PRP may_MD come_VB save_IN where_WRB expressly_RB agreed_VBN by_IN Capital_NNP employed_VBN 8,465_CD 7,388_CD governing_VBG the_DT preparation_NN and_CC dissemination_NN of_IN financial_JJ statements_NNS ._.
our_PRP$ prior_JJ consent_NN in_IN writing_VBG ._.
Access_NN to_TO the_DT website_NN is_VBZ available_JJ from_IN outside_IN the_DT UK_NNP ,_, where_WRB comparable_JJ legislation_NN may_MD be_VB different_JJ ._.
Basis_NN of_IN opinion_NN Summary_NNP consolidated_JJ cash_NN flow_NN statement_NN We_PRP conducted_VBD our_PRP$ work_NN in_IN accordance_NN with_IN Bulletin_NNP 1999_CD 6_CD ,_, The_DT 2003_CD 2002_CD auditors_NNS statement_NN on_IN the_DT Summary_NNP financial_JJ statement_NN issued_VBN by_IN the_DT m_FW m_FW Auditing_NNP Practices_NNPS Board_NNP for_IN use_NN in_IN the_DT United_NNP Kingdom_NNP ._.
Net_JJ cash_NN inflow_NN from_IN operating_VBG activities_NNS 7,005_CD 7,255_CD Opinion_NNP Dividends_NNPS from_IN joint_JJ ventures_NNS and_CC associated_VBN undertakings_NNS 1_CD 2_CD In_IN our_PRP$ opinion_NN the_DT Summary_NNP financial_JJ statements_NNS are_VBP consistent_JJ with_IN Returns_NNS on_IN investments_NNS and_CC servicing_NN of_IN finance_NN 231_CD 237_CD the_DT Annual_JJ financial_JJ statements_NNS ,_, the_DT Report_NNP of_IN the_DT Directors_NNS and_CC the_DT Taxation_NNP paid_VBD 1,917_CD 1,633_CD Remuneration_NNP Report_NNP of_IN GlaxoSmithKline_NNP plc_NN for_IN the_DT year_NN ended_VBD 31st_CD Capital_NNP expenditure_NN and_CC financial_JJ investment_NN 928_CD 1,120_CD December_NNP 2003_CD and_CC comply_VB with_IN the_DT applicable_JJ requirements_NNS of_IN Section_NN Acquisitions_NNS and_CC disposals_NNS 12_CD 20_CD 251_CD of_IN the_DT Companies_NNS Act_NNP 1985_CD and_CC the_DT regulations_NNS made_VBD thereunder_RB ._.
Equity_NNP dividends_NNS paid_VBD 2,333_CD 2,327_CD Management_NN of_IN liquid_JJ resources_NNS and_CC financing_NN 1,612_CD 1,515_CD LLP_NNP Decrease_NN increase_NN in_IN cash_NN in_IN the_DT year_NN 27_CD 405_CD Chartered_NNP Accountants_NNPS and_CC Registered_NNP Auditors_NNS Embankment_NNP Place_NNP ,_, London_NNP ,_, England_NNP ,_, 3rd_CD March_NNP 2004_CD 24_CD Annual_JJ Review_NNP 2003_CD Annual_JJ Review_NNP 2003_CD 25_CD Summary_NNP information_NN under_IN US_NNP GAAP_NNP FOR_IN THE_DT YEAR_NN TO_TO 31ST_CD DECEMBER_NNP 2003_CD Shareholder_NN information_NN The_DT following_NN is_VBZ a_DT summary_NN of_IN the_DT material_NN adjustments_NNS to_TO profit_VB and_CC shareholders_NNS funds_NNS which_WDT would_MD be_VB required_VBN if_IN US_NNP Generally_RB Accepted_JJ Ordinary_NNP shares_NNS SmithKline_NNP Beecham_NNP plc_NN Floating_VBG Rate_NNP Accounting_NNP Principles_NNPS GAAP_NNP had_VBD been_VBN applied_VBN instead_RB of_IN UK_NNP GAAP_NNP ._.
The_DT companys_NNS shares_NNS are_VBP listed_VBN on_IN the_DT London_NNP Stock_NNP Exchange_NNP ._.
Unsecured_JJ Loan_NNP Stock_NNP 1990 2010 2003 2002_CD Profit_NN m_NN m_NN Registrar_NNP Profit_NNP attributable_JJ to_TO shareholders_NNS under_IN UK_NNP GAAP_NNP 4,484_CD 3,915_CD The_DT loan_NN stock_NN is_VBZ not_RB listed_VBN on_IN any_DT exchange_NN but_CC holders_NNS may_MD require_VB The_DT companys_NNS share_VBP register_NN is_VBZ administered_VBN by_IN Lloyds_NNP TSB_NNP Registrars_NNPS ,_, US_NNP GAAP_NNP adjustments_NNS :_: SmithKline_NNP Beecham_NNP plc_NN to_TO redeem_VB their_PRP$ loan_NN stock_NN at_IN par_NN ,_, i._FW e._FW 1_CD for_IN who_WP also_RB provide_VBP the_DT following_JJ services_NNS :_: Fixed_JJ assets_NNS 28_CD 45_CD every_DT 1_CD of_IN loan_NN stock_NN held_VBN ,_, on_IN the_DT first_JJ business_NN day_NN of_IN March_NNP ,_, June_NNP ,_, GlaxoSmithKline_NNP Investment_NNP Plan_NNP enables_VBZ shareholders_NNS to_TO reinvest_VB Product_NNP rights_NNS and_CC goodwill_NN 2,378_CD 4,252_CD September_NNP and_CC December_NNP ._.
Holders_NNS wishing_VBG to_TO redeem_VB all_DT or_CC part_NN of_IN their_PRP$ quarterly_JJ dividends_NNS and_CC or_CC make_VB monthly_JJ investments_NNS in_IN the_DT Disposal_NNP of_IN products_NNS 7_CD 7_CD loan_NN stock_NN should_MD complete_VB the_DT notice_NN on_IN the_DT back_NN of_IN their_PRP$ loan_NN stock_NN company_NN 's_POS ordinary_JJ shares_NNS using_VBG a_DT special_JJ dealing_NN arrangement_NN ._.
Equity_NNP investments_NNS 31_CD 8_CD certificate_NN and_CC return_VB it_PRP to_TO the_DT registrar_NN ,_, to_TO arrive_VB at_IN least_JJS 30_CD days_NNS before_IN GlaxoSmithKline_NNP Individual_NNP Savings_NNP Account_NNP is_VBZ a_DT tax-efficient_JJ way_NN Employee_NN costs_NNS 501_CD 469_CD the_DT relevant_JJ redemption_NN date_NN ._.
to_TO invest_VB in_IN the_DT companys_NNS ordinary_JJ shares_NNS ._.
Provision_NN against_IN ESOT_NNP shares_NNS 25_CD 51_CD GlaxoSmithKline_NNP Corporate_NNP Sponsored_NNP Nominee_NNP provides_VBZ a_DT facility_NN Derivative_JJ instruments_NNS 74_CD 8_CD for_IN shareholders_NNS to_TO hold_VB shares_NNS without_IN the_DT need_NN for_IN share_NN certificates_NNS ._.
Share_NN buy-back_NN program_NN Guarantor_NNP obligations_NNS 21_CD -_: Shareholders_NNS details_NNS will_MD not_RB be_VB held_VBN on_IN the_DT main_JJ share_NN register_NN ,_, and_CC Restructuring_NNP 98_CD 37_CD so_RB will_MD remain_VB confidential_JJ ._.
In_IN October_NNP 2002_CD ,_, following_VBG the_DT completion_NN of_IN the_DT 4_CD billion_CD share_NN buy_NN Taxation_NNP 783_CD 1,169_CD Shareview_NNP service_NN provides_VBZ shareholders_NNS with_IN information_NN on_IN their_PRP$ back_JJ program_NN announced_VBN in_IN 2001_CD ,_, the_DT company_NN announced_VBD plans_NNS investment_NN in_IN the_DT company_NN ._.
Shareholders_NNS may_MD register_VB for_IN this_DT service_NN for_IN a_DT new_JJ 4_CD billion_CD share_NN buy-back_JJ program_NN ._.
The_DT program_NN covers_VBZ Net_JJ income_NN under_IN US_NNP GAAP_NNP before_IN cumulative_JJ changes_NNS in_IN accounting_NN principles_NNS 2,420_CD 503_CD at_IN www_NN ._.
co._FW uk_FW purchases_NNS by_IN the_DT company_NN of_IN shares_NNS for_IN cancellation_NN or_CC to_TO be_VB held_VBN as_IN Cumulative_JJ effect_NN of_IN changes_NNS in_IN accounting_NN principles_NNS -_: 90_CD Treasury_NNP Shares_NNP ,_, in_IN accordance_NN with_IN the_DT authority_NN given_VBN by_IN shareholders_NNS Net_JJ income_NN under_IN US_NNP GAAP_NNP after_IN cumulative_JJ effect_NN of_IN changes_NNS in_IN accounting_NN principles_NNS 2,420_CD 413_CD Share_NN dealing_VBG service_NN at_IN the_DT AGM_NNP in_IN 2003_CD ._.
In_IN total_JJ 980_CD billion_CD was_VBD spent_VBN in_IN 2003_CD ._.
Hoare_NNP Govett_NNP Limited_NNP operates_VBZ a_DT postal_JJ dealing_VBG service_NN in_IN the_DT companys_NNS Basic_JJ income_NN per_IN share_NN under_IN US_NNP GAAP_NNP :_: ordinary_JJ shares_NNS ._.
It_PRP enables_VBZ investors_NNS to_TO buy_VB or_CC sell_VB shares_NNS at_IN competitive_JJ Basic_JJ net_JJ income_NN before_IN cumulative_JJ changes_NNS in_IN accounting_NN principles_NNS 41.7_CD p_NN 8.5_CD p_NN In_IN May_NNP 2003_CD the_DT company_NN was_VBD authorised_VBN to_TO purchase_VB a_DT maximum_NN of_IN commission_NN charges_NNS ._.
Transactions_NNS are_VBP executed_VBN and_CC settled_VBN by_IN Pershing_NNP Changes_NNS in_IN accounting_NN principles_NNS -_: 1.5_CD p_NN 600_CD million_CD shares_NNS 617_CD million_CD shares_NNS in_IN May_NNP 2002_CD and_CC 81_CD million_CD shares_NNS Securities_NNP Limited_NNP ._.
Further_JJ details_NNS of_IN this_DT service_NN together_RB with_IN purchase_NN Basic_JJ net_JJ income_NN after_IN changes_NNS in_IN accounting_NN principles_NNS 41.7_CD p_NN 7.0_CD p_NN were_VBD purchased_VBN for_IN cancellation_NN during_IN 2003_CD see_VBP Note_NN to_TO the_DT Financial_NNP and_CC sale_NN forms_NNS may_MD be_VB obtained_VBN by_IN telephoning_VBG 44_CD 0_CD 20 7676 8300_CD ._.
statements_NNS ,_, Share_NN capital_NN and_CC share_NN premium_NN account_NN in_IN the_DT companys_NNS Diluted_JJ income_NN per_IN share_NN under_IN US_NNP GAAP_NNP :_: Annual_JJ Report_NNP 2003_CD ._.
The_DT exact_JJ amount_NN and_CC timing_NN of_IN future_JJ purchases_NNS Diluted_VBN net_JJ income_NN before_IN cumulative_JJ changes_NNS in_IN accounting_NN principles_NNS 41.6_CD p_NN 8.5_CD p_NN Smith_NNP Barney_NNP ,_, part_NN of_IN Citigroup_NNP ,_, also_RB offers_VBZ a_DT share_NN dealing_VBG service_NN in_IN the_DT will_MD be_VB determined_VBN by_IN the_DT company_NN and_CC is_VBZ dependent_JJ on_IN market_NN Changes_NNS in_IN accounting_NN principles_NNS -_: 1.5_CD p_NN companys_NNS ordinary_JJ shares_NNS and_CC ADSs_NNS ._.
Further_JJ details_NNS of_IN this_DT service_NN can_MD be_VB conditions_NNS and_CC other_JJ factors_NNS ._.
Diluted_JJ net_JJ income_NN after_IN changes_NNS in_IN accounting_NN principles_NNS 41.6_CD p_NN 7.0_CD p_NN obtained_VBN by_IN contacting_VBG their_PRP$ offices_NNS in_IN the_DT UK_NNP or_CC USA_NNP see_VBP contact_NN details_NNS 2003_CD 2002_CD on_IN the_DT inside_JJ back_JJ cover_NN for_IN further_JJ information_NN ._.
Cautionary_JJ statement_NN Equity_NN shareholders_NNS funds_NNS m_VBP m_NN Equity_NN shareholders_NNS funds_NNS under_IN UK_NNP GAAP_NNP 7,720_CD 6,581_CD The_DT provision_NN of_IN the_DT details_NNS above_IN are_VBP not_RB intended_VBN to_TO be_VB an_DT invitation_NN or_CC Under_IN the_DT safe_JJ harbor_NN provisions_NNS of_IN the_DT US_NNP Private_NNP Securities_NNP Litigation_NNP US_NNP GAAP_NNP adjustments_NNS :_: inducement_NN to_TO engage_VB in_IN an_DT investment_NN activity_NN ._.
Advice_NNP on_IN share_NN dealing_NN ,_, Reform_NNP Act_NNP of_IN 1995_CD ,_, the_DT company_NN cautions_VBZ investors_NNS that_IN any_DT forwardFixed_JJ assets_NNS 243_CD 215_CD should_MD be_VB obtained_VBN from_IN a_DT stockbroker_NN or_CC independent_JJ financial_JJ adviser_NN ._.
looking_VBG statements_NNS or_CC projections_NNS made_VBN by_IN the_DT company_NN ,_, including_VBG those_DT Product_NNP rights_NNS and_CC goodwill_NN 33,638_CD 36,141_CD made_VBN in_IN this_DT Annual_JJ Review_NNP ,_, are_VBP subject_JJ to_TO risks_NNS and_CC uncertainties_NNS that_WDT may_MD Marketable_JJ securities_NNS 84_CD 113_CD Share_NN price_NN information_NN cause_NN actual_JJ results_NNS to_TO differ_VB materially_RB from_IN those_DT projected_VBN ._.
Factors_NNS that_WDT Other_JJ investments_NNS 832_CD 829_CD Share_NN price_NN information_NN is_VBZ available_JJ on_IN the_DT website_NN at_IN www_NN ._.
may_MD affect_VB the_DT Groups_NNS operations_NNS are_VBP described_VBN under_IN Risk_NNP factors_NNS in_IN the_DT Employee_NN costs_VBZ 1,574_CD 1,198_CD Information_NN made_VBN available_JJ on_IN the_DT website_NN does_VBZ not_RB constitute_VB part_NN of_IN this_DT companys_VBZ Annual_JJ Report_NNP 2003_CD ._.
Employee_NN Share_NN Ownership_NNP Trust_NNP 2,775_CD 2,826_CD Annual_JJ Review_NNP ._.
Information_NN in_IN the_DT UK_NNP is_VBZ also_RB available_JJ on_IN Ceefax_NNP ,_, Teletext_NNP ,_, Derivative_JJ instruments_NNS 26_CD 98_CD and_CC from_IN FT_NNP Cityline_NNP by_IN calling_VBG 0906 003 5694_CD or_CC 0906 843 5694_CD calls_NNS Guarantor_NNP obligations_NNS 21_CD -_: charged_VBN at_IN 60p_CD a_DT minute_NN plus_CC VAT_NNP at_IN all_DT times_NNS ._.
Restructuring_NN 92_CD 6_CD Dividends_NNS 808_CD 754_CD American_JJ Depositary_NNP Shares_NNP Deferred_NNP taxation_NN 4,957_CD 5,779_CD Shareholders_NNS equity_NN under_IN US_NNP GAAP_NNP 34,116_CD 34,922_CD The_DT companys_NNS shares_NNS are_VBP listed_VBN on_IN the_DT New_NNP York_NNP Stock_NNP Exchange_NNP in_IN the_DT form_NN of_IN American_JJ Depositary_NNP Shares_NNP ADSs_NNP and_CC these_DT are_VBP evidenced_VBN by_IN American_JJ Depositary_NNP Receipts_NNPS ADRs_NNPS ,_, each_DT one_CD of_IN which_WDT represents_VBZ A_DT summary_NN of_IN the_DT material_NN differences_NNS between_IN UK_NNP and_CC US_NNP GAAP_NNP that_IN apply_VB to_TO the_DT Group_NNP is_VBZ set_VBN out_RP in_IN the_DT Annual_JJ Report_NNP 2003_CD ._.
two_CD ordinary_JJ shares_NNS ._.
During_IN the_DT year_NN ,_, the_DT Group_NNP implemented_VBD the_DT following_VBG new_JJ accounting_NN standards_NNS and_CC interpretations_NNS issued_VBN by_IN the_DT Financial_NNP Accounting_NNP Standards_NNP Board_NNP FASB_NNP :_: SFAS_NNP 132_CD revised_VBN 2003_CD Employers_NNS Disclosures_NNS about_IN Pensions_NNS and_CC other_JJ Postretirement_NNP Benefits_NNPS :_: SFAS_NNS 143_CD Accounting_NN for_IN Obligations_NNS ADR_NNP program_NN administrator_NN Associated_NNP with_IN Long-Lived_NNP Assets_NNPS :_: SFAS_NNS 146_CD Accounting_NN for_IN Costs_NNS Associated_NNP with_IN Exit_NN or_CC Disposal_NNP Activities_NNPS :_: SFAS_NNP 149_CD Amendment_NNP of_IN Statement_NNP The_NNP ADR_NNP program_NN is_VBZ administered_VBN by_IN The_DT Bank_NNP of_IN New_NNP York_NNP which_WDT 133_CD on_IN Derivative_JJ Instruments_NNPS and_CC Hedging_NNP Activities_NNPS :_: SFAS_NNS 150_CD Accounting_NN for_IN Certain_NNP Financial_NNP Instruments_NNPS with_IN Characteristics_NNPS of_IN both_DT Liabilities_NNS provides_VBZ Global_JJ BuyDIRECT_NNP ,_, a_DT direct_JJ ADS_NNPS purchase_NN sale_NN and_CC dividend_NN and_CC Equity_NN :_: FIN_NNP 45_CD Guarantors_NNP Accounting_NNP and_CC Disclosure_NNP Requirements_NNP for_IN Guarantees_NNP ,_, Including_VBG Indirect_NNP Guarantees_NNP of_IN Indebtedness_NNP of_IN Others_NNS :_: reinvestment_NN plan_NN for_IN ADR_NNP holders_NNS ._.
and_CC the_DT transitional_JJ requirements_NNS of_IN FIN_NNP 46_CD revised_VBN December_NNP 2003_CD Consolidation_NN of_IN Variable_JJ Interest_NN Entities_NNS relating_VBG to_TO 2003_CD ._.
In_IN 2004_CD ,_, the_DT Group_NNP will_MD implement_VB the_DT remaining_VBG requirements_NNS of_IN FIN_NNP 46_CD ._.
The_DT Group_NNP has_VBZ also_RB elected_VBN ,_, under_IN FASB_NNP Staff_NNP Position_NNP 106-1_CD Accounting_NNP and_CC Disclosure_NNP Requirements_NNP Related_NNP to_TO the_DT Medicare_NNP Prescription_NNP Drug_NNP ,_, Improvement_NNP and_CC Modernization_NNP Act_NNP of_IN 2003_CD ,_, to_TO defer_VB accounting_NN for_IN the_DT implications_NNS of_IN this_DT new_JJ law_NN until_IN specific_JJ authoritative_JJ guidance_NN is_VBZ issued_VBN ._.
Such_JJ guidance_NN ,_, when_WRB issued_VBN ,_, could_MD require_VB a_DT change_NN in_IN previously_RB reported_VBN information_NN ._.
26_CD Annual_JJ Review_NNP 2003_CD Annual_JJ Review_NNP 2003_CD 27_CD Shareholder_NN information_NN continued_VBD Internet_NNP Our_PRP$ Reports_NNS ANNUAL_NNP REVIEW_NNP Information_NNP for_IN investors_NNS and_CC about_IN the_DT Do_VBP more_RBR ,_, feel_VB better_RB ,_, live_VBP longer_RBR A_DT review_NN of_IN major_JJ company_NN is_VBZ available_JJ on_IN GlaxoSmithKlines_NNP communication_NN corporate_JJ website_NN at_IN www_NN ._.
com_NN themes_NNS for_IN 2003_CD and_CC an_DT abridged_JJ version_NN of_IN Financial_NNP reporting_VBG Market_NN capitalization_NN the_DT financial_JJ results_NNS ._.
The_DT market_NN capitalization_NN of_IN GlaxoSmithKline_NNP at_IN 31st_CD December_NNP 2003_CD Head_NNP Office_NNP and_CC Registered_NNP Office_NNP was_VBD 76_CD billion_CD ._.
At_IN that_DT date_NN GlaxoSmithKline_NNP was_VBD the_DT fourth_JJ largest_JJS Financial_JJ reporting_NN calendar_NN 2004_CD Improving_NN health_NN GlaxoSmithKline_NNP plc_NN company_NN by_IN market_NN capitalization_NN on_IN the_DT FTSE_NNP index_NN ._.
every_DT day_NN Announcement_NN of_IN 1st_CD Quarter_NN Results_NNS 29th_JJ April_NNP 2004_CD 980_CD Great_NNP West_NNP Road_NNP ANNUAL_NNP REVIEW_NNP 2003_CD Announcement_NN of_IN 2nd_CD Quarter_NN Results_NNS 27th_JJ July_NNP 2004_CD Brentford_NNP Dividends_NNPS Announcement_NN of_IN 3rd_CD Quarter_NN Results_NNS 28th_JJ October_NNP 2004_CD Middlesex_NNP TW8_NNP 9GS_NNP Tel_NNP :_: 44_CD 0_CD 20 8047 5000_CD Preliminary_JJ Announcement_NN of_IN Annual_JJ Results_NNS 10th_JJ February_NNP 2005_CD GlaxoSmithKline_NNP pays_VBZ dividends_NNS quarterly_RB ._.
Publication_NN of_IN Annual_JJ Report_NNP Review_NNP March_NNP 2005_CD ANNUAL_NNP REPORT_NNP The_NNP Board_NNP has_VBZ declared_VBN dividends_NNS for_IN 2003_CD as_IN follows_VBZ :_: Do_VB more_RBR ,_, feel_VB better_RB ,_, live_VBP longer_RBR The_DT full_JJ Financial_NNP Statements_NNP for_IN the_DT Results_NNS Announcements_NNP 2003_CD 2002_CD United_NNP Kingdom_NNP United_NNP States_NNPS of_IN America_NNP Dividends_NNPS per_IN share_NN pence_NN pence_NN year_NN ended_VBD 31st_CD Results_NNS Announcements_NNS are_VBP issued_VBN to_TO the_DT London_NNP Stock_NNP Exchange_NNP LSE_NNP ,_, Investor_NNP relations_NNS Investor_NNP relations_NNS December_NNP 2003_CD ._.
and_CC made_VBN available_JJ on_IN the_DT LSE_NNP news_NN service_NN ,_, and_CC at_IN the_DT same_JJ time_NN ,_, or_CC One_CD Franklin_NNP Plaza_NNP First_NNP interim_JJ paid_VBN 3rd_CD July_NNP 2003_CD 9_CD 9_CD 980_CD Great_NNP West_NNP Road_NNP shortly_RB afterwards_RB ,_, are_VBP issued_VBN to_TO the_DT media_NNS ,_, are_VBP made_VBN available_JJ on_IN the_DT PO_NNP Box_NNP 7929_CD Second_JJ interim_JJ paid_VBN 2nd_JJ October_NNP 2003_CD 9_CD 9_CD Brentford_NNP Improving_NN performance_NN companys_VBZ website_JJ and_CC in_IN the_DT USA_NNP with_IN the_DT Securities_NNPS and_CC Exchange_NNP Philadelphia_NNP PA_NNP 19101_CD Third_NNP interim_JJ paid_VBN 6th_JJ January_NNP 2004_CD 9_CD 9_CD Middlesex_NNP TW8_NNP 9GS_NNP Commission_NNP and_CC the_DT New_NNP York_NNP Stock_NNP Exchange_NNP ._.
Tel_NNP :_: 1_CD 888 825 5249_CD toll_NN free_JJ Fourth_JJ interim_JJ payable_JJ 15th_JJ April_NNP 2004_CD 14_CD 13_CD every_DT day_NN Tel_NNP :_: 44_CD 0_CD 20 8047 5557 5558_CD ANNUAL_NNP REPORT_NNP 2003_CD Tel_NNP :_: 1_CD 215 751 7003_CD outside_IN the_DT USA_NNP Total_NNP 41_CD 40_CD Fax_NN :_: 44_CD 0_CD 20 8047 7807_CD Financial_NNP reports_NNS Fax_NNP :_: 1_CD 215 751 3233_CD The_DT company_NN publishes_VBZ an_DT Annual_JJ Report_NNP and_CC ,_, for_IN the_DT investor_NN not_RB In_IN 2004_CD ,_, GSK_NNP expects_VBZ a_DT similar_JJ increase_NN in_IN total_JJ dividend_NN as_IN has_VBZ been_VBN Registrar_JJ needing_VBG the_DT full_JJ detail_NN of_IN the_DT Report_NNP ,_, an_DT Annual_JJ Review_NNP ._.
These_DT are_VBP ADR_NNP program_NN administrator_NN declared_VBD in_IN 2003_CD ._.
The_DT allocation_NN of_IN quarterly_JJ dividends_NNS will_MD be_VB rebalanced_VBN Lloyds_NNP TSB_NNP Registrars_NNPS available_JJ from_IN the_DT date_NN of_IN publication_NN on_IN the_DT GlaxoSmithKline_NNP website_NN ._.
GSK_NNP intends_VBZ to_TO increase_VB the_DT first_JJ three_CD interim_JJ dividends_NNS from_IN The_DT Causeway_NNP CORPORATE_JJ The_DT Annual_JJ Review_NNP is_VBZ sent_VBN to_TO all_DT shareholders_NNS on_IN the_DT date_NN of_IN publication_NN ._.
Shareholder_NN Relations_NNS 9p_VBP to_TO 10p_VB ,_, with_IN the_DT remainder_NN of_IN the_DT total_JJ dividend_NN for_IN the_DT year_NN being_VBG Do_VBP more_RBR ,_, feel_VB better_RB ,_, live_VBP longer_RBR Worthing_JJ RESPONSIBILITY_NN Shareholders_NNS may_MD also_RB elect_VB to_TO receive_VB the_DT Report_NNP by_IN writing_VBG to_TO the_DT PO_NNP Box_NNP 11258_CD allocated_VBN to_TO the_DT fourth_JJ quarter_NN dividend_NN ._.
West_NNP Sussex_NNP BN99_NNP 6DA_NNP REPORT_NNP companys_VBZ registrars_NNS ._.
Alternatively_RB shareholders_NNS may_MD elect_VB to_TO receive_VB Church_NNP Street_NNP Station_NNP A_NNP review_NN of_IN our_PRP$ www_NN ._.
co._FW uk_FW notification_NN by_IN email_NN of_IN the_DT publication_NN of_IN financial_JJ reports_NNS by_IN registering_VBG New_NNP York_NNP NY_NNP 10286-1258_CD Dividends_NNPS ADSs_NNPS commitment_NN to_TO on_IN www_NN ._.
Copies_NNS of_IN previous_JJ financial_JJ reports_NNS are_VBP available_JJ www_NN ._.
com_NN As_IN a_DT guide_NN to_TO holders_NNS of_IN ADRs_NNS ,_, the_DT tables_NNS below_IN set_VBN out_RP the_DT dividends_NNS paid_VBD society_NN and_CC the_DT General_NNP enquiries_NNS ,_, Annual_JJ Report_NNP orderline_NN on_IN the_DT companys_NNS website_VBP ._.
Printed_NNP copies_NNS can_MD be_VB obtained_VBN from_IN the_DT Tel_NNP :_: 1_CD 877 353 1154_CD toll_NN free_JJ environment_NN ._.
per_IN ADS_NNPS in_IN US_NNP dollars_NNS in_IN the_DT last_JJ five_CD years_NNS ._.
The_DT dividends_NNS are_VBP adjusted_VBN for_IN and_CC Corporate_JJ Nominee_NN service_NN Making_VBG a_DT difference_NN companys_VBZ registrar_NN in_IN the_DT UK_NNP and_CC from_IN the_DT companys_NNS Customer_NN Response_NNP Tel_NNP :_: 1_CD 610 382 7836_CD outside_IN the_DT USA_NNP UK_NNP tax_NN credit_NN less_RBR withholding_VBG tax_NN ,_, where_WRB applicable_JJ ,_, and_CC are_VBP translated_VBN Tel_NNP :_: 0870 600 3991_CD inside_IN the_DT UK_NNP every_DT day_NN Center_NNP in_IN the_DT USA_NNP ._.
into_IN US_NNP dollars_NNS at_IN applicable_JJ exchange_NN rates_NNS ._.
Tel_NNP :_: 44_CD 0_CD 121 415 7067_CD outside_IN the_DT UK_NNP CORPORATE_JJ RESPONSIBILITY_NN REPORT_NN 2003_CD Customer_NN Response_NNP Center_NNP Since_IN 6th_JJ April_NNP 1999_CD ,_, claims_VBZ for_IN refunds_NNS of_IN tax_NN credits_NNS on_IN dividends_NNS from_IN the_DT Publications_NNP Tel_NNP :_: 1_CD 888 825 5249_CD toll_NN free_JJ Making_VBG a_DT dif_NN Improving_NN health_NN ,_, every_DT day_NN ference_NN ,_, every_DT day_NN 101_CD 101_CD Shareholder_NN Investment_NN Plans_NNS UK_NNP tax_NN authorities_NNS are_VBP of_IN negligible_JJ benefit_NN to_TO US_NNP shareholders_NNS ._.
This_DT year_NN GlaxoSmithKline_NNP has_VBZ again_RB produced_VBN a_DT separate_JJ report_NN covering_VBG Dividend_NN re-investment_NN queries_VBZ Every_DT day_NN ,_, all_DT around_IN the_DT world_NN ,_, GlaxoSmithKline_NNP is_VBZ the_DT Groups_NNS contribution_NN to_TO society_NN ._.
The_DT 2003_CD Corporate_JJ Responsibility_NN Corporate_JJ share_NN dealing_VBG facility_NN Tel_NNP :_: 0870 241 3018_CD inside_IN the_DT UK_NNP Year_NN GSK_NNP $_$ GW_CD $_$ SB_CD $_$ trying_VBG to_TO improve_VB peoples_NNS lives_NNS and_CC have_VBP a_DT positive_JJ Report_NNP covers_VBZ the_DT issues_NNS that_WDT are_VBP of_IN primary_JJ interest_NN to_TO stakeholders_NNS ,_, Smith_NNP Barney_NNP Tel_NNP :_: 44_CD 0_CD 121 415 7067_CD outside_IN the_DT UK_NNP impact_NN on_IN all_DT our_PRP$ stakeholders_NNS ._.
Our_PRP$ three_CD annual_JJ 2003_CD 1.39_CD including_VBG the_DT contribution_NN to_TO society_NN ,_, business_NN ethics_NNS and_CC integrity_NN ,_, access_NN Attn_NNP :_: GSK_NNP Services_NNPS publications_NNS for_IN 2003_CD emphasise_NN this_DT far-reaching_JJ Ordinary_NNP holders_NNS 2002_CD 1.24_CD to_TO medicines_NNS ,_, R&D_NNP ,_, community_NN investment_NN ,_, the_DT environment_NN and_CC health_NN 53_CD State_NNP Street_NNP commitment_NN ._.
The_DT report_NN is_VBZ available_JJ from_IN the_DT Secretariat_NNP at_IN the_DT companys_NNS 39th_VBP Floor_NNP Employees_NNP 2000_CD 1.10_CD 0.87_CD head_NN office_NN and_CC the_DT website_NN at_IN www_NN ._.
Boston_NNP Produced_NNP by_IN Corporate_NNP Communications_NNPS ,_, 1999_CD 1.14_CD 0.86_CD MA_NNP 02109_CD GlaxoSmithKline_NNP ._.
Monthly_JJ Savings_NNS Plan_NNP queries_VBZ Tel_NNP :_: 1_CD 800 347 6179_CD toll_NN free_JJ Tel_NNP :_: 0870 606 0268_CD inside_IN the_DT UK_NNP Annual_JJ General_NNP Meeting_VBG 2004_CD Dividends_NNPS paid_VBD to_TO Glaxo_NNP Wellcome_NNP and_CC SmithKline_NNP Beecham_NNP ADR_NNP Design_NN consultancy_NN by_IN salterbaxter_NN ._.
Tel_NNP :_: 1_CD 617 589 3341_CD outside_IN the_DT USA_NNP Tel_NNP :_: 44_CD 0_CD 131 527 3746_CD outside_IN the_DT UK_NNP holders_NNS are_VBP expressed_VBN as_IN dividends_NNS per_IN GlaxoSmithKline_NNP ADS_NNPS ._.
Fax_NN :_: 1_CD 617 589 3474_CD Printed_NNP in_IN the_DT UK_NNP by_IN St._NNP Ives_NNP Direct_NNP Edenbridge_NNP Ltd._NNP ._.
The_DT Annual_JJ General_NNP Meeting_VBG will_MD be_VB held_VBN at_IN the_DT Queen_NNP Elizabeth_NNP II_NNP The_DT paper_NN used_VBN in_IN the_DT production_NN of_IN this_DT document_NN is_VBZ Email_NNP :_: TheTaylorGroup@SmithBarney_NNP ._.
com_NN ISA_NNP enquiries_VBZ Conference_NNP Centre_NNP ,_, Broad_NNP Sanctuary_NNP ,_, Westminster_NNP ,_, London_NNP SW1P_NNP 3EE_NNP on_IN Dividend_NN calendar_NN made_VBN from_IN pulps_NNS harvested_VBN from_IN sustainable_JJ forests_NNS ,_, Tel_NNP :_: 0870 242 4244_CD inside_IN the_DT UK_NNP also_RB using_VBG sawmill_NN residues_NNS and_CC forest_NN thinnings_NNS ._.
Tel_NNP :_: 44_CD 0_CD 1903 854 049_CD outside_IN the_DT UK_NNP Ex-dividend_NN date_NN 18th_JJ February_NNP 2004_CD Share_NN price_NN Product_NNP names_NNS throughout_IN this_DT publication_NN Record_NNP date_NN 20th_JJ February_NNP 2004 2003 2002_CD Glaxo_NNP Wellcome_NNP and_CC SmithKline_NNP Beecham_NNP are_VBP indicated_VBN in_IN italics_NNS and_CC are_VBP trademarks_NNS of_IN Share_NN price_NN Payable_JJ 15th_JJ April_NNP 2004_CD corporate_JJ PEPs_NNS GlaxoSmithKline_NNP plc_NN ,_, its_PRP$ subsidiaries_NNS or_CC associated_VBN companies_NNS ,_, with_IN the_DT exception_NN of_IN Levitra_NNP ,_, a_DT At_IN 1st_CD January_NNP 11.92_CD 17.23_CD The_DT Share_NN Centre_NNP Limited_NNP First_NNP quarter_NN 2004_CD trademark_NN of_IN Bayer_NNP ,_, and_CC Nicoderm_NNP ,_, a_DT trademark_NN High_NNP during_IN the_DT year_NN 13.90_CD 17.80_CD Oxford_NNP House_NNP of_IN Aventis_NNP ,_, all_DT of_IN which_WDT are_VBP used_VBN under_IN licence_NN by_IN Ex-dividend_NN date_NN 12th_JJ May_NNP 2004_CD Low_NNP during_IN the_DT year_NN 10.00_CD 10.57_CD Oxford_NNP Road_NNP the_DT Group_NNP ._.
Record_NNP date_NN 14th_JJ May_NNP 2004_CD At_IN 31st_CD December_NNP 12.80_CD 11.92_CD Aylesbury_NNP Payable_NNP 1st_CD July_NNP 2004_CD Increase_VB Decrease_NN over_IN year_NN 7_CD %_NN 31_CD %_NN Bucks_NNPS HP21_NNP 8SZ_NNP Tel_NNP :_: 44_CD 0_CD 1296 414 144_CD Second_JJ quarter_NN 2004_CD The_DT table_NN above_IN sets_NNS out_IN the_DT middle_JJ market_NN closing_NN prices_NNS derived_VBN from_IN Ex-dividend_NN date_NN 4th_JJ August_NNP 2004_CD the_DT London_NNP Stock_NNP Exchange_NNP Daily_NNP Official_NNP List_NN ._.
The_DT companys_NNS share_VBP price_NN Corporate_JJ share_NN dealing_VBG facility_NN Record_NNP date_NN 6th_JJ August_NNP 2004_CD increased_VBN by_IN 7_CD per_IN cent_NN in_IN 2003_CD from_IN a_DT price_NN of_IN 11.92_CD at_IN 1st_CD January_NNP Smith_NNP Barney_NNP Payable_NNP 30th_JJ September_NNP 2004_CD 2003_CD to_TO 12.80_CD at_IN 31st_CD December_NNP 2003_CD ._.
This_DT compares_VBZ with_IN an_DT increase_NN Attn_NNP :_: GSK_NNP Services_NNPS in_IN the_DT FTSE_NNP 100_CD index_NN of_IN 14_CD per_IN cent_NN during_IN the_DT year_NN ._.
Citigroup_NNP Centre_NNP ,_, Level_NNP 20_CD Third_JJ quarter_NN 2004_CD Canada_NNP Square_NNP ,_, Canary_NNP Wharf_NNP Ex-dividend_NN date_NN 3rd_CD November_NNP 2004_CD London_NNP E14_NNP 5LB_NNP Record_NNP date_NN 5th_JJ November_NNP 2004_CD Tel_NNP :_: 44_CD 0_CD 20 7508 1795_CD Payable_JJ 6th_JJ January_NNP 2005_CD Fax_NNP :_: 44_CD 0_CD 20 7890 7281_CD Email_NNP :_: TheBalaesGroup@Citigroup_NNP ._.
com_NN 28_CD Annual_JJ Review_NNP 2003_CD Do_VBP more_RBR ,_, feel_VB better_RB ,_, live_VBP longer_RBR Making_VBG a_DT difference_NN every_DT day_NN CORPORATE_JJ RESPONSIBILITY_NN REPORT_NN 2003_CD Making_VBG a_DT dif_NN Improving_NN health_NN ,_, every_DT day_NN ference_NN ,_, every_DT da_NN 101_CD 101_CD Contents_NNS Front_NN cover_NN 01_CD Introduction_NN by_IN Chairman_NNP 14_CD Community_NNP investment_NN Sri_NNP Lankan_NNP mothers_NNS and_CC children_NNS waiting_VBG and_CC Chief_NNP Executive_NNP Officer_NNP 18_CD Business_NNP ethics_NNS and_CC integrity_NN in_IN line_NN to_TO receive_VB GSKs_NNS albendazole_RB and_CC 02_CD About_IN GSK_NNP 20_CD Environment_NNP ,_, health_NN and_CC safety_NN another_DT medication_NN as_IN part_NN of_IN the_DT global_JJ 03_CD Managing_VBG corporate_JJ responsibility_NN 23_CD Valuing_NNP people_NNS program_NN to_TO eliminate_VB lymphatic_JJ 05_CD Summary_NN of_IN indicators_NNS 26_CD Research_NNP and_CC development_NN filariasis_NN LF_NNP ._.
08_CD Our_PRP$ contribution_NN to_TO society_NN 29_CD Discussion_NN with_IN others_NNS 10_CD Medicines_NNP for_IN the_DT developing_VBG world_NN 32_CD Web_NN references_NNS Highlights_NNS 2003_CD Humanitarian_JJ product_NN Community_NNP investment_NN donations_NNS valued_VBN at_IN valued_VBN at_IN 105_CD million_CD 338_CD million_CD 74_CD %_NN 94_CD million_CD more_JJR Combivir_NNP supplied_VBD to_TO developing_VBG albendazole_JJ treatments_NNS donated_VBN in_IN countries_NNS at_IN preferential_JJ prices_NNS the_DT fight_NN against_IN lymphatic_JJ filariasis_NN Not-for-profit_JJ price_NN for_IN Combivir_NNP 10_CD reduced_VBN by_IN corporate_JJ responsibility_NN principles_NNS formally_RB adopted_VBN 62_CD %_NN Greenhouse_NN gas_NN emissions_NNS 9,000_CD per_IN unit_NN sales_NNS down_IN managers_NNS certified_VBD their_PRP$ compliance_NN with_IN Code_NNP of_IN Conduct_NNP 8_CD %_NN Today_NN ..._: Corporate_JJ responsibility_NN has_VBZ particular_JJ resonance_NN for_IN the_DT pharmaceutical_JJ sector_NN ._.
Our_PRP$ business_NN is_VBZ creating_VBG medicines_NNS to_TO treat_VB and_CC prevent_VB disease_NN something_NN that_WDT society_NN needs_NNS and_CC values_NNS ._.
At_IN the_DT same_JJ time_NN healthcare_NN ,_, its_PRP$ financing_NN and_CC the_DT way_NN it_PRP is_VBZ delivered_VBN provokes_NNS much_JJ debate_NN ._.
This_DT report_NN deals_NNS with_IN important_JJ issues_NNS We_PRP have_VBP embarked_VBN on_IN a_DT program_NN of_IN continual_JJ for_IN our_PRP$ business_NN and_CC explains_VBZ what_WP we_PRP improvement_NN in_IN environment_NN ,_, health_NN and_CC safety_NN performance_NN ._.
Our_PRP$ ten-year_JJ Plan_NN for_IN Excellence_NN are_VBP doing_VBG ._.
Where_WRB possible_JJ we_PRP have_VBP includes_VBZ detailed_JJ measures_NNS and_CC targets_NNS in_IN this_DT area_NN ._.
included_VBD performance_NN measures_NNS to_TO We_PRP are_VBP already_RB well_RB on_IN the_DT way_NN to_TO meeting_VBG our_PRP$ show_NN our_PRP$ progress_NN ._.
targets_NNS for_IN the_DT first_JJ five_CD years_NNS ._.
Significant_JJ achievements_NNS this_DT year_NN include_VBP our_PRP$ In_IN 2003_CD we_PRP introduced_VBD new_JJ marketing_NN codes_NNS programs_NNS for_IN the_DT developing_VBG world_NN ._.
For_IN that_DT are_VBP backed_VBN at_IN the_DT highest_JJS level_NN by_IN the_DT Board_NNP example_NN ,_, lymphatic_JJ filariasis_NN LF_NNP or_CC elephantiasis_NN and_CC the_DT heads_NNS of_IN each_DT of_IN our_PRP$ business_NN divisions_NNS ._.
is_VBZ a_DT debilitating_VBG disease_NN affecting_VBG 120_CD million_CD Our_PRP$ efforts_NNS to_TO reinforce_VB these_DT codes_NNS leave_VBP no_DT people_NNS ._.
Our_PRP$ medicine_NN ,_, albendazole_NN ,_, helps_VBZ prevent_VB doubt_NN about_IN what_WP is_VBZ and_CC is_VBZ not_RB acceptable_JJ ,_, and_CC transmission_NN of_IN LF_NNP and_CC in_IN partnership_NN with_IN the_DT the_DT seriousness_NN of_IN contravening_VBG our_PRP$ codes_NNS ._.
World_NNP Health_NNP Organization_NNP WHO_WP we_PRP donated_VBD 94_CD million_CD treatments_NNS in_IN 2003_CD ._.
The_DT WHO_WP target_NN is_VBZ GSK_NNP has_VBZ always_RB been_VBN committed_VBN to_TO achieving_VBG to_TO eliminate_VB LF_NNP by_IN 2020_CD ,_, by_IN which_WDT time_NN we_PRP expect_VBP performance_NN with_IN integrity_NN profits_NNS without_IN to_TO have_VB donated_VBN 6_CD billion_CD treatments_NNS worth_JJ around_IN principles_NNS are_VBP not_RB sustainable_JJ ._.
This_DT will_MD be_VB one_CD of_IN the_DT pharmaceutical_JJ about_IN what_WP this_DT means_VBZ we_PRP have_VBP adopted_VBN new_JJ industry_NN 's_POS largest_JJS donation_NN programs_NNS ._.
We_PRP expect_VBP everyone_NN in_IN GSK_NNP to_TO consider_VB how_WRB they_PRP apply_VBP We_PRP will_MD continue_VB our_PRP$ research_NN and_CC development_NN to_TO their_PRP$ work_NN ._.
into_IN treatments_NNS for_IN diseases_NNS of_IN the_DT developing_VBG world_NN ._.
This_DT effort_NN is_VBZ complemented_VBN by_IN our_PRP$ access_NN We_PRP look_VBP forward_RB to_TO reporting_VBG our_PRP$ progress_NN to_TO initiatives_NNS ,_, particularly_RB for_IN AIDS_NNP in_IN Africa_NNP and_CC all_DT you_PRP again_RB next_JJ year_NN ._.
least_JJS developed_JJ countries_NNS where_WRB our_PRP$ preferential_JJ pricing_NN agreements_NNS are_VBP now_RB well_RB established_VBN ._.
However_RB ,_, real_JJ progress_NN in_IN addressing_VBG disease_NN and_CC suffering_NN in_IN poor_JJ countries_NNS will_MD only_RB occur_VB if_IN responsibility_NN is_VBZ shared_VBN by_IN all_DT sectors_NNS of_IN global_JJ society_NN -_: governments_NNS ,_, international_JJ agencies_NNS Sir_NNP Christopher_NNP Hogg_NNP JP_NNP Garnier_NNP and_CC companies_NNS such_JJ as_IN GSK_NNP ._.
Chairman_NNP Chief_NNP Executive_NNP Officer_NNP Corporate_NNP Responsibility_NNP Report_NNP 2003_CD 01_CD About_IN GSK_NNP GlaxoSmithKline_NNP GSK_NNP is_VBZ a_DT leading_VBG research-based_JJ pharmaceutical_JJ company_NN ._.
We_PRP make_VBP prescription_NN medicines_NNS ,_, vaccines_NNS ,_, over-the-counter_JJ medicines_NNS ,_, and_CC oral_JJ care_NN and_CC nutritional_JJ healthcare_NN products_NNS ._.
We_PRP are_VBP a_DT global_JJ company_NN headquartered_VBD in_IN the_DT UK_NNP ,_, with_IN major_JJ operations_NNS in_IN the_DT US_NNP ._.
Our_PRP$ business_NN accounts_NNS for_IN seven_CD per_IN cent_NN of_IN the_DT world_NN 's_POS pharmaceutical_JJ market_NN ._.
We_PRP have_VBP particularly_RB strong_JJ positions_NNS in_IN several_JJ therapeutic_JJ areas_NNS including_VBG respiratory_JJ ,_, anti-viral_JJ ,_, central_JJ nervous_JJ system_NN ,_, diabetes_NN and_CC vaccines_NNS ._.
Further_JJ information_NN on_IN all_PDT the_DT issues_NNS covered_VBN in_IN this_DT report_NN is_VBZ available_JJ on_IN our_PRP$ website_NN ,_, www_NN ._.
com_NN 02_CD Corporate_JJ Responsibility_NN Report_NNP 2003_CD Managing_VBG Corporate_JJ Responsibility_NN During_IN 2003_CD GSK_NNP formally_RB adopted_VBD Corporate_JJ Responsibility_NN Principles_NNS ._.
These_DT clearly_RB identify_VB our_PRP$ key_JJ corporate_JJ responsibility_NN CR_NN issues_NNS ,_, and_CC provide_VB guidance_NN for_IN employees_NNS on_IN the_DT standards_NNS to_TO which_WDT the_DT company_NN is_VBZ committed_VBN ._.
7_CD Standards_NNPS of_IN ethical_JJ Corporate_JJ Responsibility_NN Principles_NNS conduct_VBP The_DT mission_NN of_IN our_PRP$ business_NN to_TO improve_VB the_DT quality_NN of_IN human_JJ life_NN to_TO enable_VB people_NNS to_TO do_VB more_JJR ,_, feel_VB better_JJR and_CC live_VBP We_PRP expect_VBP employees_NNS to_TO meet_VB high_JJ ethical_JJ standards_NNS in_IN all_DT aspects_NNS of_IN our_PRP$ business_NN ,_, by_IN longer_JJR focuses_VBZ on_IN the_DT needs_NNS of_IN patients_NNS ._.
We_PRP will_MD achieve_VB conducting_VBG our_PRP$ activities_NNS with_IN honesty_NN and_CC this_DT mission_NN through_IN our_PRP$ products_NNS and_CC activities_NNS ,_, while_IN integrity_NN ,_, adhering_VBG to_TO our_PRP$ CR_NNP principles_NNS ,_, and_CC complying_VBG with_IN applicable_JJ laws_NNS and_CC regulations_NNS ._.
enhancing_VBG the_DT contribution_NN we_PRP make_VBP to_TO society_NN ,_, sustaining_VBG economic_JJ performance_NN and_CC operating_NN in_IN an_DT environmentally_RB responsible_JJ manner_NN ._.
1_CD Employment_NNP practices_NNS 4_CD Leadership_NN and_CC advocacy_NN 8_CD Research_NNP and_CC innovation_NN We_PRP will_MD treat_VB our_PRP$ employees_NNS with_IN respect_NN and_CC We_PRP will_MD establish_VB our_PRP$ own_JJ challenging_JJ standards_NNS In_IN undertaking_VBG our_PRP$ research_NN and_CC in_IN innovating_NN :_: dignity_NN ,_, encourage_VBP diversity_NN and_CC ensure_VB fair_JJ in_IN corporate_JJ responsibility_NN ,_, appropriate_JJ to_TO the_DT We_PRP may_MD explore_VB and_CC apply_VB new_JJ technologies_NNS ._.
treatment_NN through_IN all_DT phases_NNS of_IN employment_NN ._.
complexities_NNS and_CC specific_JJ needs_NNS of_IN our_PRP$ business_NN ,_, We_PRP will_MD constructively_RB engage_VB stakeholders_NNS on_IN We_PRP will_MD provide_VB a_DT safe_JJ and_CC healthy_JJ working_VBG building_NN on_IN external_JJ guidelines_NNS and_CC experience_NN ._.
any_DT concerns_NNS that_WDT may_MD arise_VB ._.
environment_NN ,_, support_NN employees_NNS to_TO perform_VB to_TO We_PRP will_MD share_VB best_JJS practice_NN and_CC seek_VB to_TO influence_VB We_PRP will_MD ensure_VB that_IN our_PRP$ products_NNS are_VBP subject_JJ their_PRP$ full_JJ potential_NN and_CC to_TO take_VB responsibility_NN for_IN others_NNS ,_, while_IN remaining_VBG competitive_JJ in_IN order_NN to_TO to_TO rigorous_JJ scientific_JJ evaluation_NN and_CC testing_NN for_IN the_DT performance_NN and_CC reputation_NN of_IN the_DT business_NN ._.
We_PRP will_MD comply_VB with_IN or_CC exceed_VB all_DT regulations_NNS and_CC legal_JJ standards_NNS applicable_JJ to_TO the_DT research_NN and_CC development_NN of_IN our_PRP$ products_NNS ._.
9_CD Products_NNPS and_CC customers_NNS 2_CD Human_JJ rights_NNS 5_CD Community_NNP investment_NN We_PRP will_MD promote_VB our_PRP$ products_NNS in_IN line_NN with_IN high_JJ We_PRP are_VBP committed_VBN to_TO upholding_VBG the_DT UN_NNP We_PRP will_MD make_VB a_DT positive_JJ contribution_NN to_TO the_DT 1_CD ethical_JJ ,_, medical_JJ and_CC scientific_JJ standards_NNS and_CC will_MD Universal_NNP Declaration_NNP of_IN Human_NNP Rights_NNPS ,_, the_DT communities_NNS in_IN which_WDT we_PRP operate_VBP ,_, and_CC will_MD 2_CD comply_VBP with_IN all_DT applicable_JJ laws_NNS and_CC regulations_NNS ._.
OECD_NNP guidelines_NNS for_IN MNEs_NNS and_CC the_DT core_NN labor_NN invest_VBP in_IN health_NN and_CC education_NN programs_NNS standards_NNS set_VBN out_RP by_IN the_DT International_NNP Labor_NNP and_CC partnerships_NNS that_WDT aim_VBP to_TO bring_VB sustainable_JJ 3_CD Organisation_NNP ._.
We_PRP expect_VBP the_DT same_JJ standards_NNS improvements_NNS to_TO under-served_JJ people_NNS in_IN the_DT of_IN our_PRP$ suppliers_NNS ,_, contractors_NNS and_CC business_NN developed_VBD and_CC developing_VBG world_NN ._.
partners_NNS working_VBG on_IN GSKs_NNS behalf_NN ._.
6_CD Engagement_NNP with_IN 10_CD Caring_NN for_IN the_DT 3_CD Access_NN to_TO medicines_NNS stakeholders_NNS environment_NN We_PRP will_MD continue_VB to_TO research_NN and_CC develop_VB medicines_NNS to_TO treat_VB diseases_NNS of_IN the_DT developing_VBG We_PRP want_VBP to_TO understand_VB the_DT concerns_NNS of_IN those_DT We_PRP will_MD operate_VB in_IN an_DT environmentally_RB responsible_JJ world_NN ._.
We_PRP will_MD find_VB sustainable_JJ ways_NNS to_TO improve_VB with_IN an_DT interest_NN in_IN corporate_JJ responsibility_NN manner_NN through_IN systematic_JJ management_NN of_IN our_PRP$ access_NN to_TO medicines_NNS for_IN disadvantaged_JJ people_NNS ,_, issues_NNS ._.
We_PRP will_MD engage_VB with_IN a_DT range_NN of_IN environmental_JJ impacts_NNS ,_, measurement_NN of_IN our_PRP$ and_CC will_MD seek_VB partnerships_NNS to_TO support_VB this_DT activity_NN ._.
stakeholders_NNS and_CC will_MD communicate_VB openly_RB performance_NN and_CC setting_VBG challenging_JJ performance_NN about_IN how_WRB we_PRP are_VBP addressing_VBG CR_NNP issues_NNS ,_, in_IN targets_NNS ._.
We_PRP will_MD improve_VB the_DT efficiency_NN of_IN all_DT our_PRP$ ways_NNS that_WDT aim_VBP to_TO meet_VB the_DT needs_NNS of_IN different_JJ activities_NNS to_TO minimize_VB material_NN and_CC energy_NN use_NN and_CC groups_NNS while_IN allowing_VBG us_PRP to_TO pursue_VB legitimate_JJ waste_NN generated_VBD ._.
We_PRP aim_VBP to_TO find_VB opportunities_NNS to_TO business_NN goals_NNS ._.
use_NN renewable_JJ materials_NNS and_CC to_TO recycle_VB our_PRP$ waste_NN ._.
Corporate_JJ Responsibility_NN Report_NNP 2003_CD 03_CD The_DT pharmaceutical_JJ sector_NN needs_VBZ to_TO demonstrate_VB responsibility_NN across_IN a_DT very_RB wide_JJ range_NN of_IN issues_NNS ._.
GSK_NNP has_VBZ shown_VBN it_PRP is_VBZ aware_JJ of_IN its_PRP$ key_JJ CR_NN issues_NNS and_CC has_VBZ clear_JJ structures_NNS for_IN managing_VBG them_PRP ._.
GSK_NNP management_NN keeps_VBZ the_DT CR_NNP Committee_NNP informed_VBD of_IN its_PRP$ activities_NNS and_CC is_VBZ responsive_JJ to_TO the_DT Committees_NNS suggestions_NNS ._.
Donald_NNP McHenry_NNP Chairman_NNP ,_, Corporate_NNP Responsibility_NNP Committee_NNP Corporate_NNP Responsibility_NNP Committee_NNP GSKs_NNP Corporate_NNP Responsibility_NNP Committee_NNP consists_VBZ of_IN four_CD non-executive_JJ Directors_NNS and_CC reports_NNS to_TO the_DT Board_NNP ._.
During_IN 2003_CD the_DT Committee_NNP met_VBD three_CD times_NNS and_CC reviewed_VBN our_PRP$ activity_NN in_IN a_DT number_NN of_IN areas_NNS including_VBG donations_NNS and_CC community_NN investment_NN ,_, consumer_NN advertising_NN ,_, corporate_JJ responsibility_NN management_NN and_CC reporting_NN ,_, political_JJ activity_NN and_CC programs_NNS for_IN diseases_NNS of_IN the_DT developing_VBG world_NN ._.
Donald_NNP McHenry_NNP Dr_NNP Michle_NNP Barzach_NNP Sir_NNP Christopher_NNP Hogg_NNP Dr_NNP Lucy_NNP Shapiro_NNP Chairman_NNP of_IN the_DT Corporate_JJ Dr_NNP Barzach_NNP is_VBZ a_DT member_NN of_IN the_DT Sir_NNP Christopher_NNP is_VBZ Non-Executive_JJ Dr_NNP Shapiro_NNP is_VBZ Ludwig_NNP Professor_NNP of_IN Responsibility_NNP Committee_NNP ._.
Mr_NNP International_NNP Cooperation_NNP High_NNP Chairman_NNP of_IN Reuters_NNP Group_NNP PLC_NNP ,_, Cancer_NNP Research_NNP in_IN the_DT Department_NNP McHenry_NNP is_VBZ a_DT Distinguished_NNP Professor_NNP Council_NNP ,_, Chairman_NNP of_IN the_DT Board_NNP of_IN a_DT member_NN of_IN the_DT Supervisory_NNP Board_NNP of_IN Developmental_NNP Biology_NNP and_CC Director_NNP in_IN the_DT Practice_NNP of_IN Diplomacy_NNP at_IN the_DT Equilibres_NNPS et_FW Populations_NNPS and_CC Director_NNP of_IN Air_NNP Liquide_NNP S._NNP A._NN and_CC Chairman_NN of_IN of_IN the_DT Beckman_NNP Centre_NNP for_IN Molecular_NNP School_NNP of_IN Foreign_NNP Service_NNP at_IN of_IN the_DT Board_NNP of_IN Project_NNP Hope_NNP ._.
The_DT Royal_NNP National_NNP Theatre_NNP ,_, as_RB well_RB and_CC Genetic_NNP Medicine_NNP at_IN the_DT Stanford_NNP Georgetown_NNP University_NNP and_CC is_VBZ International_NNP consultant_NN in_IN health_NN as_IN being_VBG Non-Executive_JJ Chairman_NNP University_NNP School_NNP of_IN Medicine_NNP ._.
President_NNP of_IN the_DT IRC_NNP Group_NNP ,_, LLC_NNP ._.
strategy_NN ,_, she_PRP was_VBD formerly_RB French_JJ of_IN GSK_NNP ._.
Minister_NNP of_IN Health_NNP and_CC Family_NNP ._.
MANAGEMENT_NN OF_IN CORPORATE_JJ RESPONSIBILITY_NN We_PRP believe_VBP that_IN corporate_JJ responsibility_NN is_VBZ most_RBS effectively_RB managed_VBN within_IN our_PRP$ business_NN operations_NNS ,_, where_WRB experts_NNS on_IN Corporate_JJ all_PDT our_PRP$ CR_NN issues_NNS are_VBP employed_VBN ._.
We_PRP GSK_NNP Board_NNP Responsibility_NN have_VBP a_DT small_JJ corporate_JJ team_NN that_WDT Committee_NNP Ethics_NNPS and_CC co-ordinates_NNS policy_NN development_NN ,_, integrity_NN reporting_NN ,_, and_CC communication_NN with_IN socially_RB responsible_JJ investors_NNS ._.
CEO_NNP Access_NNP to_TO medicines_NNS Research_NNP and_CC GSK_NNP innovation_NN Corporate_NNP Executive_NNP Stakeholder_NNP Team_NNP engagement_NN Human_NNP rights_NNS Corporate_JJ responsibility_NN strategy_NN and_CC Community_NNP reporting_VBG investment_NN Employment_NNP practices_NNS Environment_NNP Products_NNPS and_CC Advocacy_NNP customers_NNS 04_CD Corporate_JJ Responsibility_NN Report_NNP 2003_CD Key_NNP impact_NN areas_NNS 1_CD Medicines_NNP for_IN the_DT Summary_NNP of_IN indicators_NNS developing_VBG world_NN Below_NNP are_VBP the_DT main_JJ indicators_NNS we_PRP are_VBP using_VBG to_TO track_VB our_PRP$ Resear_NNP Resear_NNP ch_VBP to_TO find_VB tr_NN ch_NN to_TO find_VB tr_NN eatments_NNS for_IN diseases_NNS of_IN eatments_NNS for_IN diseases_NNS the_DT developing_VBG world_NN ._.
Pr_NN of_IN the_DT developing_VBG world_NN ._.
Pr_NNP oviding_VBG vaccines_NNS oviding_VBG performance_NN on_IN a_DT range_NN of_IN corporate_JJ responsibility_NN issues_NNS ._.
and_CC medicines_NNS for_IN the_DT poor_JJ vaccines_NNS and_CC medicines_NNS for_IN the_DT poor_JJ est_NN countries_NNS at_IN est_NN prefercountries_NNS at_IN pr_NN ential_JJ prices_NNS ._.
PAGE_NN 10_CD PAGE_NNP 10_CD Issue_NNP 2002_CD 2003_CD Medicines_NNP for_IN the_DT developing_VBG world_NN 2_CD Community_NNP investment_NN Supply_NNP arrangements_NNS for_IN preferentially_RB priced_VBN anti-retrovirals_NNS ARVs_NNS 124_CD 175_CD Our_PRP$ philanthropic_JJ work_NN primarily_RB Number_NNP of_IN countries_NNS supplied_VBN with_IN preferentially_RB priced_VBN ARVs_NNP 50_CD 56_CD focuses_VBZ on_IN health_NN and_CC education_NN ._.
PAGE_NN 14_CD Number_NN of_IN Combivir_NNP tablets_NNS shipped_VBD 6.2_CD m_NN 10.7_CD m_NN Number_NN of_IN albendazole_JJ tablets_NNS donated_VBN 66m_CD 94m_CD Number_NN of_IN countries_NNS supplied_VBN with_IN albendazole_JJ 31_CD 34_CD Community_NNP investment_NN Total_JJ community_NN investment_NN expenditure_NN 239m_JJ 338m_CD Total_JJ value_NN of_IN product_NN donations_NNS including_VBG albendazole_JJ 24m_JJ 116m_JJ 3_CD Business_NN ethics_NNS and_CC integrity_NN Total_JJ value_NN of_IN products_NNS donated_VBN through_IN GSK_NNP Patient_NNP The_NNP standards_NNS of_IN behavior_NN required_VBN Assistance_NNP Program_NNP 112m_CD 125m_CD of_IN all_PDT our_PRP$ employees_NNS and_CC the_DT steps_NNS we_PRP Business_NN ethics_NNS and_CC integrity_NN are_VBP taking_VBG to_TO ensure_VB they_PRP are_VBP achieved_VBN ._.
Number_NN of_IN employees_NNS completing_VBG certification_NN to_TO 700_CD 9,000_CD PAGE_NNP 18_CD Code_NNP of_IN Conduct_NNP Environment_NNP Number_NNP of_IN contract_NN manufacturers_NNS audited_VBD 16_CD 28_CD 4_CD Environment_NNP ,_, health_NN and_CC safety_NN Energy_NN consumption_NN million_CD gigajoules_NNS 20.1_CD 19.8_CD Water_NNP consumption_NN million_CD cubic_JJ metres_NNS 24.7_CD 23.5_CD Using_VBG resources_NNS efficiently_RB and_CC minimizing_VBG the_DT impact_NN of_IN our_PRP$ products_NNS Ozone_NN depletion_NN potential_NN from_IN metered_VBN dose_NN inhalers_NNS and_CC operations_NNS on_IN the_DT environment_NN ._.
tonnes_NNS CFC-11_NN equivalent_JJ 1,500_CD 782_CD Protecting_VBG our_PRP$ employees_NNS and_CC Ozone_NN depletion_NN potential_NN from_IN production_NN tonnes_NNS CFC-11_NN equivalent_JJ 120_CD 68_CD contractors_NNS in_IN the_DT workplace_NN ._.
Ozone_NN depletion_NN potential_NN from_IN refrigeration_NN and_CC other_JJ ancillary_JJ uses_NNS PAGE_VBP 20_CD tonnes_NNS CFC-11_NN equivalent_JJ 7.4_CD 2.2_CD Volatile_JJ organic_JJ compound_NN emissions_NNS thousand_CD tonnes_NNS 6.5_CD 6.6_CD Global_JJ warming_NN potential_NN from_IN energy_NN sources_NNS thousand_CD tonnes_VBZ CO_NNP equivalent_JJ 1,842_CD 1,815_CD 2_CD 5_CD Valuing_VBG people_NNS Hazardous_JJ waste_NN disposed_VBD thousand_CD tonnes_NNS 62.5_CD 61.4_CD Our_PRP$ commitment_NN to_TO diversity_NN ,_, equal_JJ Health_NNP and_CC safety_NN opportunity_NN and_CC creating_VBG a_DT working_VBG Lost_VBN time_NN injury_NN and_CC illness_NN rate_NN cases_NNS per_IN 100,000_CD hours_NNS worked_VBD 0.34_CD 0.31_CD environment_NN in_IN which_WDT the_DT talent_NN of_IN all_DT Lost_VBN time_NN injury_NN and_CC illness_NN rate_NN for_IN contractors_NNS working_VBG on_IN site_NN our_PRP$ people_NNS will_MD thrive_VB ._.
cases_NNS per_IN 100,000_CD hours_NNS worked_VBD 0.50_CD 0.33_CD PAGE_NNP 23_CD Valuing_VBG people_NNS Women_NNS in_IN management_NN grades_NNS %_NN 32_CD 34_CD Research_NNP and_CC development_NN Ethnic_JJ diversity_NN people_NNS of_IN color_NN US_NNP only_RB ,_, %_NN 19.0_CD 19.5_CD 6_CD Research_NNP and_CC development_NN The_DT conduct_NN and_CC publication_NN of_IN clinical_JJ trials_NNS ._.
The_DT need_NN for_IN animal_NN GSK_NNP animal_NN research_NN facilities_NNS accredited_VBN by_IN the_DT Association_NNP for_IN testing_NN and_CC safeguards_NNS for_IN their_PRP$ Assessment_NNP and_CC Accreditation_NNP of_IN Laboratory_NNP Animal_NNP Care_NNP 7_CD 7_CD treatment_NN ._.
PAGE_NN 26_CD We_PRP are_VBP assessing_VBG the_DT benefits_NNS of_IN developing_VBG further_JJ performance_NN indicators_NNS ._.
In_IN doing_VBG so_RB ,_, we_PRP will_MD continue_VB to_TO take_VB into_IN account_NN the_DT views_NNS of_IN our_PRP$ stakeholders_NNS ._.
Corporate_JJ Responsibility_NN Report_NNP 2003_CD 05_CD Each_DT and_CC ev_VB GSK_NNP plays_VBZ an_DT important_JJ role_NN in_IN society_NN through_IN research_NN into_IN new_JJ treatments_NNS and_CC vaccines_NNS ,_, product_NN donations_NNS ,_, preferential_JJ pricing_NN for_IN developing_VBG countries_NNS and_CC support_NN for_IN patients_NNS who_WP can_MD not_RB afford_VB medicines_NNS ._.
Here_RB are_VBP some_DT examples_NNS of_IN how_WRB much_JJ we_PRP contribute_VBP each_DT day_NN ._.
More_JJR than_IN 555,000_CD Americans_NNPS have_VBP access_NN to_TO our_PRP$ medicines_NNS free_JJ of_IN charge_NN or_CC at_IN subsidised_JJ rates_NNS These_DT are_VBP people_NNS who_WP do_VBP not_RB have_VB insurance_NN and_CC would_MD otherwise_RB not_RB be_VB able_JJ to_TO afford_VB medicines_NNS ._.
7million_RB invested_VBN in_IN scientific_JJ medical_JJ research_NN each_DT day_NN Society_NNP relies_VBZ on_IN the_DT pharmaceutical_JJ industry_NN to_TO discover_VB and_CC develop_VB the_DT medicines_NNS of_IN the_DT future_NN ._.
06_CD Corporate_JJ Responsibility_NN Report_NNP 2003_CD every_DT day_NN Over_IN 2_CD million_CD GSK_NNP vaccines_NNS are_VBP distributed_VBN worldwide_JJ These_DT prevent_VBP disease_NN and_CC help_NN improve_VB public_JJ health_NN ._.
and_CC over_IN 250,000_CD albendazole_JJ preventative_JJ treatments_NNS are_VBP donated_VBN to_TO people_NNS in_IN developing_VBG countries_NNS Albendazole_NNP helps_VBZ prevent_VB transmission_NN of_IN lymphatic_JJ filariasis_NN ,_, a_DT debilitating_VBG disease_NN affecting_VBG 120_CD million_CD people_NNS in_IN developing_VBG countries_NNS ._.
27,000_CD tablets_NNS of_IN Combivir_NNP are_VBP shipped_VBN to_TO treat_VB HIV_NNP AIDS_NNP patients_NNS in_IN developing_VBG countries_NNS Making_VBG anti-retrovirals_NNS more_RBR affordable_JJ through_IN sustainable_JJ preferential_JJ pricing_NN to_TO help_VB tackle_VB the_DT global_JJ HIV_NNP AIDS_NNP epidemic_NN ._.
Corporate_JJ Responsibility_NN Report_NNP 2003_CD 07_CD Our_PRP$ contributio_NN Our_PRP$ business_NN is_VBZ about_IN developing_VBG and_CC marketing_VBG medicines_NNS and_CC vaccines_NNS that_WDT improve_VBP the_DT health_NN and_CC quality_NN of_IN life_NN of_IN millions_NNS of_IN people_NNS around_IN the_DT world_NN ._.
We_PRP are_VBP a_DT commercial_JJ organization_NN that_WDT needs_VBZ to_TO make_VB profits_NNS to_TO fund_VB future_JJ investment_NN and_CC to_TO pay_VB dividends_NNS to_TO our_PRP$ shareholders_NNS ._.
Patient_NN Assistance_NNP Program_NNP in_IN the_DT US_NNP We_PRP believe_VBP governments_NNS and_CC Developing_VBG world_NN GSKs_NNP Patient_NNP Assistance_NNP Program_NNP PAP_NNP in_IN Many_JJ people_NNS in_IN the_DT developing_VBG world_NN continue_VBP intergovernmental_JJ bodies_NNS are_VBP primarily_RB the_DT US_NNP gives_VBZ low-income_JJ ,_, uninsured_JJ patients_NNS to_TO suffer_VB and_CC die_VB from_IN preventable_JJ and_CC treatable_JJ responsible_JJ for_IN meeting_VBG the_DT worlds_NNS access_NN to_TO the_DT medicines_NNS they_PRP need_VBP but_CC diseases_NNS ._.
They_PRP do_VBP not_RB have_VB access_NN to_TO the_DT health_NN challenges_NNS ,_, including_VBG those_DT in_IN can_MD not_RB afford_VB ._.
medicines_NNS they_PRP need_VBP ,_, or_CC to_TO adequate_JJ healthcare_NN the_DT developing_VBG world_NN ._.
We_PRP can_MD not_RB Commitment_VB to_TO Access_NNP covers_VBZ cancer_NN facilities_NNS ._.
GSK_NNP makes_VBZ a_DT major_JJ contribution_NN replace_VB the_DT functions_NNS of_IN governments_NNS treatments_NNS while_IN other_JJ medicines_NNS are_VBP available_JJ through_IN research_NN into_IN treatments_NNS and_CC vaccines_NNS or_CC charities_NNS but_CC we_PRP support_VBP them_PRP in_IN through_IN another_DT of_IN our_PRP$ programs_NNS ,_, Bridges_NNPS for_IN diseases_NNS that_WDT are_VBP common_JJ in_IN developing_VBG some_DT very_RB important_JJ ways_NNS we_PRP have_VBP to_TO Access_NNP ._.
countries_NNS ,_, providing_VBG products_NNS at_IN preferential_JJ a_DT significant_JJ role_NN to_TO play_VB ._.
In_IN 2003_CD ,_, over_IN 400,000_CD people_NNS received_VBD free_JJ prices_NNS and_CC investing_VBG in_IN community_NN health_NN and_CC GSK_NNP medicines_NNS through_IN these_DT programs_NNS ._.
These_DT are_VBP described_VBN in_IN Pharmaceutical_NNP research_NN Our_PRP$ total_JJ commitment_NN to_TO PAP_NNP in_IN 2003_CD was_VBD more_RBR detail_NN on_IN page_NN 10_CD ._.
In_IN developed_JJ countries_NNS we_PRP take_VBP medicines_NNS almost_RB $_$ 205_CD million_CD ._.
Eligibility_NN criteria_NNS for_IN these_DT for_IN granted_VBN ._.
We_PRP have_VBP benefited_VBN from_IN advances_NNS programs_NNS are_VBP among_IN the_DT most_RBS generous_JJ Developed_VBN world_NN offered_VBN by_IN the_DT pharmaceutical_JJ industry_NN ._.
which_WDT mean_VBP that_IN most_JJS of_IN us_PRP are_VBP no_RB longer_RB at_IN risk_NN Even_RB in_IN developed_JJ countries_NNS some_DT sections_NNS of_IN from_IN diseases_NNS such_JJ as_IN polio_NN and_CC TB_NN that_WDT were_VBD Patient_NNP eligibility_NN is_VBZ determined_VBN through_IN one_CD society_NN do_VBP not_RB have_VB sufficient_JJ access_NN to_TO medicines_NNS ._.
major_JJ threats_NNS less_RBR than_IN a_DT century_NN ago_RB ._.
But_CC there_EX phone_NN call_NN ,_, and_CC once_RB enrolled_VBD a_DT patient_NN can_MD This_DT is_VBZ a_DT particular_JJ concern_NN in_IN the_DT US_NNP ,_, where_WRB many_JJ are_VBP still_RB many_JJ serious_JJ illnesses_NNS for_IN which_WDT there_EX receive_VBP the_DT prescription_NN medicine_NN immediately_RB people_NNS are_VBP not_RB covered_VBN by_IN public_JJ or_CC private_JJ health_NN at_IN any_DT local_JJ pharmacy_NN ._.
In_IN addition_NN patients_NNS are_VBP are_VBP few_JJ treatments_NNS or_CC where_WRB treatments_NNS may_MD be_VB insurance_NN ._.
We_PRP are_VBP helping_VBG patients_NNS who_WP do_VBP not_RB helped_VBN to_TO find_VB other_JJ sources_NNS of_IN funding_VBG such_JJ improved_VBN ._.
have_VB insurance_NN coverage_NN to_TO gain_VB access_NN to_TO as_IN Medicaid_NNP ,_, AIDS_NNP Drug_NNP Assistance_NNP Program_NNP ,_, State_NNP Childrens_NNP Health_NNP Insurance_NNP Programs_NNP prescription_NN medicines_NNS via_IN a_DT number_NN of_IN initiatives_NNS ._.
Discovering_VBG and_CC developing_VBG a_DT new_JJ medicine_NN and_CC State_NN Elderly_NNP Drug_NNP Assistance_NNP Programs_NNP ._.
to_TO prevent_VB or_CC treat_VB disease_NN is_VBZ expensive_JJ the_DT GSK_NNP was_VBD the_DT first_JJ pharmaceutical_JJ company_NN in_IN the_DT The_DT company_NN promotes_VBZ the_DT PAP_NNP on_IN two_CD average_JJ cost_NN is_VBZ over_IN 450_CD million_CD and_CC it_PRP takes_VBZ 6_CD 7_CD ,_, websites_NNS which_WDT tell_VBP patients_NNS what_WDT support_NN US_NNP to_TO offer_VB a_DT card_NN providing_VBG savings_NNS on_IN medicines_NNS around_IN 12_CD years_NNS ._.
is_VBZ available_JJ and_CC help_VB to_TO increase_VB take-up_NN ._.
to_TO low_JJ income_NN senior_JJ citizens_NNS and_CC disabled_JJ people_NNS ._.
Our_PRP$ Orange_NNP Card_NNP is_VBZ available_JJ to_TO these_DT groups_NNS ,_, GSK_NNP invested_VBD almost_RB providing_VBG savings_NNS of_IN up_RB to_TO 40_CD %_NN on_IN GSKs_NNS 4_CD prescription_NN medicines_NNS ._.
By_IN the_DT end_NN of_IN 2003_CD ,_, 2.8_CD billion_CD in_IN research_NN 155,000_CD patients_NNS had_VBD enrolled_VBN in_IN this_DT program_NN ._.
GSK_NNP has_VBZ also_RB joined_VBN with_IN six_CD other_JJ This_DT enables_VBZ us_PRP to_TO employ_VB the_DT pharmaceutical_JJ companies_NNS to_TO offer_VB the_DT Together_RB Rx_JJ card_NN to_TO low_JJ income_NN patients_NNS who_WP are_VBP leading_VBG scientists_NNS and_CC provide_VB eligible_JJ for_IN Medicare_NNP and_CC would_MD otherwise_RB the_DT technology_NN they_PRP need_VBP 5_CD not_RB be_VB able_JJ to_TO afford_VB prescription_NN medicines_NNS ._.
Together_RB Rx_NNP provides_VBZ a_DT discount_NN of_IN between_IN to_TO push_VB forward_RB the_DT frontiers_NNS 20_CD %_NN and_CC 40_CD %_NN on_IN over_IN 150_CD different_JJ medicines_NNS ._.
We_PRP also_RB operate_VBP a_DT Patient_NNP Assistance_NNP Program_NNP Society_NNP now_RB relies_VBZ on_IN pharmaceutical_JJ companies_NNS which_WDT in_IN 2003_CD provided_VBN medicines_NNS worth_JJ to_TO make_VB this_DT investment_NN and_CC fund_NN research_NN ._.
These_DT were_VBD provided_VBN at_IN no_DT cost_NN ,_, or_CC funding_NN and_CC resources_NNS of_IN the_DT industry_NN are_VBP integral_JJ minimal_JJ cost_NN ,_, to_TO more_JJR than_IN 400,000_CD patients_NNS in_IN to_TO the_DT development_NN of_IN new_JJ medicines_NNS ._.
the_DT US_NNP who_WP do_VBP not_RB have_VB medical_JJ insurance_NN and_CC may_MD otherwise_RB have_VB gone_VBN without_IN their_PRP$ medicines_NNS ._.
08_CD Corporate_JJ Responsibility_NN Report_NNP 2003_CD n_NN to_TO society_NN An_DT important_JJ part_NN of_IN my_PRP$ job_NN is_VBZ helping_VBG some_DT of_IN the_DT 80,000_CD people_NNS in_IN Baltimore_NNP County_NNP who_WP do_VBP not_RB have_VB medical_JJ insurance_NN ._.
GSKs_NNS program_NN makes_VBZ it_PRP easy_JJ for_IN me_PRP to_TO help_VB :_: the_DT process_NN is_VBZ so_RB quick_JJ I_PRP always_RB hope_VBP its_PRP$ a_DT GSK_NNP medicine_NN on_IN the_DT prescription_NN ._.
Patients_NNS pay_VBP just_RB $_$ 10_CD for_IN two_CD months_NNS supply_NN of_IN medicine_NN no_DT matter_NN what_WDT drug_NN is_VBZ required_VBN ._.
This_DT is_VBZ invaluable_JJ to_TO uninsured_JJ patients_NNS who_WP might_MD otherwise_RB have_VB to_TO choose_VB between_IN medicines_NNS or_CC food_NN ._.
Wendy_NNP Freeman_NNP Case_NNP Manager_NNP ,_, Baltimore_NNP County_NNP Health_NNP Department_NNP ,_, Maryland_NNP ,_, US_NNP Corporate_NNP Responsibility_NNP Report_NNP 2003_CD 09_CD Medicines_NNP f_SYM the_DT develop_VB Lack_NN of_IN access_NN to_TO even_RB basic_JJ medication_NN and_CC healthcare_NN facilities_NNS has_VBZ led_VBN to_TO a_DT healthcare_NN crisis_NN in_IN the_DT developing_VBG world_NN ._.
GSK_NNP is_VBZ committed_VBN to_TO playing_VBG a_DT leading_VBG role_NN in_IN addressing_VBG this_DT crisis_NN ._.
GSKs_NNS response_NN to_TO this_DT crisis_NN has_VBZ three_CD elements_NNS :_: Progress_NNP in_IN 2003_CD half_NN of_IN 2002_CD was_VBD largely_RB due_JJ to_TO potential_JJ Preferential_JJ pricing_NN offering_NN anti-retrovirals_NNS Following_VBG improvements_NNS in_IN manufacturing_NN and_CC purchasers_NNS delaying_VBG placement_NN of_IN orders_NNS in_IN ARVs_NNS for_IN HIV_NNP AIDS_NNP and_CC anti-malarials_NNS on_IN a_DT economies_NNS of_IN scale_NN ,_, we_PRP cut_VBD the_DT not-for-profit_JJ anticipation_NN of_IN new_JJ funding_NN sources_NNS ._.
These_DT not-for-profit_JJ basis_NN and_CC vaccines_NNS at_IN significant_JJ prices_NNS of_IN ARVs_NNS in_IN April_NNP and_CC again_RB in_IN October_NNP ._.
became_VBD available_JJ early_RB in_IN 2003_CD ,_, hence_RB the_DT discounts_NNS to_TO the_DT poorest_JJS countries_NNS Combivir_NNP is_VBZ now_RB available_JJ at_IN $_$ 0.65_CD a_DT day_NN ,_, increase_NN in_IN shipments_NNS during_IN this_DT year_NN ._.
Research_NNP and_CC development_NN investment_NN in_IN compared_VBN to_TO $_$ 1.70_CD in_IN December_NNP 2002_CD ._.
the_DT search_NN for_IN new_JJ treatments_NNS and_CC vaccines_NNS It_PRP is_VBZ difficult_JJ to_TO quantify_VB the_DT number_NN of_IN patients_NNS for_IN diseases_NNS of_IN the_DT developing_VBG world_NN We_PRP now_RB have_VBP over_IN 175_CD public_JJ sector_NN agreements_NNS treated_VBN as_IN a_DT result_NN of_IN our_PRP$ programs_NNS because_IN Community_NNP investment_NN activities_NNS and_CC to_TO supply_VB ARVs_NNS in_IN 56_CD countries_NNS ._.
This_DT includes_VBZ 25_CD we_PRP do_VBP not_RB control_VB healthcare_NN provision_NN ._.
However_RB ,_, partnerships_NNS that_WDT support_VBP improving_VBG health_NN ARV_NNP supply_NN agreements_NNS with_IN employers_NNS in_IN suba_NN study_NN in_IN September_NNP 2003_CD by_IN the_DT UN-led_JJ in_IN under-served_JJ communities_NNS ._.
Accelerating_VBG Access_NNP Initiative_NNP AAI_NNP indicates_VBZ that_IN in_IN sub-Saharan_JJ Africa_NNP the_DT number_NN of_IN patients_NNS Preferential_JJ pricing_NN During_IN 2003_CD we_PRP shipped_VBD almost_RB 11_CD million_CD treated_VBN with_IN ARVs_NNS supplied_VBN by_IN the_DT six_CD companies_NNS All_DT GSK_NNP ARVs_NNPS and_CC anti-malarial_JJ medicines_NNS are_VBP preferentially_RB priced_VBN Combivir_NNP tablets_NNS to_TO in_IN the_DT AAI_NNP had_VBD more_RBR than_IN doubled_VBN in_IN a_DT year_NN to_TO now_RB available_JJ to_TO the_DT public_JJ sector_NN at_IN not-fordeveloping_JJ countries_NNS ,_, 74_CD %_NN more_JJR than_IN in_IN 2002_CD ._.
over_IN 75,000_CD ._.
This_DT is_VBZ still_RB a_DT very_RB small_JJ proportion_NN profit_NN prices_NNS in_IN 63_CD of_IN the_DT worlds_NNS poorest_JJS Shipment_NN figures_NNS for_IN 2002_CD exclude_VBP the_DT product_NN of_IN the_DT patients_NNS who_WP need_VBP treatment_NN ._.
Substantial_JJ 8_CD countries_NNS ,_, including_VBG all_DT of_IN sub-Saharan_JJ Africa_NNP ._.
sold_VBN at_IN not-for-profit_JJ prices_NNS to_TO West_NNP Africa_NNP and_CC coverage_NN requires_VBZ more_JJR funding_NN to_TO pay_VB for_IN better_JJR Not-for-profit_JJ prices_NNS for_IN ARVs_NNS are_VBP also_RB available_JJ illegally_RB diverted_VBN back_RB to_TO Europe_NNP ,_, amounting_VBG to_TO healthcare_NN infrastructure_NN and_CC to_TO ensure_VB the_DT safe_JJ to_TO private_JJ employers_NNS in_IN sub-Saharan_JJ Africa_NNP who_WP almost_RB a_DT quarter_NN of_IN not-for-profit_JJ Combivir_NNP sales_NNS delivery_NN of_IN more_JJR medicines_NNS to_TO patients_NNS ._.
provide_VB care_NN and_CC treatment_NN for_IN uninsured_JJ staff_NN ._.
The_DT decline_NN in_IN shipments_NNS in_IN the_DT second_JJ All_DT projects_NNS fully_RB funded_VBN by_IN the_DT Global_NNP Fund_NNP to_TO 9_CD SUPPLY_NN ARRANGEMENTS_NNS BY_IN TYPE_NNP OF_IN CUSTOMER_NNP Fight_VBP AIDS_NNP ,_, TB_NN and_CC Malaria_NN are_VBP also_RB eligible_JJ ,_, so_IN that_IN our_PRP$ not-for-profit_JJ prices_NNS are_VBP now_RB available_JJ in_IN over_IN 100_CD countries_NNS ._.
We_PRP negotiate_VBP preferential_JJ 200_CD prices_NNS with_IN middle-income_JJ countries_NNS on_IN a_DT case-by-case_JJ basis_NN ._.
150_CD Our_PRP$ not-for-profit_JJ prices_NNS are_VBP set_VBN to_TO cover_VB our_PRP$ manufacturing_NN and_CC distribution_NN costs_NNS ._.
This_DT ensures_VBZ we_PRP can_MD sustain_VB the_DT supply_NN of_IN these_DT 100_CD products_NNS for_IN as_RB long_JJ as_IN patients_NNS need_VBP them_PRP ._.
The_DT World_NNP Health_NNP Organization_NNP WHO_WP has_VBZ set_VBN a_DT target_NN to_TO treat_VB 3_CD million_CD HIV_NNP positive_JJ people_NNS in_IN 50_CD 10_CD developing_VBG countries_NNS with_IN ARVs_NNS by_IN 2005_CD ._.
We_PRP are_VBP committed_VBN to_TO making_VBG a_DT strong_JJ contribution_NN to_TO the_DT achievement_NN of_IN this_DT goal_NN ._.
0_CD Q4_CD Q1_NNP Q2_NNP Q3_NNP Q4_NNP Q1_NNP Q2_NNP Q3_NNP Q4_NNP Q1_NNP Q2_NNP Q3_NNP Q4_NNP 2000 2001 2002 2003_CD Employers_NNP Public_NNP Hospitals_NNPS NGOs_NNP Govt_NNP Non_NNP AAI_NNP AAI_NNP 10_CD Corporate_JJ Responsibility_NN Report_NNP 2003_CD 1_CD Medicines_NNP for_IN the_DT developing_VBG world_NN for_IN oping_JJ world_NN In_IN 2003_CD we_PRP extended_VBD the_DT voluntary_JJ licence_NN Pilot_NN projects_NNS are_VBP underway_JJ to_TO explore_VB world_NN ._.
A_DT similar_JJ group_NN also_RB exists_VBZ in_IN our_PRP$ vaccines_NNS granted_VBN to_TO the_DT generics_NNS manufacturer_NN ,_, Aspen_NNP opportunities_NNS for_IN extending_VBG preferential_JJ pricing_NN organization_NN based_VBN in_IN Belgium_NNP ._.
Pharmacare_NNP ,_, to_TO include_VB sales_NNS to_TO the_DT private_JJ to_TO a_DT wider_JJR range_NN of_IN medicines_NNS ._.
Under_IN this_DT agreement_NN Aspen_NNP can_MD now_RB run_VB in_IN partnership_NN with_IN NGOs_NNS in_IN Zambia_NNP ,_, Malawi_NNP ,_, Progress_NNP in_IN 2003_CD manufacture_NN and_CC sell_VB key_JJ GSK_NNP ARVs_NNS across_IN Uganda_NNP ,_, Tanzania_NNP and_CC Nigeria_NNP ._.
Early_RB observations_NNS In_IN February_NNP we_PRP launched_VBD our_PRP$ new_JJ meningitis_NNS sub-Saharan_JJ Africa_NNP ,_, in_IN both_DT the_DT public_NN and_CC suggest_VBP that_IN the_DT greatest_JJS medical_JJ need_NN is_VBZ for_IN vaccine_NN for_IN Africa_NNP ,_, Mencevax_NNP ACW_NNP ,_, developed_VBD private_JJ sectors_NNS ._.
Discussions_NNS are_VBP underway_JJ with_IN basic_JJ essential_JJ medicines_NNS ._.
Furthermore_RB ,_, even_RB with_IN the_DT WHO_WP ._.
This_DT is_VBZ available_JJ to_TO 21_CD African_NNP a_DT second_JJ generics_NNS manufacturer_NN on_IN a_DT similar_JJ when_WRB medicines_NNS are_VBP supplied_VBN at_IN the_DT lowest_JJS prices_NNS ,_, countries_NNS at_IN the_DT preferential_JJ price_NN of_IN one_CD euro_NN licence_NN for_IN GSK_NNP ARVs_NNPS across_IN Africa_NNP ._.
access_NN to_TO treatment_NN may_MD not_RB significantly_RB increase_VB per_IN dose_NN ._.
Product_NN diversion_NN like_IN that_DT seen_VBN in_IN 2002_CD denies_VBZ Phase_NN II_NNP clinical_JJ trials_NNS of_IN our_PRP$ malaria_NN vaccine_NN for_IN treatment_NN to_TO patients_NNS in_IN developing_VBG countries_NNS and_CC The_DT international_JJ community_NN made_VBD good_JJ children_NNS began_VBD in_IN Mozambique_NNP in_IN partnership_NN undermines_VBZ our_PRP$ preferential_JJ price_NN agreements_NNS ._.
To_TO progress_VB on_IN supporting_VBG access_NN to_TO medicines_NNS with_IN the_DT Malaria_NNP Vaccine_NNP Initiative_NNP ._.
We_PRP also_RB help_VBP minimize_VB diversion_NN we_PRP are_VBP introducing_VBG special_JJ initiatives_NNS in_IN 2003_CD ._.
In_IN particular_JJ we_PRP welcome_VBP started_VBD Phase_NN III_NNP clinical_JJ trials_NNS in_IN Latin_NNP America_NNP access_NN packs_VBZ to_TO differentiate_VB preferentially_RB priced_VBN funding_NN from_IN initiatives_NNS such_JJ as_IN the_DT Global_NNP Fund_NNP for_IN our_PRP$ rotavirus_NN vaccine_NN ,_, for_IN protection_NN against_IN products_NNS ._.
We_PRP are_VBP now_RB able_JJ to_TO supply_VB 58_CD countries_NNS and_CC the_DT US_NNP Emergency_NNP Plan_NNP for_IN AIDS_NNP Relief_NNP ,_, a_DT major_JJ cause_NN of_IN diarrhoea_NN ._.
The_DT dehydration_NN with_IN Combivir_NNP in_IN a_DT special_JJ pack_NN ._.
as_RB well_RB as_IN the_DT G8_NNP Action_NNP Plan_NNP on_IN Health_NNP that_WDT resulting_VBG from_IN diarrhoea_NN ,_, and_CC the_DT lack_NN of_IN a_DT clean_JJ recognizes_VBZ the_DT importance_NN of_IN preferential_JJ pricing_NN water_NN supply_NN ,_, causes_VBZ the_DT death_NN of_IN over_IN half_PDT a_DT 11_CD Similar_JJ efforts_NNS are_VBP underway_JJ to_TO secure_VB and_CC preventing_VBG product_NN diversion_NN ._.
However_RB ,_, million_CD children_NNS each_DT year_NN in_IN developing_VBG countries_NNS ._.
widespread_JJ regulatory_JJ approval_NN for_IN Trizivir_NNP and_CC much_RB more_RBR still_RB needs_VBZ to_TO be_VB done_VBN ._.
Epivir_NNP tablet_NN packs_NNS and_CC Retrovir_NNP and_CC Epivir_NNP Human_NNP clinical_JJ trials_NNS of_IN our_PRP$ HIV_NNP vaccine_NN continued_VBD solution_NN packs_NNS ._.
We_PRP will_MD also_RB be_VB using_VBG a_DT different_JJ Research_NN and_CC development_NN this_DT year_NN and_CC we_PRP are_VBP researching_VBG several_JJ other_JJ color_NN for_IN some_DT of_IN our_PRP$ ARV_NNP tablets_NNS ._.
There_EX is_VBZ currently_RB no_DT cure_NN for_IN many_JJ of_IN the_DT potential_JJ HIV_NNP vaccines_NNS ._.
We_PRP anticipate_VBP taking_VBG our_PRP$ diseases_NNS affecting_VBG developing_VBG countries_NNS ,_, and_CC TB_NN vaccine_NN into_IN Phase_NN I_PRP development_NN in_IN early_JJ 2004_CD ._.
In_IN 2003_CD we_PRP applied_VBD to_TO register_VB a_DT number_NN of_IN our_PRP$ some_DT existing_VBG treatments_NNS are_VBP becoming_VBG less_RBR ARVs_NNS under_IN the_DT EUs_NNP Anti-Diversion_NNP Regulation_NNP effective_JJ due_JJ to_TO drug_NN resistance_NN ._.
Investment_NN In_IN October_NNP we_PRP signed_VBD a_DT technology_NN transfer_NN ,_, designed_VBN to_TO prevent_VB illegal_JJ product_NN diversion_NN into_IN in_IN R&D_NNP for_IN new_JJ treatments_NNS and_CC vaccines_NNS is_VBZ supply_NN and_CC licence_NN agreement_NN with_IN the_DT Brazilian_JJ Europe_NNP ._.
Public_NNP private_JJ partnerships_NNS PPP_NNP government_NN for_IN the_DT production_NN of_IN the_DT measles_NNS ,_, are_VBP essential_JJ to_TO fund_VB research_NN where_WRB there_EX is_VBZ mumps_NNS and_CC rubella_NN vaccine_NN ._.
This_DT will_MD enable_VB no_DT commercially_RB viable_JJ market_NN for_IN a_DT potential_JJ more_JJR than_IN 100_CD million_CD children_NNS in_IN Brazil_NNP to_TO be_VB product_NN ._.
We_PRP are_VBP working_VBG with_IN many_JJ vaccinated_VBN over_IN the_DT next_JJ five_CD years_NNS ._.
SHIPMENTS_NNS OF_IN COMBIVIR_NNP TABLETS_NNP excluding_VBG diverted_VBN product_NN governments_NNS ,_, UN_NNP agencies_NNS and_CC other_JJ global_JJ funding_NN bodies_NNS in_IN this_DT area_NN ._.
In_IN July_NNP Lapdap_NNP ,_, an_DT anti-malarial_JJ treatment_NN 5_CD developed_VBN by_IN GSK_NNP through_IN a_DT PPP_NNP ,_, received_VBD We_PRP believe_VBP we_PRP are_VBP currently_RB the_DT only_JJ company_NN approval_NN from_IN the_DT UK_NNP regulatory_JJ agency_NN see_VB 4_CD researching_VBG new_JJ vaccines_NNS and_CC treatments_NNS for_IN page_NN 13_CD ._.
We_PRP expanded_VBD our_PRP$ research_NN agreement_NN 12_CD all_DT three_CD of_IN the_DT WHOs_NNS priority_NN diseases_NNS in_IN the_DT with_IN the_DT Medicines_NNP for_IN Malaria_NNP Venture_NNP ._.
This_DT developing_VBG world_NN HIV_NNP AIDS_NNP ,_, TB_NN and_CC malaria_NN ._.
includes_VBZ development_NN of_IN CDA_NNP ,_, a_DT combination_NN of_IN 3_CD We_PRP have_VBP 16_CD clinical_JJ development_NN programs_NNS Lapdap_NNP and_CC artesunate_JJ ,_, as_RB well_RB as_IN two_CD new_JJ classes_NNS for_IN products_NNS of_IN relevance_NN to_TO the_DT developing_VBG of_IN anti-malarial_JJ in_IN drug_NN discovery_NN ._.
Seven_CD of_IN these_DT are_VBP aimed_VBN specifically_RB at_IN diseases_NNS that_WDT disproportionately_RB affect_VBP developing_VBG Phase_NN II_NNP clinical_JJ trials_NNS of_IN sitamaquine_NN ,_, a_DT new_JJ oral_JJ 1_CD countries_NNS see_VBP table_NN ,_, page_NN 12_CD ._.
A_DT number_NN of_IN pretreatment_NN for_IN visceral_JJ leishmaniasis_NN ,_, were_VBD completed_VBN clinical_JJ projects_NNS are_VBP also_RB underway_JJ ._.
in_IN Kenya_NNP and_CC India_NNP and_CC demonstrated_VBD promising_JJ efficacy_NN ._.
Further_JJ clinical_JJ studies_NNS are_VBP planned_VBN for_IN 0_CD Q1_CD Q2_NNP Q3_NNP Q4_NNP Q1_NNP Q2_NNP Q3_NNP Q4_NNP Q1_NNP Q2_NNP Q3_NNP Q4_NNP A_NNP team_NN of_IN researchers_NNS in_IN the_DT UK_NNP and_CC Tres_NNP Cantos_NNP ,_, 2004_CD ._.
We_PRP discontinued_VBD development_NN of_IN 2001 2002 2003_CD Spain_NNP has_VBZ been_VBN established_VBN specifically_RB to_TO focus_VB oxibendazole_NN for_IN intestinal_JJ worms_NNS as_IN the_DT treatment_NN preferentially_RB priced_VBN on_IN research_NN into_IN diseases_NNS of_IN the_DT developing_VBG offered_VBN no_DT advantage_NN over_IN existing_VBG medicines_NNS ._.
Corporate_JJ Responsibility_NN Report_NNP 2003_CD 11_CD tablets_NNS shipped_VBN millions_NNS DEVELOPMENT_NNP PIPELINE_NNP AT_NNP END_NNP OF_IN 2003_CD FOR_IN DISEASES_NNS RELEVANT_NNP TO_TO THE_DT DEVELOPING_VBG WORLD_NN Pre_NN clinical_JJ Focus_NN PHASE_NN I_PRP PHASE_VBP II_NNP PHASE_NNP III_NNP MARKETED_VBD activity_NN HIV_NNP Non-NRTI_NNP Ziagen_NNP Epivir_NNP Epivir_NNP Retrovir_NNP CCR5_NNP antagonist_NN Ziagen_NNP Combivir_NNP Aspartyl_NNP protease_NN inhibitor_NN Agenerase_NNP Trizivir_NNP NRTI_NNP Lexiva_NNP Telzir_NNP Vaccines_NNP HIV_NNP Hepatitis_NNP E_NNP Rotarix_NNP rotavirus_VBZ Havrix_NNP hepatitis_NNP A_NNP Engerix_NNP B_NNP hepatitis_NNP B_NNP Dengue_NNP fever_NN Malaria_NNP Streptorix_NNP Twinrix_NNP hep_NN A_NNP &_CC B_NNP Infanrix_NNP diptheria_NN ,_, tetanus_NN ,_, N._NNP meningitidis_NNP S._NNP pneumoniae_NN paediatric_NN acellular_JJ pertussis_NN Cervarix_NNP HPV_NNP Tritanrix_NNP diptheria_NN ,_, tetanus_NN ,_, Polio_NNP Sabin_NNP polio_NN whole_JJ cell_NN pertussis_NN Priorix_NNP measles_NNS ,_, mumps_NNS Typherix_NNP typhoid_NN and_CC rubella_NN Hiberix_NNP hemophilus_VBZ Mencevax_NNP ACW_NNP meningitis_VBZ influenzae_NN type_NN b_NN Malaria_NNP CDA_NNP chlorproguanil_NN ,_, tafenoquine_NN Malarone_NNP Halfan_NNP dapsone_NN artesunate_NN Lapdap_NNP TB_NN Other_JJ sitamaquine_NN Zentel_NNP fide-worming_JJ agent_NN visceral_NN leishmaniasis_NN Pentostam_NNP visceral_JJ leishmaniasis_NN submitted_VBN for_IN approval_NN more_RBR detailed_JJ information_NN on_IN our_PRP$ product_NN pipeline_NN can_MD be_VB found_VBN in_IN the_DT Annual_JJ Report_NNP Against_IN AIDS_NNP in_IN Africa_NNP KENWA_NNP believes_VBZ that_IN a_DT In_IN 2003_CD our_PRP$ ten-year_JJ partnership_NN program_NN ,_, Community_NNP investment_NN in_IN Positive_NNP Action_NNP workshop_NN on_IN writing_VBG effective_JJ Action_NNP TB_NN ,_, was_VBD completed_VBN ._.
This_DT research_NN developing_VBG countries_NNS fundraising_VBG proposals_NNS helped_VBD it_PRP secure_VB a_DT grant_NN of_IN program_NN improved_VBN our_PRP$ understanding_NN of_IN We_PRP manage_VBP a_DT large_JJ community_NN investment_NN $_$ 220,000_CD from_IN the_DT Global_NNP Fund_NNP to_TO Fight_VB AIDS_NNP ,_, TB_NN and_CC should_MD help_VB the_DT in-house_JJ development_NN program_NN in_IN developing_VBG countries_NNS ._.
This_DT includes_VBZ TB_NN and_CC Malaria_NN ._.
of_IN more_JJR targeted_JJ and_CC effective_JJ treatments_NNS donations_NNS of_IN medicines_NNS ,_, as_RB well_RB as_IN financial_JJ and_CC against_IN the_DT disease_NN ._.
practical_JJ support_NN for_IN public_JJ health_NN initiatives_NNS 14_CD The_DT GSK_NNP France_NNP Foundation_NNP ,_, a_DT GSK-endowed_JJ and_CC education_NN programs_NNS ._.
The_DT largest_JJS charitable_JJ foundation_NN ,_, supports_VBZ a_DT range_NN of_IN We_PRP are_VBP supporting_VBG 27_CD clinical_JJ trials_NNS in_IN developing_VBG programs_NNS include_VBP those_DT tackling_VBG three_CD major_JJ programs_NNS to_TO improve_VB access_NN to_TO healthcare_NN countries_NNS to_TO assess_VB the_DT use_NN of_IN ARVs_NNS in_IN resourcediseases_NNS lymphatic_JJ filariasis_NN LF_NNP ,_, commonly_RB for_IN HIV-positive_JJ people_NNS in_IN Africa_NNP ,_, particularly_RB poor_JJ settings_NNS ._.
Seven_CD new_JJ studies_NNS began_VBD in_IN subknown_JJ elephantiasis_NN ,_, HIV_NNP AIDS_NNP and_CC malaria_NN ._.
Over_IN the_DT last_JJ five_CD years_NNS ,_, Saharan_NNP Africa_NNP in_IN 2003_CD ,_, bringing_VBG the_DT total_NN in_IN this_DT the_DT Foundation_NNP has_VBZ provided_VBN 2_CD million_CD to_TO region_NN to_TO 20_CD ._.
This_DT includes_VBZ the_DT DART_NNP study_NN ,_, the_DT Elimination_NN of_IN lymphatic_JJ filariasis_NN LF_NNP support_NN 32_CD programs_NNS in_IN 13_CD African_JJ countries_NNS ._.
largest_JJS adult_NN HIV_NNP treatment_NN study_NN in_IN Africa_NNP LF_NNP affects_VBZ 120_CD million_CD people_NNS ,_, mostly_RB in_IN involving_VBG 3,000_CD patients_NNS in_IN Uganda_NNP and_CC developing_VBG countries_NNS ,_, and_CC is_VBZ one_CD of_IN the_DT worlds_NNS Progress_NNP in_IN 2003_CD Zimbabwe_NNP ._.
We_PRP are_VBP supplying_VBG drugs_NNS for_IN eight_CD leading_VBG causes_NNS of_IN permanent_JJ disability_NN ._.
Over_IN one_CD Positive_NNP Action_NNP supported_VBD 38_CD programs_NNS studies_NNS of_IN prevention_NN of_IN mother-to-child_JJ HIV_NNP billion_CD people_NNS ,_, almost_RB one-fifth_NN of_IN the_DT worlds_NNS in_IN partnership_NN with_IN 28_CD organizations_NNS in_IN 34_CD transmission_NN ,_, involving_VBG 8,000_CD patients_NNS in_IN population_NN ,_, are_VBP at_IN risk_NN of_IN LF_NNP infection_NN ._.
Also_RB during_IN 2003_CD ,_, the_DT GSK_NNP France_NNP developing_VBG countries_NNS ._.
albendazole_RB prevents_VBZ transmission_NN of_IN LF_NNP when_WRB Foundation_NNP supported_VBD 17_CD initiatives_NNS and_CC pledged_VBD taken_VBN together_RB with_IN another_DT medicine_NN ._.
As_IN a_DT to_TO renew_VB its_PRP$ commitment_NN for_IN a_DT further_JJ five_CD years_NNS ._.
HIV_NNP treatment_NN regimens_VBZ can_MD be_VB very_RB complex_JJ ,_, founding_JJ partner_NN in_IN the_DT WHOs_NNPS Global_NNP Program_NNP 15_CD GSK_NNP also_RB granted_VBD $_$ 1.6_CD million_CD over_IN two_CD years_NNS to_TO requiring_VBG patients_NNS to_TO take_VB a_DT combination_NN of_IN to_TO Eliminate_VB LF_NNP ,_, we_PRP expect_VBP to_TO donate_VB 6_CD billion_CD support_NN the_DT work_NN of_IN two_CD HIV_NNP AIDS_NNP clinics_NNS in_IN several_JJ different_JJ tablets_NNS at_IN different_JJ times_NNS of_IN the_DT treatments_NNS by_IN 2020_CD ,_, worth_IN an_DT estimated_VBN Malawi_NNP and_CC Uganda_NNP ._.
This_DT increases_VBZ the_DT risk_NN of_IN patients_NNS missing_VBG $_$ 1_CD billion_CD valued_VBN at_IN wholesale_JJ prices_NNS ._.
a_DT dose_NN or_CC taking_VBG their_PRP$ medicine_NN at_IN the_DT wrong_JJ GSK_NNP African_NNP Malaria_NNP Partnership_NNP time_NN ._.
This_DT can_MD reduce_VB the_DT effectiveness_NN of_IN Progress_NNP in_IN 2003_CD This_DT partnership_NN is_VBZ providing_VBG $_$ 1.5_CD million_CD treatment_NN and_CC lead_NN to_TO drug_NN resistance_NN ._.
We_PRP are_VBP GSK_NNP donated_VBD 94_CD million_CD treatments_NNS of_IN kick-start_JJ funding_NN over_IN three_CD years_NNS to_TO support_VB looking_VBG at_IN ways_NNS to_TO simplify_VB treatment_NN regimens_NNS ._.
We_PRP have_VBP donated_VBN 18_CD malaria_NN education_NN programs_NNS ._.
The_DT initiatives_NNS In_IN 2003_CD we_PRP sought_VBD regulatory_JJ approval_NN in_IN the_DT 240_CD million_CD preventative_JJ treatments_NNS since_IN 1998_CD are_VBP designed_VBN to_TO improve_VB the_DT prevention_NN and_CC US_NNP and_CC Europe_NNP for_IN a_DT new_JJ fixed-dose_JJ combination_NN to_TO over_IN 80_CD million_CD people_NNS ._.
The_DT program_NN is_VBZ management_NN of_IN malaria_NN in_IN seven_CD African_JJ countries_NNS ._.
of_IN Epivir_NNP and_CC Ziagen_NNP which_WDT are_VBP currently_RB used_VBN expected_VBN to_TO eventually_RB reach_VB one_CD billion_CD people_NNS ._.
For_IN example_NN ,_, our_PRP$ support_NN will_MD help_VB Freedom_NN From_IN as_IN separate_JJ tablets_NNS in_IN recommended_JJ treatment_NN Hunger_NNP develop_VB a_DT malaria_NN education_NN module_NN for_IN its_PRP$ regimens_NNS ._.
If_IN approved_VBN ,_, this_DT one-tablet_JJ Programmes_NNP for_IN HIV_NNP AIDS_NNP `_`` Credit_NN with_IN Education_NNP '_POS program_NN ._.
This_DT provides_VBZ combination_NN would_MD be_VB taken_VBN once_RB a_DT day_NN and_CC For_IN 11_CD years_NNS our_PRP$ HIV_NNP AIDS_NNP program_NN ,_, Positive_NNP 16_CD a_DT package_NN of_IN financial_JJ services_NNS ,_, and_CC health_NN and_CC would_MD replace_VB the_DT two_CD tablets_NNS currently_RB taken_VBN Action_NNP ,_, has_VBZ worked_VBN at_IN the_DT community_NN level_NN business_NN education_NN to_TO help_VB very_RB poor_JJ women_NNS fight_VB twice_RB a_DT day_NN ._.
to_TO support_VB HIV_NNP care_NN ,_, education_NN and_CC prevention_NN against_IN chronic_JJ hunger_NN ,_, illness_NN and_CC poverty_NN ._.
Positive_JJ Action_NNP partnerships_NNS with_IN In_IN October_NNP ,_, US_NNP FDA_NNP approval_NN was_VBD secured_VBN for_IN organizations_NNS such_JJ as_IN the_DT Centre_NNP for_IN African_NNP Family_NNP Progress_NNP in_IN 2003_CD Lexiva_NNP ,_, a_DT new_JJ HIV_NNP protease_NN inhibitor_NN ,_, currently_RB Studies_NNPS CAFS_NNP tackle_VB issues_NNS such_JJ as_IN stigma_NN and_CC We_PRP contributed_VBD the_DT first_JJ grants_NNS to_TO our_PRP$ partners_NNS ,_, the_DT only_JJ protease_NN inhibitor_NN to_TO offer_VB flexible_JJ dosing_NN discrimination_NN ,_, a_DT significant_JJ barrier_NN to_TO healthcare_NN Freedom_NN From_IN Hunger_NNP ,_, AMREF_NNP and_CC Plan_NNP with_IN no_DT food_NN or_CC water_NN restrictions_NNS ._.
We_PRP hope_VBP to_TO in_IN many_JJ communities_NNS affected_VBN by_IN HIV_NNP AIDS_NNP ._.
We_PRP also_RB donated_VBD $_$ 25,000_CD to_TO Plan_NNP start_VB launching_VBG Lexiva_NNP also_RB known_VBN as_IN Telzir_NNP in_IN International_NNP to_TO assist_VB with_IN relief_NN operations_NNS and_CC developing_VBG countries_NNS in_IN 2004_CD 2005_CD ._.
CAFS_NNS provides_VBZ training_NN courses_NNS to_TO community_NN an_DT increase_NN in_IN malaria_NN cases_NNS in_IN Sudan_NNP following_VBG organizations_NNS working_VBG with_IN people_NNS affected_VBN by_IN severe_JJ flooding_NN ._.
In_IN December_NNP GSK_NNP was_VBD recognized_VBN for_IN its_PRP$ HIV_NNP ._.
It_PRP has_VBZ trained_VBN over_IN 250_CD key_JJ workers_NNS from_IN leadership_NN in_IN alleviating_VBG tropical_JJ infectious_JJ diseases_NNS 65_CD NGOs_NNS to_TO build_VB and_CC run_VB effective_JJ organizations_NNS and_CC improving_VBG global_JJ health_NN ,_, by_IN the_DT American_JJ helping_VBG people_NNS affected_VBN by_IN HIV_NNP ._.
Such_JJ well-placed_JJ 13_CD Society_NNP of_IN Tropical_NNP Medicine_NNP and_CC Hygiene_NNP ._.
support_NN can_MD have_VB a_DT powerful_JJ impact_NN ._.
For_IN example_NN ,_, the_DT Kenyan_NNP Network_NNP of_IN Women_NNP 12_CD Corporate_JJ Responsibility_NN Report_NNP 2003_CD Lapdap_NNP can_MD help_VB us_PRP meet_VB the_DT urgent_JJ need_NN for_IN an_DT affordable_JJ anti-malarial_JJ treatment_NN for_IN use_NN in_IN Africa_NNP ,_, as_IN it_PRP has_VBZ been_VBN shown_VBN to_TO work_VB in_IN cases_NNS where_WRB S_NNP P_NNP -LRB-_-LRB- the_DT standard_NN treatment_NN -RRB-_-RRB- has_VBZ failed_VBN ._.
Professor_NNP Peter_NNP Winstanley_NNP University_NNP of_IN Liverpool_NNP Lapdap_NNP a_DT new_JJ anti-malarial_JJ for_IN subSaharan_NNP Africa_NNP Malaria_NNP affects_VBZ more_RBR than_IN 300_CD million_CD people_NNS every_DT year_NN ._.
There_EX is_VBZ an_DT urgent_JJ need_NN for_IN new_JJ affordable_JJ treatments_NNS to_TO combat_VB the_DT disease_NN and_CC to_TO deal_VB with_IN the_DT problem_NN of_IN resistance_NN to_TO existing_VBG treatments_NNS ._.
The_DT new_JJ anti-malarial_JJ treatment_NN ,_, Lapdap_NNP ,_, launched_VBN in_IN 2003_CD ,_, is_VBZ designed_VBN to_TO tackle_VB this_DT deadly_JJ disease_NN ._.
It_PRP was_VBD developed_VBN specifically_RB for_IN use_NN in_IN sub-Saharan_JJ Africa_NNP ,_, where_WRB malaria_NN kills_VBZ more_JJR than_IN one_CD million_CD people_NNS every_DT year_NN ,_, the_DT majority_NN of_IN whom_WP are_VBP children_NNS under_IN five_CD ._.
The_DT initiative_NN brought_VBN together_RB GSK_NNP Drug_NNP Development_NNP researchers_NNS with_IN scientists_NNS in_IN Africa_NNP ,_, and_CC two_CD leading_JJ UK_NNP medical_JJ schools_NNS the_DT University_NNP of_IN Liverpool_NNP and_CC the_DT London_NNP School_NNP of_IN Hygiene_NNP and_CC Tropical_NNP Medicine_NNP ._.
GSK_NNP ,_, the_DT WHO_WP and_CC the_DT UK_NNP Government_NNP Department_NNP for_IN International_NNP Development_NNP jointly_RB funded_VBD the_DT development_NN project_NN ._.
Lapdap_NNP was_VBD approved_VBN for_IN use_NN by_IN the_DT UK_NNP Medicines_NNP and_CC Healthcare_NNP Products_NNPS Regulatory_NNP Agency_NNP and_CC ,_, in_IN line_NN with_IN best_JJS medical_JJ practice_NN ,_, GSK_NNP is_VBZ conducting_VBG postmarketing_VBG studies_NNS in_IN Africa_NNP to_TO confirm_VB the_DT long-term_JJ safety_NN of_IN the_DT treatment_NN ._.
GSK_NNP is_VBZ registering_VBG Lapdap_NNP across_IN sub-Saharan_NNP Africa_NNP ,_, where_WRB it_PRP will_MD be_VB available_JJ to_TO national_JJ malaria_NN control_NN programs_NNS at_IN preferential_JJ prices_NNS ._.
The_DT treatment_NN is_VBZ already_RB registered_VBN in_IN 14_CD African_JJ countries_NNS ._.
We_PRP are_VBP also_RB developing_VBG CDA_NNP ,_, a_DT new_JJ Lapdap_NNP plus_CC artesunate_JJ combination_NN therapy_NN ,_, with_IN the_DT WHO_WP and_CC the_DT Medicines_NNP for_IN Malaria_NNP Venture_NNP ._.
Corporate_JJ Responsibility_NN Report_NNP 2003_CD 13_CD Community_NNP investment_NN The_DT Childrens_NNP Health_NNP Fund_NNP 's_POS Referral_NNP Management_NNP Initiative_NNP Homeless_NNP and_CC disadvantaged_JJ children_NNS are_VBP especially_RB vulnerable_JJ to_TO illness_NN and_CC are_VBP more_RBR likely_JJ to_TO suffer_VB from_IN acute_JJ and_CC chronic_JJ illnesses_NNS such_JJ as_IN asthma_NN ._.
Many_JJ do_VBP not_RB receive_VB vaccinations_NNS ._.
Despite_IN needing_VBG more_JJR specialist_NN care_NN ,_, it_PRP is_VBZ difficult_JJ for_IN these_DT families_NNS to_TO keep_VB hospital_NN appointments_NNS ._.
Millions_NNS of_IN children_NNS in_IN the_DT US_NNP can_MD not_RB access_VB the_DT healthcare_NN they_PRP need_VBP because_IN of_IN a_DT lack_NN of_IN transport_NN ,_, too_RB few_JJ doctors_NNS in_IN disadvantaged_JJ communities_NNS ,_, or_CC cultural_JJ ,_, language_NN and_CC institutional_JJ barriers_NNS ._.
A_DT transient_JJ lifestyle_NN often_RB means_VBZ they_PRP lose_VBP contact_NN with_IN their_PRP$ doctor_NN ._.
Over_IN nine_CD years_NNS ,_, GSK_NNP has_VBZ provided_VBN $_$ 4.2_CD million_CD to_TO the_DT Childrens_NNP Health_NNP Fund_NNP to_TO set_VB up_RP and_CC run_VB a_DT Referral_NNP Management_NNP 19_CD Initiative_NNP RMI_NNP ._.
This_DT helps_VBZ children_NNS ,_, referred_VBD to_TO a_DT specialist_NN ,_, attend_VB their_PRP$ appointments_NNS and_CC receive_VB the_DT care_NN they_PRP need_VBP ._.
The_DT RMI_NNP reminds_VBZ families_NNS about_IN appointments_NNS by_IN phone_NN and_CC mail_NN ,_, provides_VBZ door-to-door_JJ transport_NN to_TO clinics_NNS and_CC helps_VBZ communications_NNS ,_, including_VBG providing_VBG a_DT translation_NN service_NN where_WRB necessary_JJ ._.
GSK_NNP is_VBZ sole_JJ funder_NN of_IN the_DT RMI_NNP ._.
In_IN 2003_CD we_PRP provided_VBD additional_JJ funding_NN of_IN $_$ 756,000_CD to_TO help_VB extend_VB the_DT program_NN and_CC develop_VB guidance_NN for_IN introducing_VBG similar_JJ initiatives_NNS nationwide_JJ ._.
The_DT RMI_NNP has_VBZ dramatically_RB increased_VBN the_DT number_NN of_IN children_NNS who_WP see_VBP a_DT medical_JJ specialist_NN after_IN being_VBG referred_VBN ._.
Approximately_RB 75_CD %_NN of_IN the_DT children_NNS in_IN the_DT program_NN are_VBP now_RB getting_VBG the_DT specialist_NN care_NN they_PRP need_VBP ,_, compared_VBN with_IN just_RB 5_CD %_NN when_WRB the_DT initiative_NN began_VBD ._.
The_DT Childrens_NNP Health_NNP Fund_NNP partnership_NN with_IN GSK_NNP has_VBZ been_VBN responsible_JJ for_IN positively_RB transforming_VBG the_DT lives_NNS of_IN tens_NNS of_IN thousands_NNS of_IN medically_RB under-served_JJ children_NNS in_IN need_NN of_IN specialist_NN care_NN ._.
Irwin_NNP Redlener_NNP President_NNP ,_, Childrens_NNP Health_NNP Fund_NNP 14_CD Corporate_JJ Responsibility_NN Report_NNP 2003_CD 2_CD Community_NNP investment_NN We_PRP concentrate_VBP community_NN investment_NN on_IN improving_VBG health_NN and_CC education_NN in_IN under-served_JJ and_CC vulnerable_JJ communities_NNS worldwide_NN ._.
Our_PRP$ contribution_NN is_VBZ mainly_RB through_IN donations_NNS of_IN medicines_NNS ,_, financial_JJ and_CC practical_JJ support_NN and_CC materials_NNS such_JJ as_IN laboratory_NN and_CC office_NN equipment_NN ._.
We_PRP identify_VBP programs_NNS to_TO support_VB on_IN medicines_NNS were_VBD among_IN the_DT first_JJ to_TO reach_VB Iraq_NNP the_DT basis_NN of_IN need_NN ,_, not_RB for_IN their_PRP$ potential_JJ after_IN the_DT conflict_NN began_VBD ._.
We_PRP also_RB provided_VBD medicines_NNS following_VBG earthquakes_NNS in_IN India_NNP and_CC impact_NN on_IN our_PRP$ commercial_JJ business_NN ._.
In_IN 2003_CD our_PRP$ global_JJ community_NN investment_NN and_CC Our_PRP$ humanitarian_JJ donations_NNS were_VBD higher_JJR than_IN in_IN charitable_JJ donations_NNS were_VBD valued_VBN at_IN 338_CD million_CD ,_, previous_JJ years_NNS ,_, reflecting_VBG the_DT variability_NN in_IN both_DT the_DT equivalent_JJ to_TO 5.3_CD %_NN of_IN our_PRP$ pre-tax_JJ profits_NNS statutory_JJ supply_NN and_CC demand_NN for_IN donations_NNS ._.
This_DT included_VBD 125_CD million_CD for_IN the_DT Patient_NNP the_DT need_NN for_IN humanitarian_JJ relief_NN depends_VBZ on_IN Assistance_NNP Program_NNP and_CC other_JJ medicine_NN donations_NNS events_NNS such_JJ as_IN conflict_NN and_CC natural_JJ disasters_NNS ._.
Also_RB ,_, for_IN low_JJ income_NN groups_NNS in_IN the_DT US_NNP ,_, and_CC 105_CD million_CD the_DT supply_NN of_IN product_NN that_WDT GSK_NNP has_VBZ available_JJ for_IN of_IN humanitarian_JJ product_NN donations_NNS ._.
It_PRP also_RB donation_NN can_MD vary_VB ._.
If_IN we_PRP have_VBP excess_JJ stock_NN included_VBD management_NN expenses_NNS of_IN 17_CD million_CD ,_, available_JJ this_DT is_VBZ offered_VBN to_TO charities_NNS and_CC will_MD only_RB the_DT cost_NN of_IN running_VBG our_PRP$ community_NN investment_NN be_VB placed_VBN when_WRB there_EX is_VBZ a_DT clearly_RB identified_VBN programs_NNS ._.
This_DT is_VBZ in_IN addition_NN to_TO agreements_NNS we_PRP have_VBP with_IN a_DT number_NN of_IN charities_NNS which_WDT can_MD Our_PRP$ community_NN investment_NN programs_NNS select_VBP products_NNS from_IN GSK_NNP stock_NN to_TO fulfil_VB their_PRP$ plans_NNS focus_VB on_IN major_JJ public_JJ health_NN initiatives_NNS on_IN HIV_NNP ,_, for_IN relief_NN programs_NNS and_CC emergency_NN aid_NN ._.
malaria_NN and_CC lymphatic_JJ filariasis_NN see_VBP page_NN 12_CD ,_, humanitarian_JJ aid_NN ,_, supporting_VBG communities_NNS Supporting_VBG communities_NNS around_IN the_DT world_NN around_IN the_DT world_NN ,_, and_CC employee_NN involvement_NN ._.
Our_PRP$ programs_NNS support_VBP communities_NNS in_IN need_NN throughout_IN the_DT world_NN ._.
Here_RB are_VBP some_DT examples_NNS Humanitarian_JJ aid_NN for_IN 2003_CD :_: In_IN the_DT aftermath_NN of_IN a_DT humanitarian_JJ disaster_NN it_PRP is_VBZ vital_JJ to_TO prevent_VB the_DT spread_NN of_IN infectious_JJ diseases_NNS ._.
UK_NNP Our_PRP$ antibiotics_NNS can_MD play_VB an_DT essential_JJ role_NN ._.
The_DT GSK_NNP IMPACT_NNP Awards_NNPS recognize_VBP and_CC reward_VBP the_DT work_NN of_IN smaller_JJR voluntary_JJ organizations_NNS We_PRP donate_VBP antibiotics_NNS to_TO support_VB relief_NN efforts_NNS in_IN dedicated_VBN to_TO improving_VBG community_NN healthcare_NN ._.
countries_NNS affected_VBN by_IN natural_JJ disasters_NNS or_CC war_NN ._.
In_IN 2003_CD ,_, we_PRP awarded_VBD 260,000_CD to_TO 19_CD Donations_NNS are_VBP made_VBN through_IN our_PRP$ NGO_NNP partners_NNS organizations_NNS dealing_VBG with_IN issues_NNS as_IN diverse_JJ as_IN including_VBG AmeriCares_NNP ,_, InterChurch_NNP Medical_NNP sexual_JJ abuse_NN ,_, mental_JJ health_NN problems_NNS and_CC day_NN Assistance_NNP ,_, MAP_NNP International_NNP and_CC Project_NNP HOPE_NNP ._.
New_NNP Life_NNP Counselling_NNP Service_NNP These_DT organizations_NNS can_MD request_VB GSK_NNP medicines_NNS received_VBD an_DT award_NN for_IN its_PRP$ work_NN counselling_VBG according_VBG to_TO their_PRP$ needs_NNS ._.
This_DT enables_VBZ them_PRP to_TO 20_CD families_NNS affected_VBN by_IN unrest_NN in_IN Northern_NNP Ireland_NNP ._.
respond_NN quickly_RB to_TO emergencies_NNS since_IN they_PRP have_VBP the_DT medicines_NNS in_IN their_PRP$ warehouses_NNS ._.
In_IN 2003_CD we_PRP donated_VBD medicines_NNS worth_IN I_PRP am_VBP delighted_JJ that_IN the_DT 105_CD million_CD valued_VBN at_IN wholesale_JJ prices_NNS to_TO excellent_JJ work_NN carried_VBD out_RP by_IN New_NNP Life_NNP support_NN relief_NN efforts_NNS in_IN 80_CD countries_NNS ._.
GSK_NNP 's_POS Counselling_NNP Service_NNP has_VBZ been_VBN recognized_VBN by_IN this_DT GSK_NNP IMPACT_NNP Award_NNP ._.
To_TO be_VB METHOD_NNP OF_IN GIVING_NNP honored_VBD at_IN a_DT national_JJ level_NN ,_, with_IN such_JJ including_VBG US_NNP Patient_NNP Assistance_NNP Program_NNP a_DT prestigious_JJ award_NN ,_, must_MD be_VB a_DT source_NN 3_CD 1_CD Product_NNP 59_CD %_NN of_IN great_JJ pride_NN to_TO all_DT concerned_VBN ._.
2_CD Cash_NN 40_CD %_NN Des_NNP Brown_NNP MP_NNP Former_NNP Minister_NNP with_IN Responsibility_NNP for_IN Health_NNP ,_, 3_CD In_IN kind_NN 1_CD %_NN Social_NNP Services_NNP and_CC Public_NNP Safety_NNP in_IN Northern_NNP Ireland_NNP 2_CD 1_CD Our_PRP$ product_NN donations_NNS are_VBP valued_VBN at_IN wholesale_JJ acquisition_NN Corporate_JJ Responsibility_NN Report_NNP 2003_CD 15_CD cost_NN which_WDT relates_VBZ to_TO the_DT price_NN GSK_NNP charges_NNS wholesalers_NNS and_CC warehousing_NN chains_NNS ,_, not_RB the_DT retail_JJ price_NN ._.
This_DT investment_NN by_IN GSK_NNP The_NNP Government_NNP is_VBZ to_TO build_VB basic_JJ healthcare_NN committed_VBN to_TO excellence_NN in_IN science_NN infrastructure_NN will_MD go_VB some_DT way_NN education_NN and_CC I_PRP am_VBP delighted_JJ that_IN to_TO ensuring_VBG that_IN these_DT vulnerable_JJ GSK_NNP ,_, one_CD of_IN our_PRP$ major_JJ science-based_JJ people_NNS do_VBP not_RB suffer_VB further_JJ due_JJ companies_NNS ,_, and_CC Imperial_NNP College_NNP ,_, are_VBP to_TO ill-health_NN and_CC infant_NN mortality_NN ._.
Greta_NNP Beresford_NNP Safe_NNP Childbirth_NNP Coordinator_NNP ,_, HealthProm_NNP supporting_VBG this_DT important_JJ initiative_NN ._.
Rt_NNP Hon_NNP Tony_NNP Blair_NNP MP_NNP British_NNP Prime_NNP Minister_NNP ,_, speaking_VBG at_IN the_DT launch_NN of_IN INSPIRE_NNP ,_, June_NNP 2002_CD GSK_NNP is_VBZ helping_VBG to_TO improve_VB school_NN students_NNS Young_JJ people_NNS with_IN HIV_NNP often_RB face_VBP social_JJ stigma_NN North_NNP America_NNP interest_NN and_CC achievement_NN in_IN science_NN and_CC increase_NN and_CC discrimination_NN that_WDT makes_VBZ it_PRP hard_RB for_IN them_PRP The_DT GSK_NNP IMPACT_NNP Awards_NNPS recognize_VBP not-for-profit_JJ the_DT number_NN of_IN science_NN teachers_NNS through_IN the_DT to_TO continue_VB living_VBG normal_JJ lives_NNS ._.
GSK_NNP is_VBZ supporting_VBG organizations_NNS in_IN Philadelphia_NNP that_WDT are_VBP helping_VBG to_TO 21_CD INSPIRE_VBP INnovative_JJ Scheme_NN for_IN Post-docs_JJ In_IN the_DT SEYPA_NNP program_NN that_WDT combats_VBZ this_DT social_JJ improve_VB healthcare_NN ._.
The_DT awards_NNS have_VBP helped_VBN Research_NNP and_CC Education_NNP scheme_NN ._.
GSK_NNP is_VBZ exclusion_NN in_IN five_CD European_JJ countries_NNS with_IN a_DT three_CD -_: 58_CD community_NN organizations_NNS to_TO raise_VB funds_NNS ,_, providing_VBG up_RP to_TO 1_CD million_CD over_IN four_CD years_NNS to_TO year_NN grant_NN of_IN 400,000_CD ._.
Through_IN youth-led_JJ focus_NN recruit_VB new_JJ volunteers_NNS and_CC support_NN greater_JJR the_DT scheme_NN which_WDT was_VBD developed_VBN in_IN partnership_NN groups_NNS ,_, young_JJ people_NNS find_VBP solutions_NNS to_TO the_DT numbers_NNS of_IN people_NNS ._.
In_IN 2003_CD we_PRP awarded_VBD with_IN Imperial_NNP College_NNP London_NNP and_CC the_DT Specialist_NN problems_NNS they_PRP face_VBP ._.
These_DT include_VBP developing_VBG $_$ 367,000_CD to_TO 16_CD organizations_NNS dealing_VBG with_IN Schools_NNP Trust_NNP ._.
INSPIRE_VB places_NNS post-doctoral_JJ training_NN to_TO help_VB organizations_NNS provide_VB better_JJR issues_NNS such_JJ as_IN child_NN abuse_NN ,_, breast_NN cancer_NN and_CC researchers_NNS into_IN specialist_NN science_NN schools_NNS to_TO support_VB to_TO young_JJ people_NNS affected_VBN by_IN HIV_NNP ._.
assist_VB with_IN science_NN teaching_NN and_CC to_TO study_VB towards_IN a_DT teaching_NN qualification_NN ,_, and_CC provides_VBZ Azerbaijan_NNP is_VBZ home_NN to_TO 250,000_CD refugees_NNS ._.
GSK_NNP Our_PRP$ support_NN for_IN the_DT Childrens_NNP Health_NNP Fund_NNP has_VBZ sponsorship_NN to_TO help_VB schools_NNS gain_VB specialist_NN is_VBZ providing_VBG 202,000_CD over_IN three_CD years_NNS to_TO a_DT Safe_NNP enabled_VBD it_PRP to_TO improve_VB access_NN to_TO healthcare_NN for_IN science_NN status_NN ._.
Childbirth_NNP program_NN to_TO improve_VB healthcare_NN for_IN homeless_JJ children_NNS page_NN 14_CD ._.
pregnant_JJ women_NNS and_CC reduce_VB infant_NN mortality_NN ._.
Each_DT year_NN we_PRP support_VBP up_RP to_TO five_CD medical_JJ research_NN The_DT program_NN is_VBZ run_VBN in_IN partnership_NN with_IN the_DT GSK_NNP is_VBZ the_DT major_JJ supporter_NN of_IN the_DT University_NNP charities_NNS whose_WP$ work_NN aims_VBZ to_TO benefit_VB many_JJ charity_NN HealthProm_NNP and_CC the_DT Azerbaijan_NNP Ministry_NNP of_IN North_NNP Carolina_NNP 's_POS innovative_JJ traveling_VBG science_NN people_NNS in_IN the_DT future_NN ._.
It_PRP uses_VBZ qualified_VBN doctors_NNS and_CC nurses_NNS laboratory_NN ,_, DESTINY_NNP ._.
The_DT laboratory_NN visited_VBD 73_CD 350,000_CD to_TO research_VB projects_NNS run_VBN by_IN Tommys_NNP ,_, to_TO train_VB local_JJ healthcare_NN providers_NNS such_JJ as_IN under-served_JJ secondary_JJ schools_NNS and_CC reached_VBD the_DT baby_NN charity_NN ,_, International_NNP Spinal_NNP Research_NNP midwives_VBZ ,_, and_CC to_TO develop_VB healthcare_NN training_NN 4,300_CD students_NNS during_IN 2003_CD ._.
The_DT program_NN Trust_NNP ,_, Epilepsy_NNP Research_NNP Foundation_NNP materials_NNS ._.
The_DT local_JJ GSK_NNP business_NN is_VBZ also_RB helping_VBG encourages_VBZ women_NNS and_CC minority_NN students_NNS to_TO and_CC the_DT National_NNP Osteoporosis_NNP Society_NNP ._.
to_TO vaccinate_VB refugee_NN children_NNS against_IN measles_NNS ,_, pursue_VB science_NN careers_NNS ._.
GSK_NNP 's_POS Positive_NNP Action_NNP program_NN is_VBZ funding_VBG Science_NN in_IN the_DT Summer_NNP is_VBZ a_DT free_JJ science_NN a_DT UK-based_JJ NGO_NNP called_VBD five_CD to_TO develop_VB a_DT Zippys_NNP Friends_NNPS ,_, a_DT schools_NNS initiative_NN run_VBN by_IN education_NN program_NN that_WDT aims_VBZ to_TO inspire_VB low-cost_JJ health_NN education_NN resource_NN for_IN UK_NNP Partnership_NNP for_IN Children_NNP ,_, teaches_VBZ very_RB young_JJ children_NNS to_TO pursue_VB science_NN careers_NNS ._.
The_DT Community_NNP Health_NNP ,_, Advice_NNP ,_, Support_NN children_NNS skills_NNS for_IN coping_VBG with_IN adversities_NNS such_JJ fun_NN ,_, hands-on_JJ experiments_NNS that_WDT relate_VBP science_NN and_CC Education_NNP CHASE_NNP program_NN is_VBZ designed_VBN as_IN family_NN changes_NNS ,_, bereavement_NN and_CC bullying_VBG ._.
In_IN 2003_CD over_IN 6,000_CD children_NNS to_TO raise_VB awareness_NN of_IN sexual_JJ health_NN issues_NNS and_CC In_IN 2003_CD GSKs_NNS support_NN helped_VBD extend_VB the_DT participated_VBN in_IN the_DT program_NN in_IN 142_CD libraries_NNS prevent_VBP the_DT spread_NN of_IN HIV_NNP ,_, TB_NN ,_, and_CC hepatitis_NN ._.
project_NN from_IN Denmark_NNP and_CC Lithuania_NNP to_TO Goa_NNP ,_, in_IN the_DT Philadelphia_NNP area_NN ._.
In_IN 2003_CD it_PRP was_VBD piloted_VBN in_IN 150_CD of_IN 189_CD UK_NNP prisons_NNS ._.
We_PRP hope_VBP the_DT program_NN will_MD be_VB adapted_VBN for_IN use_NN in_IN other_JJ resource-poor_JJ settings_NNS ._.
Europe_NNP Children_NNP coping_VBG with_IN cancer_NN and_CC life-threatening_JJ illnesses_NNS are_VBP encouraged_VBN to_TO rediscover_VB their_PRP$ childhood_NN at_IN Barretstown_NNP in_IN Ireland_NNP and_CC LEnvol_NNP camp_NN in_IN France_NNP ._.
In_IN 2003_CD we_PRP donated_VBD 400,000_CD to_TO support_VB these_DT programs_NNS ._.
Over_IN 60_CD GSK_NNP employees_NNS also_RB gave_VBD their_PRP$ time_NN to_TO help_VB run_VB events_NNS for_IN children_NNS at_IN Barretstown_NNP while_IN others_NNS The_DT partnership_NN provided_VBD essential_JJ business_NN expertise_NN and_CC training_NN to_TO the_DT Barretstown_NNP team_NN ._.
we_PRP have_VBP forged_VBN with_IN GSK_NNP to_TO share_VB skills_NNS and_CC resources_NNS has_VBZ been_VBN a_DT great_JJ example_NN to_TO other_JJ companies_NNS ._.
I_PRP know_VBP that_IN many_JJ other_JJ firms_NNS now_RB recognize_VBP the_DT value_NN of_IN partnering_VBG with_IN a_DT charity_NN rather_RB than_IN merely_RB donating_VBG money_NN ._.
James_NNP Hill_NNP Chairman_NNP ,_, Barretstown_NNP 16_CD Corporate_JJ Responsibility_NN Report_NNP 2003_CD 10_CD million_CD people_NNS treated_VBN against_IN lymphatic_JJ filariasis_NN in_IN one_CD day_NN Using_VBG medicines_NNS donated_VBN by_IN GSK_NNP ,_, the_DT Sri_NNP Lankan_NNP Ministry_NNP of_IN Health_NNP mobilised_VBD 50,000_CD healthcare_NN workers_NNS and_CC volunteers_NNS to_TO treat_VB half_NN of_IN its_PRP$ population_NN ,_, those_DT at_IN risk_NN of_IN LF_NNP ,_, in_IN one_CD day_NN 10_CD million_CD people_NNS ._.
Sri_NNP Lanka_NNP ,_, now_RB halfway_NN through_IN its_PRP$ 5-year_JJ treatment_NN plan_NN ,_, is_VBZ just_RB one_CD of_IN 36_CD countries_NNS on_IN several_JJ continents_NNS working_VBG to_TO eliminate_VB LF_NNP forever_RB ._.
International_NNP In_IN China_NNP we_PRP are_VBP working_VBG in_IN partnership_NN with_IN the_DT Our_PRP$ Rural_JJ Nursing_NNP Excellence_NN program_NN in_IN British_JJ and_CC Australian_JJ Red_NNP Cross_NNP ,_, reaching_VBG young_JJ Thailand_NNP has_VBZ helped_VBN 150_CD nurses_NNS qualify_VBP since_IN it_PRP people_NNS and_CC drug_NN users_NNS to_TO prevent_VB the_DT spread_NN of_IN was_VBD started_VBN in_IN 1997_CD ,_, providing_VBG support_NN to_TO 109_CD HIV_NNP ._.
During_IN 2003_CD 8,000_CD young_JJ people_NNS took_VBD part_NN hospitals_NNS and_CC clinics_NNS ._.
GSK_NNP has_VBZ donated_VBN 500,000_CD in_IN training_NN and_CC the_DT program_NN has_VBZ reached_VBN to_TO the_DT program_NN to_TO provide_VB training_NN for_IN young_JJ 14,000_CD people_NNS so_RB far_RB ._.
The_DT lack_NN of_IN nurses_NNS is_VBZ a_DT major_JJ barrier_NN to_TO improving_VBG healthcare_NN in_IN rural_JJ areas_NNS and_CC this_DT Employee_NN involvement_NN program_NN encourages_VBZ them_PRP to_TO take_VB their_PRP$ skills_NNS Many_JJ GSK_NNP employees_NNS volunteer_VBP their_PRP$ time_NN back_RB to_TO benefit_VB their_PRP$ villages_NNS ._.
and_CC expertise_NN to_TO worthy_JJ causes_NNS in_IN their_PRP$ local_JJ communities_NNS ._.
This_DT can_MD include_VB participating_VBG in_IN GSKs_NNS support_NN has_VBZ Our_PRP$ award-winning_JJ Personal_JJ Hygiene_NNP and_CC Days_NNS of_IN Caring_NN at_IN not-for-profit_JJ organizations_NNS in_IN Sanitation_NNP Education_NNP PHASE_NNP program_NN run_VBN in_IN the_DT US_NNP and_CC mentoring_VBG school_NN children_NNS through_IN helped_VBN us_PRP to_TO turn_VB a_DT simple_JJ partnership_NN with_IN AMREF_NNP and_CC Plan_NNP International_NNP our_PRP$ UK_NNP Science_NNP and_CC Engineering_NNP Ambassador_NNP idea_NN for_IN promoting_VBG childrens_NNS is_VBZ reducing_VBG diarrhoea-related_JJ disease_NN in_IN school_NN Scheme_NN and_CC our_PRP$ US_NNP Partnership_NNP for_IN Educational_NNP children_NNS ._.
In_IN 2003_CD this_DT simple_JJ hand-washing_JJ Discovery_NNP ._.
health_NN into_IN an_DT international_JJ program_NN was_VBD expanded_VBN into_IN a_DT fourth_JJ country_NN ,_, Zambia_NNP ,_, with_IN the_DT Ministry_NNP of_IN Education_NNP and_CC In_IN 2003_CD in_IN the_DT US_NNP ,_, GSK_NNP matched_VBD donations_NNS program_NN we_PRP couldnt_VBP USAID_NNP ,_, and_CC is_VBZ being_VBG rolled_VBN out_RP to_TO all_DT schools_NNS in_IN of_IN $_$ 3.8_CD million_CD made_VBN by_IN GSK_NNP employees_NNS and_CC have_VBP wished_VBN for_IN better_JJR Peru_NNP by_IN the_DT Ministry_NNP of_IN Health_NNP ._.
retirees_NNS through_IN our_PRP$ Matching_VBG Gifts_NNP Program_NNP ._.
In_IN addition_NN ,_, the_DT $_$ 1.3_CD million_CD donated_VBN by_IN GSK_NNP partners_NNS ._.
We_PRP are_VBP helping_VBG to_TO give_VB Africa_NNP 's_POS children_NNS employees_NNS to_TO the_DT United_NNP Way_NNP campaign_NN was_VBD Chris_NNP Bale_NNP Director_NNP ,_, Partnership_NNP for_IN Children_NNP a_DT healthier_RBR future_JJ through_IN the_DT Integrated_NNP matched_VBN by_IN GSK_NNP ,_, giving_VBG a_DT total_NN of_IN $_$ 2.6_CD million_CD ._.
Management_NN of_IN Childhood_NNP Illness_NNP IMCI_NNP strategy_NN ._.
The_DT GSK_NNP Investment_NNP in_IN Volunteer_NNP Excellence_NNP Developed_VBN by_IN the_DT WHO_WP and_CC Unicef_NNP ,_, IMCI_NNP aims_VBZ GIVE_VB program_NN makes_VBZ donations_NNS to_TO registered_VBN to_TO reduce_VB deaths_NNS from_IN treatable_JJ and_CC preventable_JJ charities_NNS in_IN the_DT US_NNP where_WRB GSK_NNP employees_NNS or_CC diseases_NNS by_IN improving_VBG the_DT skills_NNS of_IN health_NN workers_NNS their_PRP$ partners_NNS volunteer_NN ._.
and_CC helping_VBG families_NNS better_JJR care_NN for_IN sick_JJ children_NNS ._.
GSK_NNP has_VBZ provided_VBN funding_NN of_IN $_$ 300,000_CD and_CC In_IN the_DT UK_NNP our_PRP$ Making_VBG a_DT Difference_NN initiative_NN technical_JJ expertise_NN ._.
In_IN 2003_CD the_DT initiative_NN was_VBD provides_VBZ financial_JJ support_NN to_TO charities_NNS where_WRB expanded_VBN from_IN South_NNP Africa_NNP and_CC Ethiopia_NNP into_IN GSK_NNP employees_NNS are_VBP involved_VBN in_IN voluntary_JJ work_NN ._.
GSKs_NNS product_NN donations_NNS for_IN humanitarian_JJ relief_NN efforts_NNS allow_VBP us_PRP to_TO save_VB lives_NNS and_CC serve_VB as_IN a_DT catalyst_NN in_IN building_NN sustainable_JJ health_NN programs_NNS throughout_IN the_DT developing_VBG world_NN ._.
Veronica_NNP Arroyave_NNP Director_NNP ,_, Corporate_NNP Relations_NNPS ,_, MAP_NNP International_NNP Corporate_NNP Responsibility_NNP Report_NNP 2003_CD 17_CD GSK_NNP is_VBZ committed_VBN to_TO ensuring_VBG that_IN all_PDT our_PRP$ business_NN practices_NNS meet_VBP high_JJ standards_NNS and_CC our_PRP$ employees_NNS behave_VBP ethically_RB and_CC honestly_RB ,_, compete_VB fairly_RB and_CC avoid_VB conflicts_NNS of_IN interest_NN ._.
This_DT section_NN is_VBZ about_IN our_PRP$ business_NN Ensuring_VBG compliance_NN Departments_NNP such_JJ as_IN Finance_NNP ,_, Human_NNP Resources_NNPS ,_, standards_NNS and_CC in_IN particular_JJ those_DT relating_VBG All_DT managers_NNS are_VBP expected_VBN to_TO lead_VB by_IN example_NN in_IN Legal_NNP ,_, Compliance_NNP and_CC Internal_NNP Audit_NNP work_NN complying_VBG with_IN our_PRP$ Code_NNP of_IN Conduct_NNP and_CC other_JJ together_RB to_TO monitor_VB compliance_NN with_IN our_PRP$ policies_NNS to_TO our_PRP$ marketing_NN teams_NNS ._.
GSK_NNP policies_NNS and_CC supporting_VBG their_PRP$ staff_NN to_TO do_VB the_DT and_CC applicable_JJ laws_NNS ._.
In_IN 2002_CD we_PRP introduced_VBD an_DT annual_JJ practices_NNS are_VBP monitored_VBN by_IN our_PRP$ Internal_NNP Audit_NNP Code_NNP of_IN conduct_NN certification_NN process_NN for_IN the_DT 700_CD or_CC so_RB managers_NNS Department_NNP during_IN audits_NN of_IN our_PRP$ businesses_NNS ._.
GSKs_NNP Code_NNP of_IN Conduct_NNP sets_VBZ out_RP the_DT standards_NNS at_IN vice-president_NN level_NN and_CC above_IN to_TO ensure_VB that_IN We_PRP fully_RB investigate_VBP any_DT suspected_VBN breaches_NNS of_IN we_PRP expect_VBP employees_NNS to_TO meet_VB ._.
It_PRP requires_VBZ all_DT they_PRP understand_VBP this_DT responsibility_NN ._.
In_IN 2003_CD we_PRP policies_NNS and_CC take_VB appropriate_JJ disciplinary_JJ action_NN employees_NNS to_TO behave_VB honestly_RB ,_, in_IN line_NN with_IN extended_JJ certification_NN to_TO include_VB all_DT mid-level_JJ where_WRB warranted_VBN ._.
company_NN policy_NN and_CC with_IN the_DT law_NN ,_, to_TO avoid_VB management_NN in_IN the_DT US_NNP and_CC UK_NNP so_IN that_IN over_IN conflicts_NNS of_IN interest_NN and_CC to_TO report_VB any_DT violations_NNS 22_CD 9,000_CD managers_NNS participated_VBD in_IN the_DT certification_NN ._.
In_IN 2002_CD GSK_NNP provided_VBD input_NN into_IN the_DT Compliance_NN of_IN the_DT Code_NNP or_CC unethical_JJ behavior_NN ._.
Program_NNP Guidance_NNP for_IN Pharmaceutical_NNP If_IN employees_NNS have_VBP concerns_NNS they_PRP can_MD raise_VB them_PRP Manufacturers_NNPS developed_VBN by_IN the_DT US_NNP Health_NNP and_CC To_TO help_VB employees_NNS understand_VB the_DT Code_NNP and_CC 23_CD with_IN the_DT Corporate_JJ Compliance_NNP Officer_NNP ,_, the_DT Human_NNP Services_NNPS Office_NNP of_IN Inspector_NNP General_NNP ._.
what_WP constitutes_VBZ acceptable_JJ and_CC unacceptable_JJ business_NN unit_NN Compliance_NNP Officers_NNPS ,_, or_CC through_IN The_DT guidance_NN ,_, published_VBN in_IN April_NNP 2003_CD ,_, is_VBZ behavior_NN in_IN practice_NN we_PRP have_VBP also_RB issued_VBN an_DT our_PRP$ confidential_JJ PO_NNP Box_NNP and_CC helplines_NNS ._.
Other_JJ designed_VBN to_TO help_VB pharmaceutical_JJ companies_NNS Employee_NNP Guide_NNP to_TO Business_NNP Conduct_NNP ._.
The_DT Code_NNP stakeholders_NNS can_MD contact_VB our_PRP$ customer_NN response_NN establish_VB effective_JJ compliance_NN programs_NNS and_CC Guide_NNP are_VBP available_JJ on_IN the_DT company_NN centres_VBZ which_WDT redirect_VBP calls_NNS to_TO appropriate_JJ senior_JJ to_TO prevent_VB unlawful_JJ or_CC unethical_JJ conduct_NN ._.
are_VBP benchmarking_VBG our_PRP$ programs_NNS against_IN the_DT guidelines_NNS ._.
Business_NNP ethics_NNS and_CC integrity_NN 18_CD Corporate_JJ Responsibility_NN Report_NNP 2003_CD 3_CD Business_NN ethics_NNS &_CC integrity_NN Marketing_NNP practices_NNS These_DT regional_JJ codes_NNS are_VBP being_VBG introduced_VBN across_IN The_DT advertising_NN and_CC selling_NN of_IN medicines_NNS are_VBP the_DT company_NN and_CC we_PRP have_VBP designated_VBN area_NN subject_NN to_TO regulations_NNS set_VBN out_RP by_IN governments_NNS champions_NNS to_TO co-ordinate_VB the_DT distribution_NN of_IN the_DT and_CC medicines_NNS agencies_NNS ._.
GSKs_NNS internal_JJ policies_NNS codes_NNS and_CC training_NN for_IN staff_NN ._.
Codes_NNS are_VBP translated_VBN encompass_VB and_CC build_VB on_IN these_DT requirements_NNS ._.
into_IN local_JJ languages_NNS and_CC all_DT sales_NNS and_CC marketing_NN employees_NNS receive_VBP a_DT copy_NN ._.
Most_JJS of_IN our_PRP$ products_NNS are_VBP marketed_VBN by_IN sales_NNS representatives_NNS ._.
They_PRP regularly_RB meet_VBP doctors_NNS Training_VBG workshops_NNS and_CC electronic_JJ media_NNS and_CC pharmacists_NNS to_TO inform_VB them_PRP about_IN our_PRP$ ensure_VB staff_NN understand_VB the_DT codes_NNS and_CC what_WP medicines_NNS and_CC their_PRP$ approved_VBN uses_NNS ._.
We_PRP also_RB constitutes_VBZ acceptable_JJ promotional_JJ activities_NNS ._.
Performance_NNP with_IN integrity_NN market_NN some_DT products_NNS directly_RB to_TO consumers_NNS All_DT employees_NNS involved_VBN in_IN sales_NNS and_CC marketing_NN where_WRB this_DT is_VBZ permitted_VBN ._.
receive_VB regular_JJ training_NN on_IN our_PRP$ products_NNS so_IN they_PRP in_IN all_DT its_PRP$ aspects_NNS is_VBZ absolutely_RB non_NN can_MD provide_VB accurate_JJ information_NN to_TO doctors_NNS ._.
negotiable_JJ ,_, and_CC adherence_NN to_TO the_DT Specific_JJ policies_NNS and_CC guidance_NN for_IN sales_NNS and_CC new_JJ Code_NNP is_VBZ a_DT major_JJ way_NN in_IN which_WDT marketing_NN employees_NNS at_IN a_DT national_JJ level_NN ensure_VB that_IN all_PDT our_PRP$ marketing_NN is_VBZ accurate_JJ ,_, based_VBN on_IN valid_JJ we_PRP show_VBP that_IN ._.
scientific_JJ evidence_NN and_CC complies_NNS with_IN the_DT law_NN ._.
Russell_NNP Greig_NNP President_NNP Pharmaceuticals_NNP International_NNP ,_, GSK_NNP We_PRP are_VBP committed_VBN to_TO GSK_NNP also_RB has_VBZ a_DT company-wide_JJ policy_NN on_IN conducting_VBG our_PRP$ business_NN with_IN Pharmaceutical_NNP Marketing_NNP and_CC Promotion_NNP Activity_NNP which_WDT applies_VBZ to_TO all_DT employees_NNS and_CC agents_NNS ._.
It_PRP sets_VBZ integrity_NN and_CC that_DT means_VBZ complying_VBG out_RP our_PRP$ commitment_NN to_TO promotional_JJ practices_NNS fully_RB ,_, not_RB only_RB with_IN the_DT letter_NN of_IN the_DT that_WDT are_VBP ethical_JJ ,_, responsible_JJ ,_, principled_JJ and_CC patient-centred_JJ ._.
It_PRP prohibits_VBZ bribery_NN or_CC other_JJ law_NN ,_, but_CC with_IN the_DT spirit_NN ._.
It_PRP is_VBZ not_RB our_PRP$ inducements_NNS to_TO doctors_NNS to_TO prescribe_VB a_DT medicine_NN ._.
objective_NN to_TO look_VB for_IN loop-holes_NNS or_CC creative_JJ interpretations_NNS of_IN the_DT law_NN ,_, More_JJR detailed_JJ guidance_NN is_VBZ provided_VBN by_IN the_DT international_JJ and_CC regional_JJ industry_NN codes_NNS of_IN nor_CC shall_MD it_PRP be_VB our_PRP$ benchmark_NN to_TO practice_VB that_IN we_PRP adhere_VBP to_TO ,_, including_VBG the_DT simply_RB compare_VB ourselves_PRP with_IN our_PRP$ International_NNP Federation_NNP of_IN Pharmaceutical_NNP Manufacturers_NNP Associations_NNPS IFPMA_NNP Code_NNP of_IN competitors_NNS and_CC be_VB satisfied_VBN that_IN 24_CD Pharmaceutical_NNP Marketing_NNP Practices_NNPS ._.
we_PRP are_VBP as_RB good_JJ as_IN ,_, or_CC no_DT worse_JJR than_IN them_PRP ._.
In_IN addition_NN GSK_NNP has_VBZ developed_VBN ,_, and_CC keeps_VBZ under_IN review_NN ,_, its_PRP$ own_JJ regional_JJ marketing_NN codes_NNS that_WDT Andrew_NNP Witty_NNP President_NNP Pharmaceuticals_NNP Europe_NNP ,_, GSK_NNP ensure_VB differences_NNS in_IN market_NN structure_NN ,_, national_JJ healthcare_NN systems_NNS and_CC legal_JJ framework_NN are_VBP appropriately_RB reflected_VBN ._.
Enhancing_VBG a_DT compliance_NN culture_NN in_IN sales_NNS and_CC A_DT regular_JJ High_JJ Road_NNP newsletter_NN and_CC audio_JJ program_NN marketing_NN help_NN reinforce_VB key_JJ points_NNS from_IN training_NN and_CC keep_VB employees_NNS up_RB to_TO date_NN on_IN new_JJ developments_NNS ._.
Our_PRP$ pharmaceutical_JJ sales_NNS and_CC marketing_NN division_NN in_IN the_DT US_NNP has_VBZ introduced_VBN a_DT program_NN to_TO make_VB business_NN The_DT company_NN has_VBZ also_RB established_VBN an_DT advisory_JJ board_NN integrity_NN a_DT key_JJ requirement_NN ._.
The_DT initiative_NN ,_, called_VBN Take_VB of_IN sales_NNS managers_NNS from_IN across_IN the_DT business_NN to_TO provide_VB the_DT High_NNP Road_NNP on_IN Ethics_NNPS and_CC Legal_NNP Compliance_NNP ,_, aims_VBZ to_TO feedback_VB on_IN new_JJ initiatives_NNS and_CC help_VB ensure_VB compliance_NN ensure_VB employees_NNS understand_VB and_CC comply_VB with_IN our_PRP$ sales_NNS programs_NNS are_VBP practical_JJ and_CC user-friendly_RB ._.
The_DT compliance_NN department_NN and_CC confidential_JJ GSK_NNP Education_NNP is_VBZ an_DT essential_JJ element_NN ._.
A_DT comprehensive_JJ Integrity_NNP Helpline_NNP have_VBP been_VBN publicised_VBN so_RB employees_NNS paper_NN and_CC on-line_JJ manual_NN has_VBZ been_VBN developed_VBN ,_, know_VBP where_WRB to_TO go_VB if_IN they_PRP have_VBP any_DT questions_NNS or_CC containing_VBG our_PRP$ sales_NNS and_CC marketing_NN policies_NNS ,_, guidelines_NNS concerns_NNS ._.
Sales_NNS employees_NNS used_VBN this_DT facility_NN to_TO ask_VB more_JJR for_IN employees_NNS and_CC Q&A_NNP s_VBZ on_IN key_JJ subjects_NNS ._.
This_DT is_VBZ available_JJ than_IN 1,100_CD questions_NNS on_IN sales_NNS and_CC marketing_NN policies_NNS to_TO over_IN 10,000_CD employees_NNS across_IN the_DT US_NNP ._.
All_DT new_JJ in_IN 2003_CD ._.
and_CC existing_VBG sales_NNS and_CC marketing_NN employees_NNS attend_VBP compliance_NN training_NN and_CC 11_CD new_JJ computer-based_JJ training_NN Monitoring_NN behavior_NN is_VBZ an_DT important_JJ element_NN of_IN modules_NNS have_VBP been_VBN developed_VBN ._.
A_DT full-time_JJ project_NN team_NN looked_VBD employees_NNS completed_VBN compliance_NN training_NN in_IN 2003_CD ._.
in_IN detail_NN at_IN our_PRP$ monitoring_NN processes_VBZ for_IN sales_NNS and_CC A_DT video_NN ,_, Performing_VBG With_IN Integrity_NN ,_, supports_VBZ the_DT training_NN marketing_NN and_CC introduced_VBN improvements_NNS where_WRB and_CC includes_VBZ perspectives_NNS from_IN GSK_NNP sales_NNS people_NNS ._.
Audits_NNS have_VBP been_VBN conducted_VBN in_IN key_JJ compliance_NN areas_NNS during_IN the_DT past_JJ two_CD years_NNS ._.
Corporate_JJ Responsibility_NN Report_NNP 2003_CD 19_CD Environme_NNP health_NN and_CC Environment_NNP ,_, health_NN and_CC safety_NN EHS_NNP issues_NNS are_VBP managed_VBN through_IN an_DT integrated_JJ system_NN that_WDT ensures_VBZ issues_NNS and_CC risks_NNS are_VBP identified_VBN ,_, training_NN is_VBZ provided_VBN ,_, targets_NNS set_VBN and_CC audits_NN conducted_VBN ._.
Our_PRP$ EHS_NNP standards_NNS apply_VB throughout_IN our_PRP$ operations_NNS and_CC in_IN 2002_CD we_PRP developed_VBD a_DT ten-year_JJ strategic_JJ 25_CD plan_NN our_PRP$ Plan_NN for_IN Excellence_NN ._.
Environment_NNP Important_NNP environmental_JJ issues_NNS include_VBP :_: We_PRP have_VBP a_DT systematic_JJ plan_NN to_TO improve_VB Air_NNP quality_NN Volatile_NNP organic_JJ compounds_NNS VOCs_NNS environment_NN ,_, health_NN and_CC safety_NN performance_NN used_VBN as_IN solvents_NNS in_IN manufacturing_NN can_MD contribute_VB the_DT EHS_NNP Plan_NNP for_IN Excellence_NNP ._.
Our_PRP$ long-term_JJ goal_NN to_TO the_DT formation_NN of_IN smog_NN ._.
is_VBZ to_TO drive_VB down_RP manufacturing_NN impacts_NNS and_CC switch_VB to_TO using_VBG renewable_JJ resources_NNS so_IN that_IN our_PRP$ Climate_NN Burning_NN fossil_JJ fuels_NNS for_IN energy_NN operations_NNS become_VBP increasingly_RB compatible_JJ with_IN produces_VBZ carbon_NN dioxide_NN which_WDT contributes_VBZ to_TO the_DT principles_NNS of_IN sustainable_JJ development_NN ._.
global_JJ warming_NN and_CC climate_NN change_NN ._.
We_PRP have_VBP identified_VBN appropriate_JJ parameters_NNS Ozone_NN depletion_NN Some_DT of_IN our_PRP$ products_NNS and_CC to_TO track_VB progress_NN in_IN each_DT of_IN our_PRP$ main_JJ impacts_NNS ._.
These_DT gases_NNS Following_VBG the_DT formation_NN of_IN GSK_NNP we_PRP established_VBD damage_NN the_DT ozone_NN layer_NN if_IN released_VBN into_IN the_DT baseline_NN values_NNS for_IN these_DT parameters_NNS in_IN 2001_CD atmosphere_NN ._.
and_CC set_VBN improvement_NN targets_NNS to_TO be_VB achieved_VBN by_IN the_DT end_NN of_IN 2005_CD see_VBP chart_NN ,_, page_NN 22_CD ._.
Waste_NNP Some_DT of_IN the_DT raw_JJ materials_NNS used_VBN in_IN pharmaceutical_JJ production_NN processes_NNS are_VBP An_DT important_JJ element_NN of_IN our_PRP$ approach_NN is_VBZ hazardous_JJ and_CC require_VB special_JJ disposal_NN methods_NNS ._.
consultation_NN with_IN people_NNS outside_IN GSK_NNP either_CC experts_NNS or_CC community_NN neighbors_NNS who_WP may_MD be_VB Water_NNP Waste_NNP water_NN discharges_VBZ from_IN affected_VBN by_IN our_PRP$ sites_NNS ._.
We_PRP do_VBP this_DT routinely_RB and_CC at_IN manufacturing_VBG sites_NNS require_VBP treatment_NN before_IN several_JJ levels_NNS ._.
The_DT aim_NN is_VBZ for_IN our_PRP$ stakeholders_NNS to_TO they_PRP are_VBP released_VBN ._.
have_VB access_NN to_TO the_DT information_NN they_PRP need_VBP and_CC the_DT opportunity_NN to_TO tell_VB us_PRP what_WP they_PRP think_VBP and_CC how_WRB they_PRP want_VBP us_PRP to_TO improve_VB ._.
20_CD Corporate_JJ Responsibility_NN report_NN 2003_CD 4_CD Environment_NNP health_NN &_CC safety_NN nt_NN safety_NN Technological_JJ changes_NNS improve_VBP materials_NNS recovery_NN New_NNP technology_NN can_MD help_VB improve_VB our_PRP$ environmental_JJ performance_NN ._.
GSKs_NNS manufacturing_VBG site_NN at_IN Ulverston_NNP in_IN the_DT UK_NNP has_VBZ introduced_VBN a_DT new_JJ membrane_NN filtration_NN system_NN that_WDT has_VBZ reduced_VBN hazardous_JJ waste_NN by_IN 50_CD tonnes_NNS and_CC emissions_NNS of_IN VOCs_NNS by_IN 3_CD tonnes_NNS per_IN annum_NN ._.
The_DT new_JJ system_NN saves_VBZ the_DT site_NN around_IN 1_CD million_CD a_DT year_NN ._.
Ulverston_NNP is_VBZ one_CD of_IN our_PRP$ largest_JJS primary_JJ manufacturing_NN plants_NNS with_IN over_IN 600_CD staff_NN on_IN a_DT 60-acre_JJ site_NN ._.
It_PRP is_VBZ situated_VBN near_IN the_DT Lake_NNP District_NNP ,_, an_DT area_NN of_IN natural_JJ beauty_NN and_CC ecological_JJ importance_NN ._.
The_DT plant_NN makes_VBZ active_JJ ingredients_NNS for_IN many_JJ of_IN our_PRP$ antibiotics_NNS ._.
Acetone_NNP ,_, a_DT VOC_NNP ,_, is_VBZ used_VBN as_IN a_DT solvent_JJ during_IN manufacturing_VBG when_WRB axetil_NN ,_, an_DT oral_JJ antibiotic_JJ ,_, is_VBZ spray_NN dried_VBD ._.
This_DT process_NN ensures_VBZ the_DT medicines_NNS can_MD be_VB absorbed_VBN efficiently_RB from_IN the_DT stomach_NN and_CC gut_NN into_IN the_DT patients_NNS bloodstream_NN ._.
Acetone_NNP is_VBZ also_RB used_VBN to_TO wash_VB the_DT equipment_NN used_VBN in_IN processing_NN ._.
Antibiotic_JJ residue_NN in_IN the_DT acetone_NN is_VBZ valuable_JJ and_CC needs_VBZ to_TO be_VB recovered_VBN before_IN disposal_NN of_IN the_DT acetone_NN ._.
Previously_RB this_DT was_VBD done_VBN in_IN a_DT remote_JJ area_NN of_IN the_DT site_NN but_CC the_DT system_NN was_VBD inefficient_JJ so_IN a_DT lot_NN of_IN the_DT product_NN was_VBD wasted_VBN ._.
Acetone_NNP is_VBZ highly_RB flammable_JJ so_IN pumping_VBG it_PRP across_IN the_DT site_NN created_VBD a_DT potential_JJ health_NN and_CC safety_NN risk_NN ._.
In_IN 2002_CD the_DT site_NN introduced_VBD a_DT new_JJ membrane_NN filtration_NN system_NN ._.
This_DT separates_VBZ antibiotic_JJ from_IN other_JJ residues_NNS in_IN the_DT acetone_NN ,_, allowing_VBG it_PRP to_TO be_VB concentrated_VBN for_IN more_RBR efficient_JJ recovery_NN ._.
As_IN a_DT result_NN of_IN installing_VBG the_DT new_JJ equipment_NN ,_, the_DT overall_JJ process_NN has_VBZ become_VBN much_RB more_RBR efficient_JJ ._.
Up_IN to_TO 97_CD %_NN of_IN the_DT antibiotic_JJ is_VBZ now_RB recovered_VBN ,_, so_IN there_EX is_VBZ less_JJR waste_NN ._.
The_DT filtration_NN system_NN was_VBD installed_VBN next_JJ to_TO the_DT production_NN building_NN ,_, reducing_VBG the_DT amount_NN of_IN solvent_JJ transferred_VBN across_IN the_DT site_NN and_CC the_DT health_NN and_CC safety_NN risks_NNS ._.
The_DT site_NN won_VBD a_DT GSK_NNP CEOs_NNS EHS_NNP Excellence_NNP Award_NNP in_IN 2003_CD for_IN its_PRP$ work_NN in_IN implementing_VBG the_DT new_JJ system_NN ._.
Corporate_JJ Responsibility_NN Report_NNP 2003_CD 21_CD Progress_NNP in_IN 2003_CD emissions_NNS from_IN the_DT use_NN of_IN inhalers_NNS and_CC from_IN CAUSES_NNPS OF_IN LOST_NNP INJURY_NNP TIME_CD %_NN Our_PRP$ performance_NN relating_VBG to_TO resources_NNS ,_, waste_NN manufacturing_NN ,_, resulting_VBG in_IN 48_CD %_NN less_JJR ozone_NN disposal_NN ,_, climate_NN change_NN and_CC air_NN quality_NN depleting_VBG potential_JJ overall_JJ ._.
Some_DT of_IN our_PRP$ targets_NNS 2_CD 2_CD Caught_NNP in_IN on_IN between_IN 8_CD %_NN 6_CD and_CC the_DT percentage_NN reductions_NNS achieved_VBN are_VBP Health_NNP and_CC safety_NN 3_CD Motor_NNP vehicle_NN accidents_NNS 20_CD %_NN shown_VBN in_IN the_DT chart_NN ._.
The_DT health_NN and_CC safety_NN of_IN our_PRP$ employees_NNS and_CC 4_CD Over-exertions_NNS strains_NNS 23_CD %_NN 3_CD 5_CD Slips_VBZ trips_NNS falls_VBZ 26_CD %_NN contractors_NNS is_VBZ a_DT high_JJ priority_NN for_IN GSK_NNP ._.
The_DT risks_NNS 6_CD Striking_VBG against_IN struck_VBN 10_CD %_NN 5_CD During_IN 2003_CD we_PRP made_VBD particularly_RB good_JJ progress_NN and_CC hazards_NNS associated_VBN with_IN our_PRP$ products_NNS and_CC 7_CD Other_JJ 7_CD %_NN toward_IN our_PRP$ targets_NNS in_IN six_CD areas_NNS ._.
Comparing_VBG with_IN operations_NNS are_VBP systematically_RB assessed_VBN and_CC includes_VBZ contact_NN with_IN sharps_NNS ,_, animal_NN insect_NN ,_, electric_JJ fire_NN explosion_NN ,_, foreign_JJ 2001_CD figures_NNS ,_, the_DT year_NN we_PRP set_VBD our_PRP$ targets_NNS ,_, and_CC measures_NNS are_VBP taken_VBN to_TO protect_VB employees_NNS and_CC 4_CD bodies_NNS objects_NNS ,_, workplace_NN violence_NN with_IN all_DT measures_NNS normalised_VBN against_IN sales_NNS ,_, others_NNS coming_VBG into_IN contact_NN with_IN the_DT hazards_NNS ._.
energy_NN consumption_NN was_VBD down_RB 8_CD %_NN ,_, associated_VBN global_JJ warming_NN potential_NN was_VBD down_RB 8_CD %_NN ,_, water_NN We_PRP track_VBP the_DT number_NN of_IN cases_NNS of_IN injury_NN or_CC illness_NN consumption_NN was_VBD down_RB 17_CD %_NN ,_, ozone_NN depletion_NN resulting_VBG in_IN time_NN off_RP work_NN and_CC have_VBP set_VBN a_DT potential_NN from_IN production_NN was_VBD down_RB 64_CD %_NN ,_, challenging_VBG target_NN of_IN reducing_VBG this_DT by_IN 15_CD %_NN every_DT ozone_NN depletion_NN potential_NN from_IN ancillary_JJ sources_NNS year_NN until_IN 2005_CD ._.
In_IN 2002_CD we_PRP cut_VBD our_PRP$ injury_NN and_CC was_VBD down_RB 66_CD %_NN and_CC hazardous_JJ waste_NN disposed_VBD illness_NN rate_NN by_IN 21_CD %_NN ,_, and_CC in_IN 2003_CD we_PRP reduced_VBD it_PRP was_VBD down_RB 8_CD %_NN ._.
CFCs_NNS are_VBP used_VBN as_IN propellants_NNS in_IN metered_JJ dose_NN We_PRP also_RB monitor_VBP the_DT causes_NNS of_IN incidents_NNS and_CC inhalers_NNS MDIs_NNS and_CC we_PRP also_RB use_VBP ozone_NN depleting_NN assess_VBP what_WP can_MD be_VB learned_VBN to_TO avoid_VB similar_JJ substances_NNS for_IN refrigeration_NN ._.
When_WRB a_DT patient_NN uses_VBZ injuries_NNS again_RB ._.
The_DT main_JJ causes_NNS of_IN injury_NN are_VBP slips_VBZ ,_, an_DT MDI_NNP the_DT propellant_NN is_VBZ released_VBN into_IN the_DT trips_NNS ,_, falls_VBZ ,_, strains_NNS from_IN over-exertion_NN and_CC motor_NN atmosphere_NN ._.
This_DT is_VBZ our_PRP$ largest_JJS source_NN of_IN CFC_NNP vehicle_NN accidents_NNS ._.
We_PRP deeply_RB regret_VBP that_IN during_IN emissions_NNS ,_, amounting_VBG to_TO 782_CD metric_JJ tonnes_NNS ,_, 2003_CD there_EX were_VBD five_CD work-related_JJ fatalities_NNS about_IN 92_CD %_NN of_IN the_DT total_NN ._.
Releases_NNS from_IN our_PRP$ among_IN GSK_NNP employees_NNS ._.
Four_CD died_VBD in_IN driving_VBG factories_NNS that_WDT manufacture_VBP MDIs_NNS are_VBP our_PRP$ second_JJ accidents_NNS and_CC one_CD from_IN mesothelioma_NN due_JJ to_TO most_RBS significant_JJ source_NN and_CC refrigeration_NN is_VBZ the_DT asbestos_NN exposure_NN in_IN the_DT 1950s_CD ._.
Replacement_NN of_IN MDIs_NNS using_VBG CFC_NNP as_IN a_DT one_CD contractor_NN died_VBD in_IN a_DT fork-lift_JJ truck_NN accident_NN ._.
propellant_NN with_IN alternative_JJ technologies_NNS has_VBZ cut_VBN 2003_CD PROGRESS_NN AGAINST_IN TARGETS_NNS -15_CD %_NN Lost_VBD time_NN injury_NN and_CC illness_NN rate_NN -9_CD %_NN -8_CD %_NN Energy_NN -8_CD %_NN consumption_NN -10_CD %_NN Water_NNP consumption_NN -17_CD %_NN ODP_NNP refrigeration_NN and_CC -100_CD %_NN ancillary_JJ CFC_NNP emissions_NNS -66_CD %_NN -50_CD %_NN ODP_NNP production_NN CFC-11_NN equivalent_JJ emissions_NNS -64_CD %_NN -30_CD %_NN Volatile_JJ organic_JJ compound_NN emissions_NNS -7_CD %_NN -8_CD %_NN Global_JJ warming_VBG potential_JJ -8_CD %_NN from_IN energy_NN sources_NNS -15_CD %_NN Hazardous_JJ waste_NN disposed_VBD -8_CD %_NN 2005_CD Targets_NNPS except_IN for_IN lost_VBN time_NN injury_NN and_CC illness_NN rate_NN which_WDT is_VBZ an_DT annual_JJ target_NN 2003_CD Improvements_NNP against_IN 2001_CD baseline_NN Environmental_NNP measures_NNS are_VBP normalised_VBN by_IN sales_NNS ODP_NNP is_VBZ ozone_NN depletion_NN potential_NN Global_JJ warming_NN potential_NN is_VBZ measured_VBN as_IN CO_NNP equivalents_NNS 2_CD An_DT explanation_NN of_IN all_DT EHS_NNP data_NN is_VBZ in_IN the_DT full_JJ EHS_NNP report_NN on_IN our_PRP$ website_NN ,_, www_NN ._.
com_NN EHS_NNP data_NNS for_IN 2003_CD not_RB yet_RB verified_VBN 22_CD Corporate_JJ Responsibility_NN Report_NNP 2003_CD 5_CD Valuing_VBG people_NNS Valuing_VBG people_NNS GSK_NNP employs_VBZ over_IN 100,000_CD people_NNS in_IN 117_CD countries_NNS ._.
Getting_VBG the_DT best_JJS from_IN our_PRP$ people_NNS is_VBZ vital_JJ to_TO the_DT success_NN of_IN our_PRP$ business_NN and_CC a_DT key_JJ source_NN of_IN competitive_JJ advantage_NN ._.
Below_IN we_PRP report_VBP on_IN :_: More_JJR than_IN two-thirds_NNS of_IN GSK_NNP employees_NNS our_PRP$ work_NN to_TO embed_VB the_DT GSK_NNP Spirit_NN and_CC culture_NN participate_VB in_IN our_PRP$ individual_JJ appraisal_NN process_NN ,_, across_IN our_PRP$ operations_NNS worldwide_VBP Performance_NNP and_CC Development_NNP Planning_NNP PDP_NNP ._.
the_DT development_NN of_IN our_PRP$ diversity_NN initiatives_VBZ This_DT helps_VBZ employees_NNS set_VBN objectives_NNS ,_, rewards_NNS introducing_VBG human_JJ rights_NNS standards_NNS into_IN our_PRP$ strong_JJ performance_NN and_CC helps_VBZ them_PRP identify_VB procurement_NN processes_NNS ._.
the_DT training_NN they_PRP need_VBP to_TO develop_VB their_PRP$ careers_NNS ._.
As_IN part_NN of_IN the_DT PDP_NNP process_NN ,_, employees_NNS and_CC The_DT GSK_NNP Spirit_NN their_PRP$ managers_NNS assess_VBP how_WRB well_RB they_PRP have_VBP This_DT sets_VBZ out_RP the_DT values_NNS and_CC qualities_NNS we_PRP expect_VBP implemented_VBD the_DT GSK_NNP Spirit_NN in_IN their_PRP$ work_NN ,_, and_CC employees_NNS to_TO embrace_VB in_IN their_PRP$ work_NN ._.
this_DT can_MD have_VB a_DT significant_JJ impact_NN on_IN the_DT bonus_NN Its_PRP$ principles_NNS are_VBP :_: payments_NNS awarded_VBD to_TO eligible_JJ employees_NNS ._.
performance_NN with_IN integrity_NN entrepreneurial_JJ spirit_NN We_PRP use_VBP a_DT global_JJ survey_NN of_IN 11,000_CD managers_NNS to_TO focus_VB on_IN innovation_NN help_VBP us_PRP analyze_VB how_WRB effectively_RB we_PRP are_VBP building_VBG a_DT sense_NN of_IN urgency_NN the_DT GSK_NNP Spirit_NN ._.
Last_JJ year_NN we_PRP reported_VBD on_IN the_DT passion_NN for_IN achievement_NN ._.
2002_CD results_NNS ,_, which_WDT were_VBD generally_RB positive_JJ ._.
Since_IN then_RB ,_, work_NN has_VBZ been_VBN taking_VBG place_NN to_TO Getting_VBG our_PRP$ culture_NN right_NN address_NN areas_NNS identified_VBN for_IN development_NN ._.
``_`` We_PRP aim_VBP to_TO build_VB a_DT culture_NN in_IN which_WDT our_PRP$ people_NNS Progress_NNP will_MD be_VB measured_VBN when_WRB the_DT next_JJ are_VBP clear_JJ about_IN the_DT companys_NNS expectations_NNS and_CC survey_NN takes_VBZ place_NN during_IN 2004_CD ._.
instinctively_RB ''_'' ``_`` do_VBP the_DT right_JJ thing_NN ''_'' ''_'' ._. ''_''
Each_DT of_IN our_PRP$ operations_NNS has_VBZ been_VBN working_VBG with_IN employees_NNS to_TO Diversity_NNP ensure_VB they_PRP understand_VBP and_CC adopt_VBP the_DT principles_NNS GSK_NNP is_VBZ committed_VBN to_TO employing_VBG a_DT diverse_JJ of_IN the_DT GSK_NNP Spirit_NN ._.
Our_PRP$ approach_NN is_VBZ tailored_VBN to_TO workforce_NN ._.
Both_DT individual_JJ employees_NNS and_CC reflect_VB local_JJ circumstances_NNS ,_, with_IN events_NNS including_VBG GSK_NNP benefit_NN from_IN a_DT workplace_NN where_WRB talented_VBN workshops_NNS ,_, team_NN meetings_NNS ,_, presentations_NNS and_CC people_NNS can_MD thrive_VB ,_, and_CC where_WRB their_PRP$ diversity_NN of_IN awards_NNS ._.
For_IN example_NN ,_, GSK_NNP in_IN Nigeria_NNP used_VBD a_DT background_NN ,_, culture_NN and_CC outlook_NN helps_VBZ us_PRP better_JJR costumed_VBD storyteller_NN to_TO introduce_VB the_DT Spirit_NN understand_VBP the_DT needs_NNS of_IN patients_NNS and_CC customers_NNS to_TO employees_NNS ._.
In_IN Argentina_NNP every_DT employee_NN worldwide_NN ._.
Our_PRP$ aim_NN is_VBZ to_TO create_VB an_DT inclusive_JJ work_NN attended_VBD a_DT half-day_JJ culture_NN awareness_NN workshop_NN ._.
environment_NN free_JJ from_IN discrimination_NN on_IN grounds_NNS of_IN race_NN ,_, ethnicity_NN ,_, gender_NN ,_, religion_NN ,_, sexual_JJ Our_PRP$ leadership_NN development_NN programs_NNS are_VBP orientation_NN ,_, disability_NN or_CC age_NN ._.
designed_VBN to_TO encourage_VB employees_NNS to_TO apply_VB the_DT GSK_NNP Spirit_NN ._.
These_DT programs_NNS are_VBP available_JJ to_TO We_PRP held_VBD our_PRP$ first_JJ Diversity_NNP &_CC Multi-Cultural_NNP managers_NNS globally_RB at_IN all_DT levels_NNS ._.
This_DT year_NN 286_CD Marketing_NNP Awards_NNPS in_IN Philadelphia_NNP in_IN May_NNP 2003_CD ._.
people_NNS attended_VBD Leadership_NNP Edge_NNP ,_, our_PRP$ global_JJ The_DT awards_NNS ,_, which_WDT will_MD be_VB made_VBN annually_RB ,_, have_VBP program_NN for_IN senior_JJ managers_NNS ,_, and_CC 235_CD been_VBN set_VBN up_RP to_TO demonstrate_VB the_DT impact_NN diversity_NN attended_VBD Leadership@GSK,_NNP the_DT program_NN for_IN can_MD have_VB on_IN improving_VBG business_NN performance_NN ,_, middle_JJ managers_NNS ._.
The_DT programs_NNS are_VBP designed_VBN and_CC to_TO share_VB best_JJS practices_NNS around_IN the_DT company_NN ._.
to_TO help_VB managers_NNS to_TO achieve_VB performance_NN through_IN others_NNS and_CC to_TO increase_VB their_PRP$ insight_NN into_IN differing_VBG work_NN styles_NNS ,_, strengths_NNS and_CC motivations_NNS ._.
Corporate_JJ Responsibility_NN Report_NNP 2003_CD 23_CD Current_JJ diversity_NN initiatives_NNS include_VBP our_PRP$ Women_NNS Human_JJ rights_NNS in_IN Leadership_NN program_NN in_IN the_DT US_NNP to_TO support_VB Compliance_NN with_IN our_PRP$ human_JJ rights_NNS requirements_NNS career_NN development_NN ._.
Additionally_RB in_IN 2004_CD we_PRP will_MD has_VBZ been_VBN included_VBN as_IN one_CD of_IN our_PRP$ criteria_NNS for_IN be_VB holding_VBG a_DT Women_NNS in_IN Science_NNP day_NN in_IN the_DT UK_NNP to_TO selecting_VBG suppliers_NNS ._.
We_PRP are_VBP also_RB introducing_VBG attract_VB more_JJR female_JJ science_NN graduates_VBZ into_IN the_DT binding_JJ clauses_NNS into_IN our_PRP$ procurement_NN contracts_NNS industry_NN ._.
We_PRP are_VBP also_RB undertaking_VBG a_DT review_NN in_IN which_WDT require_VBP suppliers_NNS to_TO meet_VB our_PRP$ standards_NNS on_IN the_DT UK_NNP of_IN how_WRB we_PRP can_MD improve_VB the_DT working_VBG human_JJ rights_NNS ._.
environment_NN and_CC access_NN to_TO our_PRP$ facilities_NNS and_CC websites_NNS for_IN disabled_JJ employees_NNS ,_, potential_JJ In_IN 2003_CD we_PRP began_VBD incorporating_VBG human_JJ rights_NNS employees_NNS and_CC visitors_NNS ._.
This_DT will_MD conclude_VB in_IN clauses_NNS into_IN our_PRP$ central_JJ contract_NN templates_NNS for_IN use_NN early_RB 2004_CD ._.
with_IN new_JJ suppliers_NNS ._.
This_DT process_NN will_MD be_VB completed_VBN in_IN 2004_CD ._.
We_PRP are_VBP also_RB adding_VBG these_DT clauses_NNS to_TO In_IN 2003_CD we_PRP widened_VBD the_DT scope_NN of_IN our_PRP$ employee_NN contract_NN templates_NNS used_VBN by_IN local_JJ operations_NNS ._.
networks_NNS in_IN the_DT US_NNP ,_, with_IN new_JJ groups_NNS for_IN sales_NNS staff_NN and_CC in_IN the_DT Delaware_NNP Valley_NNP ._.
Our_PRP$ broad_JJ Risk_NN of_IN human_JJ rights_NNS issues_NNS varies_VBZ around_IN the_DT spread_NN of_IN existing_VBG network_NN activities_NNS includes_VBZ world_NN ,_, and_CC where_WRB appropriate_JJ we_PRP are_VBP contacting_VBG career_NN development_NN programs_NNS for_IN Asian_JJ ,_, major_JJ existing_VBG suppliers_NNS to_TO assess_VB whether_IN they_PRP African_JJ American_NNP ,_, Hispanic_NNP and_CC gay_JJ and_CC lesbian_JJ meet_VB our_PRP$ standards_NNS ._.
Key_NNP suppliers_NNS have_VBP been_VBN employees_NNS ._.
asked_VBD to_TO confirm_VB in_IN writing_VBG that_IN they_PRP comply_VBP ,_, and_CC the_DT requirements_NNS are_VBP being_VBG introduced_VBN into_IN GLOBAL_NNP MANAGEMENT_NNP POPULATION_NNP existing_VBG contracts_NNS when_WRB they_PRP are_VBP reviewed_VBN ._.
BY_IN GENDER_NNP 2003_CD Implementing_VBG the_DT GSK_NNP Spirit_NN in_IN MEN_NNP WOMEN_NNP TOTAL_NNP Consumer_NNP Healthcare_NNP India_NNP We_PRP have_VBP contacted_VBN over_IN 400_CD suppliers_NNS so_RB far_RB to_TO In_IN a_DT country_NN as_IN diverse_JJ as_IN India_NNP ,_, creating_VBG a_DT gain_NN their_PRP$ agreement_NN to_TO the_DT standards_NNS ._.
To_TO date_NN Bands_NNS A_NNP &_CC B_NNP 550_CD 80_CD %_NN 135_CD 20_CD %_NN 685_CD unified_VBN spirit_NN and_CC culture_NN is_VBZ critical_JJ to_TO the_DT success_NN no_DT companies_NNS have_VBP declined_VBN to_TO co-operate_VB ,_, and_CC Bands_NNP C_NNP 1-3_JJ 2,557_CD 69_CD %_NN 1,158_CD 31_CD %_NN 3,715_CD of_IN GSKs_NNP Consumer_NNP Healthcare_NNP business_NN ._.
Bands_NNS C_$ 4-5_CD 4,221_CD 63_CD %_NN 2,432_CD 37_CD %_NN 6,653_CD we_PRP are_VBP following_VBG up_RP with_IN those_DT that_WDT have_VBP not_RB yet_RB The_DT main_JJ product_NN is_VBZ Horlicks_NNP which_WDT is_VBZ a_DT major_JJ responded_VBD to_TO our_PRP$ request_NN ._.
The_DT business_NN employs_VBZ 3,000_CD people_NNS at_IN ten_NN sites_NNS ._.
Employees_NNS are_VBP Questions_NNS on_IN human_JJ rights_NNS issues_NNS have_VBP been_VBN Corporate_JJ Executive_NNP Team_NNP ,_, Vice_NNP Presidents_NNPS and_CC Senior_NNP drawn_VBN from_IN across_IN India_NNP so_IN there_EX are_VBP huge_JJ Vice_NNP Presidents_NNP added_VBD to_TO the_DT standard_JJ list_NN of_IN topics_NNS discussed_VBN differences_NNS of_IN background_NN ,_, religion_NN and_CC Director_NNP Level_NNP at_IN supplier_NN visits_NNS by_IN our_PRP$ procurement_NN and_CC EHS_NNP culture_NN ._.
At_IN least_JJS four_CD different_JJ languages_NNS are_VBP Manager_NNP Level_NNP commonly_RB spoken_VBD in_IN the_DT workplace_NN ._.
This_DT year_NN we_PRP have_VBP seen_VBN an_DT increase_NN in_IN the_DT Each_DT site_NN has_VBZ developed_VBN initiatives_NNS to_TO bring_VB the_DT number_NN of_IN women_NNS in_IN management_NN positions_NNS If_IN a_DT supplier_NN is_VBZ found_VBN not_RB to_TO meet_VB our_PRP$ standards_NNS GSK_NNP Spirit_NN to_TO life_NN and_CC enable_VB employees_NNS to_TO in_IN the_DT company_NN from_IN 32_CD %_NN in_IN 2002_CD to_TO 34_CD %_NN we_PRP will_MD work_VB with_IN them_PRP to_TO achieve_VB compliance_NN ._.
understand_VB its_PRP$ relevance_NN in_IN an_DT Indian_JJ working_NN environment_NN ._.
These_DT are_VBP supported_VBN by_IN businessin_NN 2003_CD ._.
We_PRP will_MD conduct_VB regular_JJ audits_NN to_TO ensure_VB that_IN wide_JJ tools_NNS such_JJ as_IN a_DT Spirit_NN website_NN with_IN they_PRP have_VBP improved_VBN their_PRP$ performance_NN so_IN it_PRP is_VBZ in_IN regularly_RB updated_VBN games_NNS and_CC quizzes_VBZ on_IN how_WRB We_PRP report_VBP ethnicity_NN data_NNS for_IN US_NNP employees_NNS ._.
We_PRP will_MD terminate_VB a_DT to_TO apply_VB the_DT Spirit_NN in_IN practice_NN ._.
In_IN 2002_CD people_NNS of_IN color_NN accounted_VBD for_IN 19.0_CD %_NN ._.
contract_NN if_IN a_DT supplier_NN will_MD not_RB or_CC can_MD not_RB work_VB The_DT companys_NNS Nabha_NNP manufacturing_VBG site_NN in_IN This_DT increased_VBN very_RB slightly_RB in_IN 2003_CD to_TO 19.5_CD %_NN towards_IN compliance_NN ._.
the_DT rural_JJ Punjab_NNP area_NN ,_, where_WRB literacy_NN rates_NNS are_VBP of_IN the_DT US_NNP workforce_NN of_IN 24,000_CD ._.
We_PRP intend_VBP to_TO low_JJ ,_, uses_VBZ posters_NNS with_IN cricket_NN cartoons_NNS to_TO collect_VB and_CC report_VB ethnicity_NN data_NNS for_IN our_PRP$ UK_NNP illustrate_VBP the_DT Spirits_NNS principles_NNS ._.
Employees_NNS have_VBP operations_NNS for_IN 2004_CD ._.
also_RB made_VBN their_PRP$ own_JJ motivational_JJ film_NN for_IN use_NN in_IN team_NN meetings_NNS ._.
ETHNICITY_NNP OF_IN US_NNP EMPLOYEE_NN POPULATION_NN 2003_CD Employees_NNS at_IN manufacturing_VBG sites_NNS are_VBP encouraged_VBN to_TO get_VB involved_VBN in_IN our_PRP$ global_JJ Operational_NNP Excellence_NN campaign_NN and_CC Total_JJ US_NNP demonstrate_VBP passion_NN in_IN their_PRP$ work_NN ,_, by_IN employees_NNS 24,000_CD 19.5_CD %_NN developing_VBG a_DT Just_RB do_VB it_PRP JDI_NNP concept_NN ._.
These_DT are_VBP simple_JJ ideas_NNS to_TO improve_VB efficiency_NN and_CC People_NNS of_IN color_NN effectiveness_NN ._.
In_IN 2003_CD every_DT one_CD of_IN over_IN 1,000_CD employees_NNS at_IN Nabha_NNP contributed_VBD at_IN least_JJS one_CD JDI_NNP ,_, including_VBG ideas_NNS to_TO improve_VB health_NN and_CC safety_NN and_CC reduce_VB waste_NN at_IN the_DT site_NN ._.
JDIs_NNS developed_VBD at_IN our_PRP$ Sonepat_NNP plant_NN helped_VBD save_VB over_IN 30,000_CD during_IN 2003_CD ._.
Employees_NNS are_VBP rewarded_VBN for_IN their_PRP$ ideas_NNS through_IN Spirit_NN recognition_NN awards_NNS ._.
The_DT companys_NNS focus_VB on_IN getting_VBG its_PRP$ culture_NN right_NN has_VBZ helped_VBN it_PRP gain_VB recognition_NN as_IN one_CD of_IN Indias_NNP top_JJ employers_NNS ._.
In_IN 2003_CD it_PRP was_VBD declared_VBN fifth_JJ best_JJS employer_NN in_IN the_DT annual_JJ Business_NN Today_NN Hewitt_NNP awards_NNS ,_, which_WDT are_VBP partly_RB determined_VBN by_IN employee_NN feedback_NN ._.
24_CD Corporate_JJ Responsibility_NN Report_NNP 2003_CD Corporate_JJ Responsibility_NN Report_NNP 2003_CD 25_CD Research_NNP a_DT developme_NN Medical_JJ research_NN can_MD give_VB rise_VB to_TO ethical_JJ concerns_NNS and_CC we_PRP engage_VBP openly_RB in_IN constructive_JJ debate_NN on_IN these_DT matters_NNS ._.
Here_RB we_PRP discuss_VBP the_DT disclosure_NN of_IN clinical_JJ trial_NN information_NN and_CC the_DT use_NN of_IN animals_NNS in_IN research_NN ._.
Evaluating_VBG potential_JJ new_JJ medicines_NNS in_IN We_PRP believe_VBP that_IN healthcare_NN decisions_NNS should_MD clinical_JJ trials_NNS is_VBZ an_DT essential_JJ and_CC mandatory_JJ be_VB made_VBN in_IN the_DT knowledge_NN of_IN all_DT relevant_JJ information_NN ._.
GSK_NNP supports_VBZ scientific_JJ and_CC medical_JJ step_NN in_IN developing_VBG new_JJ treatments_NNS ._.
Trials_NNS progress_NN by_IN making_VBG the_DT results_NNS of_IN clinical_JJ trials_NNS may_MD also_RB be_VB conducted_VBN once_RB a_DT medicine_NN more_RBR widely_RB available_JJ ._.
Whenever_NNP possible_JJ ,_, we_PRP is_VBZ on_IN the_DT market_NN to_TO further_JJ investigate_VB its_PRP$ publish_VB our_PRP$ clinical_JJ trial_NN results_NNS in_IN peer-reviewed_JJ role_NN in_IN the_DT treatment_NN of_IN patients_NNS ._.
In_IN all_DT scientific_JJ and_CC medical_JJ journals_NNS and_CC in_IN conference_NN studies_NNS ,_, our_PRP$ first_JJ concern_NN is_VBZ the_DT safety_NN abstracts_NNS and_CC proceedings_NNS ._.
The_DT research_NN and_CC and_CC well-being_NN of_IN trial_NN participants_NNS and_CC healthcare_NN communities_NNS look_VBP to_TO these_DT sources_NNS future_JJ patients_NNS ._.
Our_PRP$ clinical_JJ trials_NNS are_VBP conducted_VBN in_IN accordance_NN We_PRP worked_VBD with_IN other_JJ pharmaceutical_JJ with_IN all_DT applicable_JJ laws_NNS and_CC regulations_NNS ,_, as_RB well_RB companies_NNS in_IN 2002_CD to_TO help_VB clarify_VB the_DT industrys_NNS as_IN recognized_VBN principles_NNS of_IN good_JJ clinical_JJ practice_NN ._.
approach_NN to_TO the_DT communication_NN of_IN clinical_JJ trial_NN We_PRP are_VBP legally_RB obliged_VBN to_TO disclose_VB all_DT data_NNS from_IN results_NNS and_CC to_TO develop_VB the_DT PhRMA_NNP Principles_NNPS on_IN clinical_JJ trials_NNS to_TO the_DT regulatory_JJ authorities_NNS when_WRB the_DT Conduct_NNP of_IN Clinical_NNP Trials_NNP &_CC Communication_NNP we_PRP seek_VBP approval_NN for_IN a_DT new_JJ product_NN ._.
We_PRP fully_RB support_VBP these_DT principles_NNS and_CC apply_VB them_PRP to_TO all_DT our_PRP$ clinical_JJ Approval_NN to_TO market_VB a_DT product_NN is_VBZ only_RB given_VBN if_IN studies_NNS worldwide_VBP ._.
the_DT regulators_NNS are_VBP satisfied_VBN that_IN the_DT product_NN is_VBZ safe_JJ and_CC effective_JJ ,_, and_CC can_MD be_VB manufactured_VBN to_TO high_JJ In_IN particular_JJ we_PRP reaffirm_VBP our_PRP$ commitment_NN to_TO :_: and_CC consistent_JJ quality_NN standards_NNS ._.
After_IN a_DT medicine_NN The_DT timely_JJ communication_NN of_IN all_DT meaningful_JJ or_CC vaccine_NN has_VBZ been_VBN approved_VBN for_IN marketing_NN ,_, we_PRP results_NNS of_IN controlled_JJ clinical_JJ trials_NNS of_IN marketed_VBN continue_VBP to_TO provide_VB regulatory_JJ authorities_NNS with_IN products_NNS or_CC investigational_JJ products_NNS that_WDT are_VBP further_JJ safety_NN information_NN ._.
approved_VBN for_IN marketing_NN ,_, whether_IN the_DT results_NNS are_VBP positive_JJ or_CC negative_JJ 26_CD Corporate_JJ Responsibility_NN Report_NNP 2003_CD 6_CD Research_NNP and_CC development_NN nd_NN nt_NN Advancing_VBG management_NN of_IN Review_NNP and_CC discuss_VB manuscripts_NNS with_IN the_DT NUMBER_NNP OF_IN PUBLICATIONS_NNPS OF_IN GSK_NNP CLINICAL_NNP TRIALS_VBZ heart_NN disease_NN clinical_JJ investigators_NNS who_WP conducted_VBD GSKHeart_NNP failure_NN is_VBZ a_DT serious_JJ condition_NN ,_, with_IN five_CD sponsored_VBN studies_NNS before_IN they_PRP are_VBP submitted_VBN million_CD people_NNS affected_VBN in_IN the_DT US_NNP alone_RB ._.
Half_NN to_TO a_DT journal_NN or_CC conference_NN for_IN publication_NN 600_CD of_IN these_DT patients_NNS will_MD die_VB within_IN five_CD years_NNS of_IN 549_CD Ensure_NN that_WDT anyone_NN who_WP contributes_VBZ diagnosis_NN and_CC new_JJ treatments_NNS are_VBP urgently_RB significantly_RB to_TO the_DT study_NN and_CC writing_VBG or_CC 500_CD required_VBN ._.
437_CD revising_VBG of_IN the_DT manuscript_NN receives_VBZ appropriate_JJ GSK_NNP ,_, partnering_VBG with_IN another_DT company_NN ,_, rose_VBD 364_CD recognition_NN as_IN an_DT author_NN or_CC contributor_NN when_WRB 400_CD to_TO this_DT challenge_NN by_IN investigating_VBG new_JJ uses_NNS the_DT manuscript_NN is_VBZ published_VBN for_IN Coreg_NNP ,_, a_DT GSK_NNP beta-blocker_NN medicine_NN for_IN 300_CD Publish_JJ results_NNS gathered_VBN from_IN all_PDT the_DT centres_NNS treating_VBG high_JJ blood_NN pressure_NN ._.
involved_VBN in_IN a_DT multi-centre_JJ trial_NN before_IN those_DT Clinical_JJ trial_NN results_NNS were_VBD positive_JJ ,_, 200_CD from_IN individual_JJ centres_NNS ._.
demonstrating_VBG that_DT adding_VBG Coreg_NNP to_TO current_JJ medication_NN reduced_VBD the_DT mortality_NN rate_NN among_IN 100_CD Publication_NN in_IN journals_NNS and_CC at_IN many_JJ conferences_NNS patients_NNS with_IN heart_NN failure_NN by_IN 35_CD %_NN and_CC slowed_VBD progression_NN of_IN the_DT disease_NN ._.
This_DT can_MD help_VB is_VBZ subject_JJ to_TO peer_VB review_NN and_CC is_VBZ at_IN the_DT discretion_NN 0_CD patients_NNS to_TO live_VB longer_JJR and_CC to_TO feel_VB better_RB ._.
of_IN journal_NN editors_NNS and_CC conference_NN organisers_NNS ._.
2001 2002 2003_CD This_DT means_VBZ that_IN GSK_NNP can_MD not_RB guarantee_VB that_IN The_DT product_NN licence_NN was_VBD expanded_VBN so_RB clinical_JJ trial_NN information_NN will_MD be_VB published_VBN in_IN Coreg_NNP can_MD now_RB be_VB prescribed_VBN by_IN doctors_NNS for_IN treatment_NN of_IN heart_NN failure_NN as_RB well_RB as_IN these_DT ways_NNS ._.
We_PRP are_VBP therefore_RB assessing_VBG additional_JJ The_DT number_NN of_IN publications_NNS each_DT year_NN depends_VBZ hypertension_NN ._.
options_NNS to_TO communicate_VB clinical_JJ trial_NN information_NN ._.
on_IN the_DT number_NN of_IN trials_NNS completed_VBN and_CC the_DT This_DT was_VBD the_DT first_JJ time_NN a_DT beta-blocker_NN was_VBD number_NN accepted_VBN for_IN publication_NN ._.
shown_VBN to_TO be_VB effective_JJ and_CC safe_JJ in_IN treating_VBG heart_NN failure_NN ._.
Previously_RB it_PRP was_VBD believed_VBN that_IN In_IN 2003_CD 437_CD papers_NNS describing_VBG the_DT results_NNS of_IN beta-blockers_NNS were_VBD unsafe_JJ in_IN heart_NN failure_NN GSKs_NNS clinical_JJ trials_NNS were_VBD published_VBN in_IN journals_NNS patients_NNS ._.
Corporate_JJ Responsibility_NN Report_NNP 2003_CD 27_CD Animal_NNP research_NN We_PRP are_VBP committed_VBN to_TO the_DT 3_CD Rs_NNS :_: reducing_VBG the_DT The_DT number_NN of_IN animals_NNS used_VBN may_MD fluctuate_VB Animal_NNP research_NN is_VBZ essential_JJ to_TO understand_VB number_NN of_IN animals_NNS used_VBN in_IN each_DT study_NN :_: refining_NN from_IN year_NN to_TO year_NN and_CC depends_VBZ on_IN several_JJ factors_NNS disease_NN ._.
It_PRP enables_VBZ us_PRP to_TO evaluate_VB the_DT studies_NNS to_TO minimize_VB pain_NN and_CC maximize_VB the_DT such_JJ as_IN the_DT number_NN of_IN compounds_NNS in_IN research_NN effectiveness_NN and_CC safety_NN of_IN new_JJ medicines_NNS before_IN information_NN obtained_VBN from_IN each_DT animal_NN :_: and_CC and_CC development_NN ,_, regulatory_JJ requirements_NNS and_CC they_PRP are_VBP given_VBN to_TO people_NNS ._.
Regulations_NNPS require_VBP the_DT replacing_VBG animal_NN studies_NNS with_IN alternative_JJ methods_NNS the_DT introduction_NN of_IN new_JJ non-animal_JJ research_NN use_NN of_IN animals_NNS to_TO establish_VB that_IN new_JJ medicines_NNS wherever_WRB possible_JJ ._.
are_VBP safe_JJ and_CC to_TO test_VB some_DT types_NNS of_IN vaccines_NNS after_IN 27_CD each_DT batch_NN is_VBZ produced_VBN ._.
For_IN example_NN ,_, we_PRP have_VBP replaced_VBN many_JJ animal_NN Our_PRP$ laboratories_NNS comply_VBP with_IN strict_JJ national_JJ studies_NNS with_IN new_JJ research_NN methods_NNS such_JJ as_IN laws_NNS ,_, guidelines_NNS and_CC codes_NNS of_IN conduct_NN and_CC are_VBP We_PRP believe_VB it_PRP is_VBZ important_JJ to_TO explain_VB the_DT need_NN for_IN computer_NN modelling_NN and_CC tests_NNS on_IN isolated_JJ cells_NNS regularly_RB inspected_VBN by_IN government_NN agencies_NNS ._.
Our_PRP$ animal_NN research_NN and_CC to_TO be_VB open_JJ about_IN what_WP we_PRP and_CC tissues_NNS ._.
We_PRP have_VBP refined_VBN many_JJ procedures_NNS employees_NNS and_CC any_DT laboratories_NNS working_VBG on_IN our_PRP$ do_VBP ._.
We_PRP host_VBP visits_NNS from_IN schools_NNS and_CC colleges_NNS ,_, to_TO use_VB non-invasive_JJ techniques_NNS such_JJ as_IN magnetic_JJ behalf_NN must_MD also_RB follow_VB a_DT GSK_NNP code_NN of_IN practice_NN ._.
animal_NN welfare_NN organizations_NNS such_JJ as_IN the_DT RSPCA_NNP resonance_NN imaging_NN ,_, which_WDT have_VBP helped_VBN to_TO reduce_VB Research_NNP teams_NNS ensure_VB that_IN studies_NNS are_VBP refined_VBN and_CC other_JJ stakeholders_NNS to_TO our_PRP$ laboratories_NNS in_IN the_DT the_DT number_NN of_IN animals_NNS used_VBN in_IN each_DT study_NN ._.
to_TO minimize_VB any_DT animal_NN suffering_NN ._.
In_IN 2003_CD we_PRP also_RB made_VBD over_IN 70_CD visits_NNS to_TO UK_NNP schools_NNS to_TO discuss_VB issues_NNS arising_VBG from_IN animal_NN We_PRP run_VBP award_NN programs_NNS to_TO encourage_VB We_PRP also_RB obtain_VB additional_JJ independent_JJ research_NN ._.
We_PRP consult_VBP with_IN other_JJ organizations_NNS researchers_NNS to_TO find_VB alternative_JJ approaches_NNS evaluation_NN from_IN the_DT Association_NNP for_IN Assessment_NNP such_JJ as_IN the_DT Nuffield_NNP Council_NNP on_IN Bioethics_NNPS and_CC to_TO the_DT use_NN of_IN animals_NNS ._.
GSKs_NNS R&D_NNP Chairman_NNP &_CC Accreditation_NNP of_IN Laboratory_NNP Animal_NNP Care_NNP the_DT Universities_NNS Federation_NNP for_IN Animal_NNP Welfare_NNP ._.
presents_NNS several_JJ Animal_NNP Welfare_NNP Awards_NNPS each_DT AAALAC_NNP International_NNP ,_, which_WDT gives_VBZ year_NN to_TO employees_NNS who_WP have_VBP made_VBN outstanding_JJ accreditation_NN to_TO sites_NNS that_WDT meet_VBP the_DT highest_JJS 29_CD GSK_NNP has_VBZ 12_CD animal_JJ research_NN facilities_NNS in_IN the_DT US_NNP ,_, advances_NNS in_IN implementing_VBG the_DT 3_CD Rs_NNS ._.
All_DT seven_CD of_IN GSKs_NNS animal_JJ 28_CD Europe_NNP and_CC Japan_NNP ._.
Some_DT research_NN approximately_RB European_JJ GSK_NNP Laboratory_NNP Animal_NNP Welfare_NNP Prize_NNP laboratories_NNS in_IN the_DT US_NNP and_CC UK_NNP are_VBP accredited_VBN ._.
4_CD %_NN is_VBZ conducted_VBN by_IN external_JJ contractors_NNS on_IN for_IN external_JJ laboratories_NNS is_VBZ awarded_VBN to_TO We_PRP have_VBP made_VBN good_JJ progress_NN working_VBG towards_IN our_PRP$ behalf_NN ._.
individuals_NNS or_CC groups_NNS who_WP have_VBP developed_VBN new_JJ accreditation_NN of_IN sites_NNS in_IN continental_JJ Europe_NNP and_CC techniques_NNS that_WDT enhance_VBP our_PRP$ ability_NN to_TO implement_VB Japan_NNP and_CC plan_NN to_TO complete_VB this_DT process_NN as_RB soon_RB Over_IN 99_CD %_NN of_IN the_DT animals_NNS we_PRP use_VBP are_VBP rodents_NNS ._.
This_DT years_NNS winner_NN was_VBD the_DT Norwegian_JJ as_IN possible_JJ ._.
The_DT remaining_VBG 1_CD %_NN includes_VBZ fish_NN ,_, amphibians_NNS ,_, Reference_NNP Centre_NNP for_IN Laboratory_NNP Animal_NNP Science_NNP rabbits_NNS ,_, pigs_NNS ,_, dogs_NNS ,_, cats_NNS and_CC primates_NNS ._.
This_DT approach_NN is_VBZ achieving_VBG results_NNS ._.
The_DT number_NN of_IN animals_NNS used_VBN by_IN GSK_NNP is_VBZ broadly_RB the_DT same_JJ as_IN nine_CD years_NNS ago_RB despite_IN a_DT significant_JJ increase_NN in_IN R&D_NNP activity_NN ._.
ANIMALS_NNS USED_VBD IN_IN RESEARCH_NNP CHANGE_NNP IN_IN R&D_NNP ACTIVITY_NNP COMPARED_VBD WITH_IN NUMBER_NN OF_IN ANIMALS_NNP USED_NNP BY_IN GSK_NNP 200_CD Mice_NNP 65_CD %_NN 150_CD Rats_NNS 26_CD %_NN Guinea_NNP pigs_NNS 7_CD %_NN 100_CD Other_JJ rodents_NNS 1_CD %_NN Others_NNS 1_CD %_NN 50_CD 0_CD 1994 1995 1996 1997_CD 1998 1999 2000 2001_CD 2002_CD Year_NN R&D_NN activity_NN Animals_NNS used_VBN Figures_NNS normalised_VBD to_TO 1994_CD levels_NNS 28_CD Corporate_JJ Responsibility_NN Report_NNP 2003_CD %_NN change_NN since_IN 1994_CD Discussion_NN with_IN others_NNS Engaging_VBG with_IN stakeholders_NNS is_VBZ an_DT important_JJ aspect_NN of_IN our_PRP$ approach_NN to_TO corporate_JJ responsibility_NN ._.
We_PRP believe_VBP it_PRP is_VBZ essential_JJ to_TO listen_VB to_TO other_JJ peoples_NNS views_NNS and_CC to_TO communicate_VB our_PRP$ own_JJ opinions_NNS externally_RB ._.
Communication_NNP with_IN employees_NNS Employee_NNP satisfaction_NN surveys_NNS give_VBP us_PRP feedback_VB We_PRP interact_VB with_IN many_JJ different_JJ people_NNS Internal_NNP communication_NN is_VBZ particularly_RB important_JJ ._.
on_IN our_PRP$ company_NN programs_NNS and_CC identify_VB and_CC groups_NNS who_WP are_VBP interested_JJ in_IN our_PRP$ We_PRP aim_VBP to_TO keep_VB everyone_NN well_RB informed_VBN and_CC areas_NNS where_WRB we_PRP can_MD do_VB better_JJR ._.
Our_PRP$ global_JJ survey_NN business_NN or_CC affected_VBN by_IN our_PRP$ products_NNS and_CC involved_VBN in_IN company_NN activities_NNS ,_, and_CC we_PRP seek_VBP in_IN 2002_CD involved_JJ 11,000_CD managers_NNS from_IN around_IN operations_NNS :_: employees_NNS ,_, investors_NNS ,_, doctors_NNS ,_, their_PRP$ feedback_NN ._.
We_PRP have_VBP a_DT range_NN of_IN initiatives_NNS to_TO the_DT world_NN ._.
The_DT next_JJ management_NN survey_NN will_MD patients_NNS ,_, suppliers_NNS ,_, non-governmental_JJ ensure_VB that_IN we_PRP reach_VBP employees_NNS right_JJ across_IN the_DT take_NN place_NN in_IN 2004_CD ._.
organizations_NNS NGOs_NNS ,_, multilateral_JJ company_NN ._.
These_DT include_VBP :_: At_IN a_DT local_JJ level_NN ,_, many_JJ sites_NNS produce_VBP regular_JJ agencies_NNS ,_, governments_NNS and_CC local_JJ newsletters_NNS for_IN staff_NN ,_, often_RB spotlighting_VBG communities_NNS ._.
Much_JJ of_IN this_DT discussion_NN myGSK_NNP ,_, our_PRP$ global_JJ intranet_NN site_NN ,_, with_IN updates_NNS environment_NN ,_, health_NN or_CC safety_NN issues_NNS and_CC takes_VBZ place_NN as_IN part_NN of_IN the_DT normal_JJ course_NN on_IN company_NN and_CC industry_NN news_NN and_CC a_DT Q&A_NNP programs_NNS ._.
We_PRP also_RB have_VBP meetings_NNS page_NN where_WRB employees_NNS can_MD put_VB questions_NNS Confidential_NNP feedback_NN mechanisms_NNS enable_VBP specifically_RB to_TO review_VB corporate_JJ directly_RB to_TO the_DT CEO_NNP ._.
Up_IN to_TO 100_CD questions_NNS are_VBP employees_NNS to_TO raise_VB concerns_NNS ._.
These_DT include_VBP responsibility_NN issues_NNS ,_, for_IN example_NN with_IN answered_VBN each_DT month_NN ._.
integrity_NN helplines_NNS in_IN the_DT UK_NNP and_CC US_NNP ._.
socially_RB responsible_JJ investors_NNS and_CC NGOs_NNS ._.
Behind_IN the_DT News_NNP ,_, a_DT section_NN of_IN the_DT GSK_NNP In_IN Europe_NNP our_PRP$ Works_NNP Councils_NNPS and_CC European_JJ intranet_NN ,_, giving_VBG the_DT companys_NNS position_NN on_IN Employee_NNP Consultation_NNP Forum_NNP provide_VBP regular_JJ important_JJ issues_NNS linked_VBN to_TO press_VB clippings_NNS opportunities_NNS for_IN employees_NNS and_CC company_NN about_IN GSK_NNP ._.
Spirit_NN ,_, our_PRP$ internal_JJ magazine_NN ,_, is_VBZ available_JJ to_TO employees_NNS company-wide_JJ four_CD times_NNS a_DT year_NN ._.
An_DT events_NNS program_NN with_IN more_JJR than_IN 100_CD meetings_NNS in_IN 2003_CD ._.
Events_NNS enable_VBP employees_NNS at_IN all_DT levels_NNS to_TO meet_VB the_DT CEO_NNP and_CC senior_JJ management_NN and_CC discuss_VB the_DT progress_NN of_IN the_DT business_NN ,_, to_TO raise_VB questions_NNS and_CC to_TO give_VB feedback_NN ._.
Corporate_JJ Responsibility_NN Report_NNP 2003_CD 29_CD Discussion_NN with_IN external_JJ stakeholders_NNS The_DT way_NN we_PRP interact_VBP with_IN these_DT groups_NNS depends_VBZ very_RB much_RB on_IN their_PRP$ needs_NNS and_CC the_DT type_NN of_IN work_NN we_PRP are_VBP doing_VBG with_IN them_PRP ._.
Here_RB are_VBP some_DT of_IN the_DT ways_NNS we_PRP interact_VBP :_: Type_NN of_IN communication_NN Stakeholder_NNP Healthcare_NNP We_PRP meet_VBP regularly_RB with_IN doctors_NNS and_CC pharmacists_NNS to_TO tell_VB them_PRP about_IN our_PRP$ products_NNS and_CC discuss_VB any_DT issues_NNS professionals_NNS and_CC concerns_NNS they_PRP may_MD have_VB ._.
We_PRP also_RB conduct_VBP market_NN research_NN among_IN doctors_NNS and_CC other_JJ healthcare_NN for_IN example_NN ,_, doctors_NNS professionals_NNS to_TO get_VB feedback_NN ._.
and_CC pharmacists_NNS We_PRP work_VBP with_IN medical_JJ organizations_NNS to_TO develop_VB and_CC sponsor_VB continuing_VBG medical_JJ education_NN for_IN doctors_NNS and_CC other_JJ healthcare_NN professionals_NNS such_JJ as_IN accredited_JJ training_NN courses_NNS in_IN asthma_NN care_NN for_IN nurses_NNS ._.
We_PRP partner_NN with_IN healthcare_NN professionals_NNS to_TO design_VB and_CC conduct_VB clinical_JJ trials_NNS and_CC research_NN projects_NNS ._.
Research_NNP results_NNS ,_, including_VBG those_DT from_IN our_PRP$ clinical_JJ trials_NNS ,_, are_VBP peer-reviewed_JJ and_CC published_VBN in_IN medical_JJ journals_NNS ._.
Governments_NNS and_CC We_PRP have_VBP regular_JJ dialogue_NN with_IN regulators_NNS to_TO share_VB information_NN on_IN new_JJ science_NN and_CC technologies_NNS ._.
regulators_NNS For_IN example_NN ,_, we_PRP have_VBP supported_VBN a_DT genetic_JJ research_NN education_NN program_NN to_TO discuss_VB issues_NNS raised_VBN by_IN genetics_NNS and_CC its_PRP$ potential_JJ applications_NNS in_IN healthcare_NN ._.
Our_PRP$ operations_NNS liaise_VBP regularly_RB with_IN environment_NN ,_, health_NN and_CC safety_NN authorities_NNS to_TO ensure_VB we_PRP are_VBP complying_VBG fully_RB with_IN our_PRP$ legal_JJ obligations_NNS ._.
Many_JJ of_IN our_PRP$ specialist_NN environment_NN ,_, health_NN and_CC safety_NN employees_NNS also_RB participate_VB in_IN government_NN committees_NNS and_CC consultations_NNS to_TO help_VB develop_VB better_JJR regulation_NN for_IN the_DT future_NN ._.
In_IN 2003_CD we_PRP sponsored_VBD the_DT annual_JJ conference_NN of_IN the_DT UK_NNP Environment_NNP Agency_NNP ,_, where_WRB GSKs_NNS work_VBP on_IN green_JJ chemistry_NN was_VBD acknowledged_VBN in_IN a_DT presentation_NN by_IN Baroness_NNP Young_NNP ,_, Chief_NNP Executive_NNP of_IN the_DT agency_NN ._.
Investors_NNS Senior_JJ managers_NNS present_JJ final_JJ year-end_NN results_NNS to_TO institutional_JJ investors_NNS and_CC analysts_NNS in_IN London_NNP and_CC New_NNP York_NNP ._.
There_EX are_VBP also_RB teleconferences_NNS after_IN the_DT release_NN of_IN quarterly_JJ results_NNS ._.
These_DT presentations_NNS can_MD be_VB accessed_VBN via_IN our_PRP$ website_NN ._.
The_DT Annual_JJ General_NNP Meeting_VBG takes_VBZ place_NN in_IN London_NNP ._.
This_DT includes_VBZ a_DT business_NN presentation_NN to_TO shareholders_NNS ,_, and_CC Directors_NNS are_VBP available_JJ to_TO answer_VB questions_NNS ._.
Senior_JJ managers_NNS discuss_VBP the_DT companys_NNS plans_NNS ,_, objectives_NNS and_CC governance_NN with_IN institutional_JJ shareholders_NNS ._.
This_DT includes_VBZ regular_JJ meetings_NNS and_CC participation_NN in_IN external_JJ investor_NN conferences_NNS ._.
We_PRP held_VBD an_DT R&D_NNP day_NN in_IN December_NNP 2003_CD to_TO inform_VB investors_NNS about_IN products_NNS in_IN our_PRP$ development_NN pipeline_NN ._.
Our_PRP$ annual_JJ Corporate_JJ Responsibility_NN forum_NN for_IN investors_NNS was_VBD held_VBN in_IN July_NNP ._.
Senior_JJ GSK_NNP managers_NNS with_IN expertise_NN in_IN relevant_JJ areas_NNS met_VBD representatives_NNS of_IN more_JJR than_IN 30_CD investment_NN funds_NNS and_CC rating_NN agencies_NNS and_CC responded_VBD to_TO their_PRP$ questions_NNS ._.
We_PRP also_RB meet_VBP regularly_RB with_IN investors_NNS to_TO discuss_VB our_PRP$ corporate_JJ responsibility_NN policies_NNS and_CC performance_NN ._.
Meetings_NNS held_VBN in_IN 2003_CD included_VBD discussions_NNS on_IN all_PDT the_DT key_JJ impact_NN areas_NNS addressed_VBD in_IN this_DT report_NN ._.
30_CD Corporate_JJ Responsibility_NN Report_NNP 2003_CD Type_NN of_IN communication_NN Stakeholder_NNP Non-governmental_JJ We_PRP discuss_VBP approaches_NNS to_TO the_DT healthcare_NN needs_NNS of_IN developing_VBG countries_NNS with_IN NGOs_NNS such_JJ as_IN Mdecins_NNP Sans_NNP organizations_NNS and_CC Frontires_NNS ,_, Freedom_NNP from_IN Hunger_NNP and_CC Oxfam_NNP ._.
communities_NNS We_PRP work_VBP with_IN NGOs_NNS ,_, patient_JJ groups_NNS and_CC consumer_NN groups_NNS ,_, for_IN example_NN on_IN smoking_NN cessation_NN ,_, asthma_NN and_CC vaccination_NN campaigns_NNS ._.
Through_IN our_PRP$ community_NN investment_NN programs_NNS we_PRP work_VBP in_IN partnership_NN with_IN organizations_NNS and_CC community_NN groups_NNS ._.
We_PRP meet_VBP together_RB regularly_RB around_IN the_DT world_NN to_TO evaluate_VB progress_NN in_IN meeting_NN local_JJ community_NN needs_NNS ._.
Our_PRP$ Environment_NNP ,_, Health_NNP and_CC Safety_NNP EHS_NNP Workshop_NNP in_IN September_NNP 2003_CD brought_VBD together_RB key_JJ NGOs_NNS ,_, trade_NN unions_NNS and_CC government_NN representatives_NNS to_TO discuss_VB our_PRP$ environmental_JJ performance_NN and_CC our_PRP$ long-term_JJ strategy_NN for_IN achieving_VBG leadership_NN and_CC excellence_NN in_IN EHS_NNP ._.
The_DT key_JJ issues_NNS highlighted_VBN by_IN this_DT discussion_NN will_MD form_VB part_NN of_IN our_PRP$ improvement_NN program_NN in_IN 2004_CD ._.
We_PRP partner_NN with_IN a_DT number_NN of_IN environmental_JJ NGOs_NNS ._.
Examples_NNS include_VBP sponsoring_VBG Green_NNP Alliance_NNP in_IN a_DT project_NN to_TO raise_VB awareness_NN of_IN the_DT links_NNS between_IN environment_NN and_CC health_NN and_CC funding_NN Earthwatch_NNP to_TO send_VB school_NN teachers_NNS on_IN conservation_NN projects_NNS ._.
We_PRP host_VBP tours_NNS of_IN our_PRP$ laboratories_NNS and_CC visit_NN schools_NNS to_TO help_VB improve_VB understanding_NN of_IN scientific_JJ research_NN ,_, for_IN example_NN the_DT use_NN of_IN animals_NNS ._.
Many_JJ of_IN our_PRP$ operations_NNS produce_VBP newsletters_NNS to_TO keep_VB local_JJ communities_NNS informed_VBN of_IN their_PRP$ work_NN ,_, and_CC each_DT year_NN several_JJ sites_NNS host_NN open_JJ days_NNS ._.
At_IN many_JJ GSK_NNP sites_NNS ,_, employees_NNS undertake_VBP projects_NNS to_TO improve_VB the_DT environment_NN in_IN their_PRP$ local_JJ area_NN ._.
A_DT number_NN of_IN our_PRP$ operations_NNS also_RB have_VBP outreach_JJ projects_NNS ._.
For_IN example_NN ,_, in_IN 2003_CD ,_, a_DT Horlicks_NNP plant_NN in_IN Rajahmundry_NNP ,_, India_NNP ,_, was_VBD recognized_VBN with_IN the_DT CEOs_NNS EHS_NNP Excellence_NNP Award_NNP in_IN Community_NNP Partnership_NNP for_IN local_JJ projects_NNS including_VBG the_DT provision_NN of_IN drinking_NN water_NN to_TO villages_NNS experiencing_VBG drought_NN ,_, donation_NN of_IN desks_NNS and_CC chairs_NNS to_TO schools_NNS ,_, building_VBG a_DT bridge_NN to_TO improve_VB access_NN to_TO a_DT school_NN ,_, and_CC organising_VBG a_DT fide-worming_JJ program_NN for_IN children_NNS ._.
We_PRP collaborate_VBP with_IN academics_NNS ,_, researchers_NNS and_CC other_JJ pharmaceutical_JJ companies_NNS to_TO research_NN and_CC develop_VB Scientific_NNP community_NN new_JJ treatments_NNS and_CC encourage_VB the_DT transfer_NN of_IN expertise_NN and_CC skills_NNS ._.
We_PRP work_VBP with_IN education_NN authorities_NNS to_TO develop_VB and_CC sponsor_VB initiatives_NNS that_WDT further_RB science_NN education_NN in_IN schools_NNS ,_, for_IN example_NN through_IN our_PRP$ INSPIRE_NN program_NN ._.
We_PRP hold_VBP a_DT regular_JJ science_NN policy_NN conference_NN in_IN the_DT UK_NNP ,_, in_IN partnership_NN with_IN government_NN and_CC non_JJ government_NN stakeholders_NNS ,_, to_TO discuss_VB issues_NNS of_IN common_JJ interest_NN ._.
The_DT 2004_CD meeting_NN will_MD discuss_VB clinical_JJ sciences_NNS in_IN the_DT UK_NNP ._.
We_PRP sponsor_VBP university_NN research_NN in_IN environment_NN ,_, health_NN and_CC safety_NN issues_NNS ,_, including_VBG projects_NNS in_IN green_JJ chemistry_NN ,_, eco-efficiency_NN and_CC alternative_NN technologies_NNS to_TO reduce_VB environmental_JJ impacts_NNS ._.
We_PRP regularly_RB meet_VBP with_IN UN_NNP agencies_NNS ,_, including_VBG the_DT WHO_WP ,_, UNAAI_NNP ,_, Unicef_NNP and_CC the_DT Global_NNP Fund_NNP to_TO Fight_VB AIDS_NNP ,_, TB_NN and_CC Malaria_NN ,_, to_TO discuss_VB a_DT wide_JJ range_NN of_IN issues_NNS ._.
These_DT include_VBP addressing_VBG the_DT HIV_NNP AIDS_NNP epidemic_JJ Multilateral_NNP agencies_NNS through_IN preferential_JJ pricing_NN arrangements_NNS ,_, creating_VBG public_JJ private_JJ partnerships_NNS for_IN R&D_NNP into_IN diseases_NNS of_IN the_DT developing_VBG world_NN and_CC targeting_VBG our_PRP$ product_NN donations_NNS ._.
We_PRP collaborate_VBP with_IN the_DT WHO_WP ,_, Ministries_NNPS of_IN Health_NNP and_CC 40_CD other_JJ partners_NNS as_IN part_NN of_IN the_DT Global_JJ Alliance_NNP to_TO Eliminate_VB LF_NNP ._.
We_PRP take_VBP part_NN in_IN the_DT annual_JJ WHO-IFPMA_NN round_NN tables_NNS at_IN which_WDT the_DT WHO_WP and_CC industry_NN discuss_VBP partnership_NN opportunities_NNS to_TO improve_VB global_JJ health_NN ._.
Corporate_JJ Responsibility_NN Report_NNP 2003_CD 31_CD Web_NN references_NNS Our_PRP$ corporate_JJ website_NN can_MD be_VB found_VBN at_IN www_NN ._.
com_NN Websites_NNS cited_VBD in_IN this_DT report_NN :_: 1_CD www_NN ._.
org_RB public_JJ english_NN standards_NNS norm_NN index_NN ._.
com_NN community_NN impact_NN awards_NNS uk_VBP ._.
com_NN community_NN impact_NN awards_NNS us_PRP ._.
org_NN publications_NNS policy_NN 2003-11-20_CD .871_CD ._.
pdf_NN 27_CD www_NN ._.
org_NN 32_CD Corporate_JJ Responsibility_NN Report_NNP 2003_CD Internet_NNP Information_NNP about_IN the_DT company_NN is_VBZ available_JJ on_IN GlaxoSmithKlines_NNP corporate_JJ website_NN at_IN www_NN ._.
com_NN Head_NNP Office_NNP and_CC Registered_NNP Office_NNP GlaxoSmithKline_NNP plc_NN 980_CD Great_NNP West_NNP Road_NNP Brentford_NNP Middlesex_NNP TW8_NNP 9GS_NNP UK_NNP Tel_NNP :_: 44_CD 0_CD 20 8047 5000_CD You_PRP can_MD contact_VB the_DT company_NN directly_RB about_IN corporate_JJ responsibility_NN issues_NNS on_IN csr_NN ._.
com_NN Our_PRP$ Reports_NNS ANNUAL_JJ REVIEW_NNP Do_VBP more_RBR ,_, feel_VB better_RB ,_, live_VBP longer_RBR A_DT review_NN of_IN major_JJ themes_NNS for_IN 2003_CD and_CC an_DT abridged_JJ version_NN of_IN the_DT financial_JJ results_NNS ._.
Improving_NN health_NN every_DT day_NN ANNUAL_NNP REVIEW_NNP 2003_CD ANNUAL_NNP REPORT_NNP Do_VBP more_RBR ,_, feel_VB better_RB ,_, live_VBP longer_RBR The_DT full_JJ financial_JJ statements_NNS for_IN 2003_CD ._.
Improving_NN performance_NN every_DT day_NN ANNUAL_NNP REPORT_NNP 2003_CD Produced_VBN by_IN Corporate_NNP Communications_NNPS ,_, GlaxoSmithKline_NNP ._.
CORPORATE_JJ Do_VBP more_RBR ,_, feel_VB better_RB ,_, live_VBP longer_JJR Design_NN consultancy_NN by_IN salterbaxter_NN ._.
RESPONSIBILITY_NN REPORT_NN A_DT review_NN of_IN our_PRP$ Corporate_JJ responsibility_NN consultancy_NN by_IN Context_NNP ._.
commitment_NN to_TO society_NN and_CC the_DT environment_NN ._.
Photograph_NNP on_IN page_NN 14_CD ,_, courtesy_NN of_IN Monika_NNP Graff_NNP ._.
Printed_NNP in_IN the_DT UK_NNP by_IN The_DT Colourhouse_NNP ._.
The_DT paper_NN used_VBN in_IN the_DT production_NN of_IN this_DT document_NN is_VBZ made_VBN Making_VBG a_DT difference_NN from_IN pulps_NNS harvested_VBN from_IN sustainable_JJ forests_NNS ,_, also_RB every_DT day_NN using_VBG sawmill_NN residues_NNS and_CC forest_NN thinnings_NNS ._.
It_PRP is_VBZ CORPORATE_JJ RESPONSIBILITY_NN REPORT_NN 2003_CD elemental_JJ chlorine-free_NN ._.
Making_VBG a_DT dif_NN Improving_NN health_NN ,_, every_DT day_NN ference_NN ,_, every_DT day_NN 101_CD 101_CD Product_NNP names_NNS throughout_IN this_DT publication_NN are_VBP indicated_VBN in_IN italics_NNS and_CC are_VBP trademarks_NNS of_IN GlaxoSmithKline_NNP plc_NN ,_, its_PRP$ subsidiaries_NNS or_CC associated_VBN Every_DT day_NN ,_, all_DT around_IN the_DT world_NN ,_, GlaxoSmithKline_NNP is_VBZ companies_NNS ,_, with_IN the_DT exception_NN of_IN Levitra_NNP ,_, a_DT trying_VBG to_TO improve_VB peoples_NNS lives_NNS and_CC have_VBP a_DT positive_JJ trademark_NN of_IN Bayer_NNP AG_NNP and_CC Nicoderm_NNP ,_, a_DT trademark_NN impact_NN on_IN all_DT its_PRP$ stakeholders_NNS ._.
This_DT years_NNS reports_NNS of_IN Aventis_NNP SA_NNP ,_, both_DT of_IN which_WDT are_VBP used_VBN under_IN licence_NN emphasise_NN this_DT far-reaching_JJ commitment_NN ._.
